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ABSTRACT 
PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to 





The importance of metabolism in tumor initiation and progression is becoming increasingly clear.  
Metabolic changes induced by oncogenic drivers of cancer contribute to tumor growth and are 
attractive targets for cancer treatment.  Phosphatase and Tensin homolog deleted from chromosome 
ten (PTEN) is one of the most commonly mutated tumor suppressors in cancer and operates in multiple 
roles, rendering it a hub for understanding cancer biology and for developing targeted therapy.  PTEN’s 
canonical function is its ability to antagonize the phosphoinositide 3-kinase (PI3K) pathway by 
dephosphorylating the lipid second messenger phosphatidylinositol (3,4,5) tri-phosphate (PIP3).  This 
thesis focuses on the effects of PTEN loss on cellular metabolism, and the therapeutic vulnerability that 
stems from metabolic alterations.   
 
First, we discovered that loss of Pten in mouse embryonic fibroblasts (MEFs) increases cellular 
proliferation and the number of replication forks per cell, launching our investigation into metabolic 
pathways that may be altered to support increased growth.  Indeed, we found that Pten-/- cells exhibited 
a dependence on glutamine for their faster rate of growth, and that glutamine was channeled into the 
de novo synthesis of pyrimidines.   
 
The next chapter examined dihydroorotate dehydrogenase (DHODH), a rate limiting enzyme for 
pyrimidine ring synthesis in the de novo pyrimidine synthesis pathway.  We found that PTEN-deficient 
primary cells and cancer cell lines were more sensitive to inhibition of DHODH than PTEN WT cells were, 
and that the growth inhibition could be rescued by metabolites downstream of DHODH.  Furthermore, 
we found that xenografted human triple negative breast cancer tumors in mice could be diminished by 
treatment with leflunomide, a DHODH inhibitor. 
 
In the following chapter, we aimed to identify the mechanisms leading to cell death in PTEN mutant cells 
upon DHODH inhibition.  We found that inherent defects in checkpoint regulation in PTEN-deficient cells 
were exacerbated by the stress of obstructed de novo pyrimidine synthesis, leading to a buildup of DNA 
damage at replication forks and ultimately chromosomal breaks.  This was instigated by AKT-mediated 
phosphorylation of TOPBP1 that caused inadequate ATR activation, as well as AKT-mediated 
phosphorylation and inactivation of CHK1.   
 
In sum, the findings of this thesis indicate that enhanced glutamine flux to de novo pyrimidine synthesis 
in PTEN mutant cells generates vulnerability to DHODH inhibition.  The integration of altered glutamine 
regulation with PTEN’s effect on replication, DNA damage, and the checkpoint response manifests as 
synthetic lethality upon DHODH inhibition in cells with PTEN inactivation.  Inhibition of DHODH could 
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Chapter 1: Introduction 
 
Cancer is an ancient disease.  Tumors in other species occurred well before the evolution of humans, 
and even among people cancer was medically recognized early in civilization.  The first written record of 
cancer is from Egypt in 2500 BCE, in which a papyrus scroll thought to be the notes of the physician 
Imhotep described a hard mass bulging from the breast of a patient — the first known documentation of 
what was likely breast cancer.  While we cannot be certain that this was indeed the first case report for 
cancer, further early proof of human cancer came from archeologists who found evidence of a 
preserved abdominal cancer from 400 CE as well as a 2000-year-old mummy with what looks like bone 
cancer.  Archeologists have also found a 2 million-year-old bone with markings that appear to have been 
caused by lymphoma (Mukherjee 2010). 
 
A modern history of cancer 
In the present day, cancer is now the 2nd leading cause of death in the United States (as concluded by 
the CDC, Centers for Disease Control and Prevention).  We have come a long way since 4500 years ago in 
our understanding of the disease, and new research in the field is growing at a remarkable pace.  
However, much remains to be learned about this deadly foe.  The introduction to this thesis will give a 
brief overview of cancer, discuss the field of cancer metabolism, and describe an important gene in 
tumor suppression called PTEN. 
 
Cancer is primarily characterized by abnormal growth.  This can be due to a genetic mutation either in 1) 
a proto-oncogene, which when mutated is an oncogene, or 2) a tumor suppressor gene.  Oncogene 
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changes are usually gain-of-function, creating either a constitutively active protein or enhancing 
expression or activity, ultimately causing excessive pro-growth signaling in the cell.  Tumor suppressor 
changes have the same ultimate effect but are typically loss-of-function, thereby removing the brakes 
on cellular growth (Lodish, Berk et al. 2000). 
 
Such mutations are the root of the “hallmarks of cancer,” a phrase coined by Drs. Hanahan and 
Weinberg in 2000.  They organized known facets of cancer into a set of defining characteristics which 
they argued collectively create tumors in most cases.  In their review, the authors described the 
following capabilities that define a tumor: to begin with, a cancer cell must exhibit sustained 
proliferative signaling due to oncogenic alterations described above.  This leads to the deregulation of 
signaling pathways so that a tumor cell can maintain growth even in the absence of growth signals.  
Coupled to this is the ability to ignore growth suppressive signals and avoid cell death.  Cancer cells must 
also be immortal and able to replicate indefinitely.  In order to do so, the tumor must undergo 
angiogenesis to facilitate adequate avenues for nutrients.  Lastly, most tumors metastasize to other 
parts of the body distinct from the site of the primary tumor (Hanahan and Weinberg 2000). 
 
11 years later, the authors revised the original list to include newly found characteristics that may also 
be essential for tumor development. The first of these traits is the ability of a tumor cell to evade attack 
by the immune system; while immune cell inflammation can actually enable a tumor-promoting 
microenvironment, immune cells also target cancer cells for elimination.  The second trait exhibited by 
cancer cells is the reprogramming of cellular energetics and metabolism (Hanahan and Weinberg 2011).  





One of the most commonly mutated tumor suppressors is PTEN: Phosphatase and Tensin homolog 
deleted from chromosome ten (Keniry and Parsons 2008).  It was first discovered in 1997 by two 
independent groups: Li et al mapped a region on chromosome 10 that they found to be frequently 
mutated (Li, Yen et al. 1997), and Steck et al scanned the region deleted in gliomas and isolated a gene 
they termed MMAC1 (mutated in multiple advanced cancers 1) (Steck, Pershouse et al. 1997).  We now 
know that MMAC1 is PTEN.   
 
Germline mutations of PTEN can cause autosomal dominant disorders such as Cowden syndrome, 
characterized by benign growths called hamartomas; patients with Cowden syndrome do have a higher 
risk of getting cancer (Liaw, Marsh et al. 1997).  Recently, an analysis of over 4700 tumors revealed PTEN 
to be among the top three genes significantly mutated both within a tumor type as well as in a pan-
cancer cohort, validating the importance of PTEN as a hub for our understanding of cancer (Lawrence, 
Stojanov et al. 2014).  
 
As a tumor suppressor, PTEN has an interesting property: it is haploinsufficient, meaning that just one 
mutated copy of the gene is enough to cause a phenotype.  Pten heterozygous mice had neoplasms in 
the liver, GI tract, endometrium, and prostate, among others, and homozygous loss of Pten was actually 
found to be embryonic lethal in mice (Podsypanina, Ellenson et al. 1999).   Intermittent levels of Pten in 
shRNA engineered mice led to hyperplasia in lymph nodes and prostate, as well as sebaceous 
adenomas, corroborating that partial reduction of Pten is sufficient for a tumorigenic phenotype (Shen-
Li, Koujak et al. 2010).  A series of mice with incremental Pten also revealed dose-dependency for 
prostate cancer progression (Trotman, Niki et al. 2003).  This is an interesting feature because tumor 
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suppressors have previously been thought to behave recessively; that is, if one intact copy of the gene is 
present, the cell is protected from adverse effects.  Haploinsufficency in a tumor suppressive setting can 
be due to interactions with other tumor suppressors or oncogenes.  For example, either heterozygous or 
homozygous loss of PTEN hastened the progression of HER2+ breast cancer in mice, leading to an 
increase in HER2 protein levels without increasing HER2 transcript levels and ultimately causing a more 
basal-like and aggressive tumor (Dourdin, Schade et al. 2008).  Additionally, while the genetic disruption 
of PTEN may be heterozygous, the intact copy of PTEN may not be well expressed.  Both the liver and 
thymus of Pten heterozygous mice were found to have downregulated the wild-type (WT) copy of Pten 
(Podsypanina, Ellenson et al. 1999).  This downregulation would cause the effective expression of Pten 
to be (potentially much) less than 50%, initiating cellular effects similar to those produced by 
homozygous mutations.  As a corollary, “Super-PTEN” mice with elevated PTEN had anti-tumorigenic 
properties, and the cells were resistant to oncogenic transformation (Garcia-Cao, Song et al. 2012).  
Overall, the sum of these studies demonstrates the importance of PTEN levels in cancer progression.   
 
PTEN is a fulcrum of multiple cellular functions.  Its canonical role is that of a lipid phosphatase; in fact, 
its lipid phosphatase activity has been shown to be critical for tumor suppression.  PTEN 
dephosphorylates the lipid second messenger phosphatidylinositol (3,4,5) tri-phosphate (PIP3) on the 
D3 phosphate site, resulting in phosphatidylinositol (4,5) bi-phosphate (PIP2) (Maehama and Dixon 
1998, Myers, Pass et al. 1998).  Through this, PTEN directly reverses the action of phosphoinositide 3-






The PI3K pathway 
PI3K can be activated by receptor tyrosine kinases (RTKs) on the cell surface, which dimerize and are 
activated upon binding to a ligand (Vanhaesebroeck and Waterfield 1999).  For example, the PDGF 
(platelet-derived growth factor) receptor is autophosphorylated when it is bound by PDGF.  This 
subsequently actives PI3K, as long as RAS is also activated (Klinghoffer, Duckworth et al. 1996).  Tyrosine 
phosphorylation of IRS-1 (Insulin receptor substrate 1) upon binding insulin also activates PI3K (Backer, 
Myers Jr et al. 1992).  Interestingly, the PI3K-activating RTKs HER2 (human epidermal growth factor 
receptor 2) and EGFR (epidermal growth factor receptor) have been found to be amplified in cancer 
(Sauter, Maeda et al. 1996, Moasser 2007).  G-protein-coupled receptors can also activate PI3K in 
certain cells (Vanhaesebroeck and Waterfield 1999).  Activated PI3K then sets off a chain of pro-growth 
signaling effects.  First, PI3K phosphorylates PIP2 to generate PIP3; PIP3 levels have been found to 
correlate with cellular growth and transformation (Serunian, Auger et al. 1990).  This is in part due to a 
protein called AKT.  
 
AKT, also called protein kinase B (PKB), is a serine/threonine protein kinase.  At the plasma membrane, 
AKT binds PIP3 through its lipid-binding PH (pleckstrin homology) domain, thereby causing a 
conformational change and exposing its phosphorylation sites.  This allows phosphoinositide-dependent 
kinase 1 (PDK1), which is also activated by PIP3, to phosphorylate AKT on its threonine 308 site (Alessi, 
James et al. 1997, Stephens, Anderson et al. 1998).  The partially phosphorylated AKT is then able to 
phosphorylate and suppress TSC2 and PRAS40, suppressors of mTOR (mammalian target of rapamycin), 
thus indirectly activating mTOR (Inoki, Li et al. 2002, Manning, Tee et al. 2002, Haar, Lee et al. 2007).  
mTOR has the ability to form 2 complexes: rapamycin-sensitive mTORC1 with raptor, and mTORC2 with 
rictor (Hara, Maruki et al. 2002, Kim, Sarbassov et al. 2002, Loewith, Jacinto et al. 2002, Dos, Ali et al. 
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2004).  AKT is further phosphorylated at its serine 473 site by mTORC2 and DNA-PK (DNA-dependent 
protein kinase) (Feng, Park et al. 2004, Sarbassov, Guertin et al. 2005).  In fact, it was found that S473 
phosphorylation by DNA-PK increased AKT activity 10 fold (Feng, Park et al. 2004).   
 
An active mTORC1 phosphorylates its downstream effectors, including p70 S6 kinase and 4E-BP1.  
Phosphorylation of the latter allows release from a repressive complex and initiation of translation 
(Burnett, Barrow et al. 1998).  S6 kinase further enhances translation by phosphorylating the ribosomal 
protein S6 as well as eukaryotic translation initiation factor 4B (eIF4B) (Raught, Peiretti et al. 2004).   
 
Tumor cells from Pten+/- mice have been shown to have both elevated phospho-AKT and active S6 
kinase.  The latter was affected by an mTOR inhibitor while phospho-AKT was intact, and the observed 
reduction in tumor size indicates the importance of this downstream effector in neoplastic development 
(Podsypanina, Lee et al. 2001). 
 
Fully-activated AKT with both T308 and S473 phosphorylated triggers increased proliferation as well as 
anti-apoptotic signals.  This can be accomplished in multiple ways; for example, AKT phosphorylates the 
cell cycle regulator p21, localizing the protein to the cytoplasm to prevent its nuclear function (Zhou, 
Liao et al. 2001).  GSK-3β phosphorylates cyclin D1, encouraging its export from the nucleus and 
subsequent degradation.  AKT phosphorylates and inhibits GSK-3β, thus allowing cyclin D1 action and 
progression through G1 and S phases (Diehl, Cheng et al. 1998, Alt, Cleveland et al. 2000).  Furthermore, 
AKT promotes cell survival by phosphorylating and inhibiting the pro-apoptotic protein BAD (Datta, 
Dudek et al. 1997, Peso, González-Garcıá et al. 1997, Datta, Katsov et al. 2000) as well as by 
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phosphorylating MDM2, allowing the latter’s localization to the nucleus to inhibit pro-apoptotic p53 
(Mayo and Donner 2001, Zhou, Liao et al. 2001).  AKT also phosphorylates and inhibits FoxO (Forkhead 
box O) transcription factors, preventing their growth inhibitory effects (Zhang, Tang et al. 2011).   
 
Consequently, unchecked AKT activation is oncogenic, and phosphatases of AKT as well as the action of 
PTEN upstream curb AKT activity.  Loss of PTEN, therefore, could mimic constitutively active AKT that 
could otherwise occur from sustained growth factors or cytokine signaling (Stambolic, Suzuki et al. 
1998).  By limiting PI3K and hence AKT, PTEN acts as a brake on excessive cellular growth.  Notably, 
mutations in PIK3CA (encoding the catalytic p110α subunit of PI3K) are also found in cancer, signifying 




PTEN has additional functions outside the PI3K pathway.  It has the capability of dephosphorylating 
proteins on serine, threonine, and tyrosine residues, earning it the title of a dual-specificity phosphatase 
(Myers, Stolarov et al. 1997).  While PTEN’s protein phosphatase activity has not been as well 
characterized as its role as a lipid phosphatase, there is evidence that it is important in cell cycle 
regulation.   
 
Furnari et al showed in 1998 that introducing PTEN in U87 cells (which are PTEN null) caused GI cell cycle 
arrest, as tested by a BrdU assay.  This phenotype was detectable in 2% serum but not in 10% serum 
conditions, indicating that the effect was growth factor related.  Based on a TUNEL assay which detects 
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DNA fragmentation, they also showed that PTEN expression in U87 cells did not cause apoptosis 
(Furnari, Huang et al. 1998).  Building on these data, Weng et al created PTEN mutants which were 
either completely phosphatase dead (C124S) or lipid phosphatase dead but with its protein phosphatase 
activity retained (G129E).  Both mutants restored growth in MCF-7 cells compared to WT PTEN which 
reduced growth, indicating that its protein phosphatase activity plays a role in growth suppression.  
Furthermore, WT PTEN caused G1 arrest, the G129E mutant restored the defect, and the C124S 
enhanced the cell cycle even more, suggesting a role for both protein and lipid phosphatase activities.  
The authors also found that PTEN lipid phosphatase activity upregulates p27 while its protein 
phosphatase activity down regulates cyclin D1, both having the effect of preventing cell cycle 
progression at G1 (Weng, Brown et al. 2001).  We will discuss PTEN’s role in the cell cycle in more detail 
in chapter 4.   
 
Additionally, PTEN affects cell migration and invasion in a mechanism independent of the PI3K pathway.  
PTEN was found to bind PREX2 and inhibit its GEF activity, thereby preventing activation of RAC1, a 
protein that drives cell mobility.  Interestingly, PREX2 is mutated in cancer and these mutants appear to 
lose the ability to be inhibited by PTEN (Mense, Barrows et al. 2015). 
 
Nuclear PTEN 
The cell membrane is the site of action for PTEN’s role in the PI3K pathway, but PTEN has also been 
found in the nucleus of cells, including breast ducts and neurons.  It is thought that the presence of PTEN 
in the nucleus is important for tumor suppression, since neoplastic cells exhibit more cytosolic 
localization of the protein (Planchon, Waite et al. 2008).  It was also shown in a screen of 92 patients 
with primary melanoma that a majority of the tumors had decreased nuclear PTEN.  In this study, 
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immunohistochemistry stains were scored on a 3-level scale of negative/low, decreased, and normal 
levels of PTEN levels; while 33% of samples had decreased cytoplasmic staining, 91% exhibited 
decreased nuclear staining, suggesting an association between melanoma and loss of nuclear 
localization (Whiteman, Zhou et al. 2002). 
 
Exclusion of PTEN from the nucleus can be due to mutation.  The lysine 289 site on PTEN is normally 
monoubiquitinated by the E3 ubiquitin ligase NEDD4, which allows PTEN to cross the nuclear 
membrane.  Once inside the nucleus, the site is deubiquitinated so that PTEN can no longer permeate 
the membrane and remains localized in the nucleus.  However, a naturally occurring mutation in 
Cowden syndrome, K289E, is unable to be ubiquitinated and cannot get into (or out of) the nucleus.  An 
additional mutation that occurs in gliomas, K13E, confers a similar defect in nuclear import (Trotman, 
Wang et al. 2007). 
 
Along the same lines, it has been shown that PTEN is SUMOylated (SUMO, small ubiquitin-like modifier) 
on lysine 254.  A mutation of this site, K254R, renders PTEN no longer localized to nucleus.  Addition of a 
nuclear export inhibitor revealed PTEN to still be found in the nucleus.  Therefore, mutation of the 
SUMO site, unlike the ubiquitination site above, allows PTEN to enter the nucleus but not be retained 
there (Bassi, Ho et al. 2013). 
 
Once inside the nucleus, the role of PTEN may involve chromatin stability and the cell cycle, as described 





Ubiquitination of PTEN can also affect its protein levels.  While monoubiquitination led to nuclear 
transport, as described above, polyubiquitination by NEDD4 led to degradation by the proteasome.   
Knockdown of NEDD4 led to increased PTEN protein levels, showing that NEDD4 acts as a negative 
regulator of PTEN.  Furthermore, in human bladder cancer samples the amount of PTEN protein was 
anticorrelated with NEDD4 mRNA (Wang, Trotman et al. 2007). 
 
PTEN protein stability is also regulated by phosphorylation of its C-terminal tail domain.  S380, T382, and 
T383 residues are phosphorylated by protein kinase CK2 (casein kinase II ) (Torres and Pulido 2001).  
Vazquez et al found that mutating these sites from serine or threonine to alanine lowered the half-life of 
the protein but also increased its enzymatic activity.  Removal of the tail domain resulted in less stability 
but not less function, because the resulting protein had a higher enzymatic capability.  Phosphorylation 
of the tail domain thus appears to regulate PTEN in dual manner, by maintaining protein stability while 
keeping its function in check (Vazquez, Ramaswamy et al. 2000).  Phosphorylation of the C-terminal 
region in this manner also protects PTEN from cleavage by caspase 3, thereby preventing further protein 
instability (Torres, Rodriguez et al. 2003).  Dephosphorylation of PTEN, on the other hand, exposed 
cationic residues that can electrostatically interact with the lipid bilayer and allowed its targeting to the 
membrane.  This can explain the increased activity of PTEN in a dephosphorylated state, since the 
membrane is the site of action for PTEN’s role in the PI3K pathway (Das, Dixon et al. 2003). 
 
In addition to regulation by phosphorylation, acetylation can alter the function of PTEN.  It has been 
shown that PTEN and the histone acetyltransferase PCAF (p300/CBP-associated factor) can physically 
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interact, resulting in acetylation of lysines 125 and 128 on PTEN.  This led to a reduction of PTEN activity 
and a consequent increase in AKT phosphorylation (Okumura, Mendoza et al. 2006). 
 
PTEN can be regulated not only at the level of protein stability, but also transcriptional expression.  
Methylation of the PTEN promoter can induce loss of expression of the gene, as seen in secondary 
glioblastomas.  Interestingly, this can occur independently of any genetic mutation of PTEN (Wiencke, 
Zheng et al. 2007).  PTEN has also been found to be the target of several microRNAs (miRs), short non-
coding RNAs that can repress translation of mRNAs (Meng, Henson et al. 2007, Mouw, Yui et al. 2014, 
Tokudome, Sasaki et al. 2015).  These discoveries corroborate the findings of Podsypanina et al 
described above, in which WT Pten alleles were downregulated; in light of the successive research, 
epigenetic changes and post-transcriptional repression are likely contributing causes of such 
dysregulation.  
 
As described above, PTEN can regulate the activity of PREX2.  As an interesting complementarity, PREX2 
can regulate PTEN as well.  PREX2 was found to inhibit the lipid phosphatase function of PTEN, and the 
ability of PREX2 to activate PI3K was dependent on its inhibition of PTEN.  Its expression positively 
correlated with human cancer cells with WT PTEN and mutant PIK3CA, and in the setting of a PIK3CA 
mutation PREX2 assisted oncogenic transformation and growth (Fine, Hodakoski et al. 2009). 
 
p53 is an important tumor suppressor; in fact, it has been revealed to be the gene with the highest 
penetration within a tumor subtype as well as across all cancers (Lawrence, Stojanov et al. 2014).  
Interestingly, there is a p53 binding site on the PTEN promoter, and increased p53 protein has been 
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shown to lead to increased PTEN mRNA expression (Stambolic, MacPherson et al. 2001).  As an ancillary 
finding, PTEN can also regulate p53.  Freeman et al showed that adding either WT or phosphatase-dead 
PTEN to cells lacking PTEN increased the protein stability of p53, indicating that the enzymatic activity of 
PTEN is not required to stabilize p53.  Additionally, PTEN increased the ability of p53 to bind DNA to 
carry out its transcriptional activity (Freeman, Li et al. 2003).  Thus, PTEN positively affects p53 function 
in two ways, and p53 positively regulates PTEN in kind.  These results demonstrate a thought-provoking 
way in which an inter-tumor suppressor network is mediated. 
 
PTEN in cancer 
Allow us to now pivot from the intracellular facets of PTEN to the part it plays in cancer as a whole.  In 
this section we will cover brain, breast, and prostate cancer, as PTEN is frequently deregulated in these 
tumor types.  
 
Glioblastoma multiform (GBM) is a subset of gliomas and the most common type of malignant brain 
tumor. The current available treatment options are surgical resection, radiation, and the adjuvant 
administration of the chemotherapeutic agent temozolomide (TMZ).  TMZ is an oral medication and is a 
DNA-alkylating agent, which damages DNA and causes cell death.  However, even with the above 
treatments, median survival for patients with GBM is only 12-18 months (Bush, Chang et al. 2016).  75% 
monoallelic loss and 30% biallelic loss of PTEN have been observed in gliomas (Keniry and Parsons 2008).  
Furthermore, PTEN loss has been correlated to a shorter average survival time in these patients (Yang, 




Prostate cancer is the second most common type of cancer in men (Siegel, Miller et al. 2016). In addition 
to surgery and radiation therapy, prostate cancer patients are most commonly given androgen 
deprivation therapy.  Testosterone is the primary androgen in the body, and many prostate tumors are 
at least partly androgen-dependent; i.e. circulating systemic androgens fuel the cancer.  Castration-
resistant disease is characterized by the progression of a prostate tumor despite lower systemic 
testosterone levels due to androgen deprivation therapy.  Although a few other endocrine therapies or 
immunotherapies are options, patients with castration-resistant prostate cancer are typically given 
chemotherapy, usually docetaxel.  The PI3K pathway is altered in some way in almost all cases of this 
disease, and the most common alteration in prostate cancer overall is PTEN loss: 42% exhibit 
monoallelic loss and 10% exhibit biallelic loss (Keniry and Parsons 2008, Statz, Patterson et al. 2016).  
Several mTOR and PI3K inhibitors have been in clinical trials, either alone or in combination with 
chemotherapy, but so far only modest effects have been observed (Statz, Patterson et al. 2016).  PTEN 
loss also leads to resistance to chemotherapy in prostate cancer, perhaps due to upregulation of the 
anti-apoptotic protein Bcl-2 (Huang, Cheville et al. 2001).   
 
Of the several subtypes of breast cancer, the most aggressive is triple negative breast cancer (TNBC), 
characterized by low expression of estrogen receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (HER2).  There are currently no targeted therapies for this disease 
that have been approved, leaving only chemotherapy (usually paclitaxel or carboplatin) as the standard 
of care.  Hence, 50% of women with TNBC choose mastectomies (Sharma 2016).  TNBC also bears 
frequent PTEN alterations, with 40-50% of cases containing monoallelic loss, and 5% biallelic loss (Keniry 




It is important to note that the actual level of PTEN protein loss in these cancers may be even more 
pronounced than their respective mutational frequencies, due to epigenetic downregulation or other 
regulatory mechanisms described above which could further depress the amount of functional PTEN. 
 
A common theme in the cancers we described here is a dependence on chemotherapy for treatment.  
Chemotherapy can fall under two major categories:  Taxanes are compounds originally derived from 
yew trees (of the genus Taxus).  These compounds disrupt microtubules by stabilizing their GDP-bound 
form and preventing their deploymerization.  Microtubule function is dependent on its ability to 
dynamically polymerize and depolymerize, and disruption by taxanes leads to an inhibition of mitosis.  
Preventing cell division reduces tumor growth, but also leads to systemic toxicities including peripheral 
neuropathy.  Patients may also exhibit neutropenia, described by an abnormally low count of 
neutrophils, a type of white blood cell, ultimately leading to an increased susceptibility to bacterial 
infection (Rowinsky 1997).  Anthracyclines, on the other hand, intercalate DNA and thereby prevent its 
synthesis.  These compounds inhibit topoisomerase, a protein which uncoils DNA to assist replication.  In 
patients, anthracyclines can cause cardiotoxicity (Minotti, Menna et al. 2004).   
 
These methods of chemotherapy usually affect any dividing cell, thus disturbing some healthy non-
tumor cells in the body as well.  Radiation also does not necessarily discriminate between tumor vs non-
tumor tissue.  Finding successful targeted therapies for cancer is a great challenge, but an important 
goal in the face of insufficient treatment options.  Targeted therapies that are tumor-specific are much 
needed, and identifying changes based on specific tumor suppressor or oncogene alterations will 
facilitate this effort.  In fact, targeted therapies for certain subtypes of breast cancer, among others, 
15 
 
have already been proven to be clinically successful.  Due to the high mutation rate of PTEN in cancer, 
the effects of PTEN could be at the heart of targeted therapy.  
 
Metabolism 
Allow us to pivot to cancer metabolism, which could be the core of both developing new targeted 
therapies and indeed our understanding of cancer en masse.  Cancer metabolism is presently a cutting-
edge field, and there has been a storm of new research in the past 15 years or so.   
 
To understand cancer metabolism we must first review some normal metabolic pathways, the 
corruption of which will be the topic of this section.  
 
In brief:  
Glucose is an important sugar for the cell, and is processed through glycolysis which produces NADH, 
minor amounts of ATP, and pyruvate.  Intermediates of glycolysis are also used for biosynthesis, such as 
ribose 5-phosphate from the glucose 6-phosphate-derived pentose phosphate pathway (PPP).  The PPP 
also generates reducing power in the form of NADPH, and the ratio of NADP+ to NADPH helps determine 
the flux into the pathway.   
 
In anaerobic conditions (such as highly active skeletal muscle), pyruvate is fermented to lactate for the 
regeneration of NAD+.  In aerobic conditions, pyruvate is transported into the mitochondrion and used 
for the tricarboxylic acid (TCA) cycle, which further produces NADH and FADH2 as electron carriers for 
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respiration.  As with glycolysis, intermediates of the TCA cycle such as aspartate and citrate can also be 
used for biosynthesis of macromolecules.  The TCA cycle has multiple imports as well; glutamine and 
other amino acids can be oxidized by this circular pathway.   
 
In the electron transport chain, the flow of electrons through various complexes pumps protons into the 
mitochondrial intermembrane space.  The motion of the proton gradient through ATP synthase 
generates copious amounts of ATP, providing energy for various cellular reactions.  
 
Glutamine is another critical metabolite for cellular function.  As mentioned, it can join the TCA cycle 
and by doing so can maintain adequate levels of TCA intermediates.  Nitrogen from glutamine is 
donated to nucleotide synthesis, a function that will be important in this thesis (Nelson, Lehninger et al. 
2008). 
 
In actuality, the metabolic processes in mammalian cells are far more complex and involve myriad other 
interacting players and pathways.  Although drastically simplified, the above framework will help us 
compare normal metabolism to the distorted versions found in tumors. 
 
It is somewhat surprising that the metabolic links to cancer were overlooked until fairly recently, 
because the targeting of metabolites was among the first developments in cancer therapy.  The first 
antimetabolite was an antifolate, designed and produced by Yellapragada Subbarao (Hutchings, Mowat 
et al. 1947) and given to patients by Sydney Farber.  At the time, folates were given to patients with 
anemia; but, when Farber administered folates to leukemia patients their condition worsened.  He 
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reasoned that an antifolate would have the opposite effect, and Subbarao developed a compound that 
was similar to folate but with slight differences that would inhibit its activity.  They found that of 16 
patients given this experimental drug, 10 improved and several were in remission for a few months, a 
considerable amount of time for leukemia patients.  Although the leukemia eventually relapsed, the 
antifolate was considered quite successful (Farber , Diamond  et al. 1948). 
 
Glucose metabolism 
Even before the advent of a metabolic therapy, an abnormal metabolic state in tumors was observed by 
a man named Otto Warburg.  In 1924, he discovered that rat liver carcinomas produced a heightened 
level of lactic acid but did not consume more oxygen, and published another paper the same year 
quantifying that the amount of lactate produced by tumor cells was actually double that of normal cells 
(Koppenol, Bounds et al. 2011).  Warburg also discovered that tumor cells take up more glucose than 
normal cells: he measured the concentrations of glucose in blood vessels leading to and from the tumor, 
and found that while most normal cells take up 2-16mg glucose from 100cc blood, tumors take up 70mg 
glucose from the same volume.  A key aspect here is his calculation that 66% of the glucose was 
converted to lactate regardless of oxygen availability, with the remainder left for respiration (Warburg, 
Wind et al. 1927).  This phenomenon is called aerobic glycolysis. 
 
The seminal papers by Warburg laid the groundwork for a plethora of research into altered metabolic 
pathways in cancer.  In fact, the observation that most tumors consume high levels of glucose is what 
allows visualization of tumors in the clinic by FDG-PET: 18-fluoro-2-deoxyglucose positron emission 
tomography uses radio-labeled glucose which is taken up by tumors and visualized by sensors that can 




There remained, however, an outstanding question: why do tumors take up extra glucose?  Since it 
occurs even in the presence of sufficient oxygen for respiration and intact mitochondria, the tumors are 
not being forced to use glycolysis for energy.  In fact, the use of glycolysis for ATP production is far less 
efficient than production via the electron transport chain, and Warburg’s evidence showed that even 
after lactate production there was enough glucose left to be fully oxidized in the mitochondria.  The 
current theory is that the increased glucose uptake is not for energy at all; rather, it is used as a 
precursor for synthesizing macromolecules required for cellular (and tumor) growth.   
 
Normal adult tissues express the M1 isoform of pyruvate kinase, the enzyme that converts 
phosphoenolpyruvate to pyruvate in glycolysis.  Christofk et al showed that tumor cells express the M2 
isoform, which actually has less enzymatic activity than M1 does.  This may instigate the switch to 
aerobic glycolysis since glucose is less efficiently brought to the mitochondria, and cause a backup of the 
pathway intermediates into anabolic channels that branch off of glycolysis.  The authors also found that 
knockdown of the M2 isoform in lung cancer cells reduced glucose metabolism and slowed proliferation 
(Christofk, Vander Heiden et al. 2008).   
 
The pentose phosphate pathway is one such offshoot from glycolysis that has multiple anabolic 
capabilities.  The PPP generates NADPH for reductive biosynthesis reactions, ribose 5-phophate as a 
sugar for nucleotides, and erythrose 4-phosphate used in amino acids with ring structures.  Glucose-6-
phosphate dehydrogenase (G6PD) shunts glucose-6-phosphate from glycolysis into the first step of the 
PPP.  Backup of pathway intermediates (e.g. by PKM2 described above) could increase the production of 
PPP metabolic building blocks.  X-linked deficiency of G6PD, found in men, does not decrease their risk 
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of cancer and this finding has shed some doubt on the importance of the PPP in cancer development 
(Ward and Thompson 2012).  However, it is difficult to associate risk factors with molecular 
mechanisms.  It is possible that the PPP is more vital for cancer progression in certain tissues or under 
specific regulation; since these factors were not used to stratify the risk study, a meaningful association 
could be clouded.  Other anabolic pathways may also be employed in the face of G6PD deficiency.  This 
does not mean that the shunting of glucose into the pathway is irrelevant to cancer development. 
 
Aerobic glycolysis can be triggered by oncogenic mutations as well.  HIF-1 is a transcription factor, which 
during hypoxia is not degraded and increases the transcription of glucose transporters and lactose 
dehydrogenase A (LDH-A) which converts pyruvate to lactate.  When faced with insufficient oxygen cells 
are forced to increase glucose uptake and produce energy from glycolysis, and HIF-1 mediates this 
transition.  However, mutations in VHL, which usually targets HIF-1 for degradation, can constitutively 
activate HIF-1, leading to aerobic glycolysis.  Mutations in fumarate hydratase (FH) or succinate 
dehydrogenase (SDH) can also cause constitutively active HIF-1 (DeBerardinis, Lum et al. 2008). 
 
A surge in glucose uptake can initiate increased synthesis of lipids.  Downstream of glycolysis, citrate is 
generated in the TCA cycle.  Citrate can also be exported from mitochondria to be made into 
oxaloacetate and acetyl-CoA, the latter of which is used as a lipid precursor. In fact, citrate efflux from 
mitochondria correlated with proliferation rate in hepatomas, suggesting that the biosynthesis of lipids 






An additional branch off of glycolysis is initiated by 3-phosphoglycerate (3PG).  Single-carbon 
metabolism is so named due to the donation of individual carbons from amino acids for nucleotide 
production.  3PG can be converted to the amino acid serine, which is then converted to glycine.  This 
process concurrently converts tetrahydrofolate (THF) to methyl tetrahydrofolate (mTHF), facilitating the 
folate cycle that contributes to making purines.  2PG can also activate 3PG.   
 
Phosphoglycerate dehydrogenase (PHGDH) is the enzyme responsible for committing 3PG into serine 
synthesis, and has been found to be upregulated in melanoma and some breast cancers.  PHGDH 
expression correlated with cancer progression, and its knockdown led to reduced cellular growth 
(Locasale, Grassian et al. 2011).  Furthermore, in the NCI-60 panel of human cancer cell lines, the 
Warburg effect itself was not correlated with cell proliferation rate, while glycine uptake was the 
metabolite most strongly correlated with growth (Locasale 2013).  Glycine cleavage also contributes to 
the folate cycle, linking this piece of data to the importance of single-carbon metabolism in cancer 
growth.  When mice with xenografted colon cancer cells were deprived of serine and glycine from their 
diet, their tumors exhibited reduced growth (Locasale 2013). 
 
5-fluorouracil (5FU) is the standard of care for some cancers.  This drug blocks the methylation of dUMP 
to dTMP and disrupts the folate cycle.  Metformin, also being explored as a cancer treatment, can inhibit 
one-carbon metabolism (Locasale 2013).   It appears that the investigation of folates in cancer has come 
full circle from Syndey Farber’s experiments with antifolates in the 1940s.  Actually, inhibition of 
nucleotides in general has been studied as a therapeutic approach.  Gemcitabine, used for pancreatic 
cancer, interferes with cytidine production (Locasale 2013).  Conversely, it has been shown that 
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expression of the HPV oncogene leads to a decrease in all nucleotides, and that adding exogenous 
nucleotides decreased DNA damage (Bester, Roniger et al. 2011).  Interfering with nucleotide synthesis 




Glutamine is a biologically thought-provoking amino acid.  Mammals are capable of synthesizing it in 
most settings, but rapidly proliferating cells have a requirement for glutamine greater than what is 
internally produced – making it a conditionally essential amino acid (DeBerardinis and Cheng 2010). 
 
Human hepatoma cells have been shown to take up glutamine faster than normal hepatocytes (Bode 
2002).  Once inside the cell, glutamine is processed to glutamate by the enzyme glutaminase; 
interestingly, glutaminase activity was correlated with the growth rate of hepatic tumors in rats (Linder-
Horowitz, Knox et al. 1969). 
 
The association between glutamine uptake and cancer raises the question of its objective in a tumor 
cell.  From the annals of literature, it appears that glutamine serves multiple purposes in different 
situations.  A schematic of some of the functions of glutamine is depicted in figure 1.2 (DeBerardinis, 




Glutamate is converted to alphaketoglutarate, an intermediate of the TCA cycle, which can then 
continue being processed through the TCA cycle.  Using 14C labeling, Coles and Johnstone found that 
Ehrlich ascites-carcinoma cells have greater glutamine usage than normal cells, and that it is used 
primarily for replenishing TCA cycle components (Coles 1962).  It is possible that if the majority of 
intracellular glucose is being used for anabolic purposes rather than processing by the TCA cycle, 
glutamine is required to fill in the gaps.   
 
However, glutamine can be more than just a stand-in for glucose.  Even in cells with adequate glucose 
flux through the TCA cycle, glutamine was used for the majority of TCA cycle intermediates and energy 
— these transformed HeLa cells preferentially chose to use glutamine as a major source of cellular 
energetics (Reitzer, Wice et al. 1979).  Glutamine is also used for the generation of reducing equivalents.  
One of the steps of glutaminolysis converts malate to pyruvate and NADPH, catalyzed by malic enzyme.  
In glioblastoma cells, glutamine produced enough NADPH in this manner to support a substantial 
amount of fatty acid synthesis that uses NADPH as an electron donor (DeBerardinis, Mancuso et al. 
2007). 
 
As discussed in the discourse about glucose metabolism, mutations in various genes can affect glucose 
utilization in different ways.  A similar situation is paralleled in glutamine metabolism.  One such 
important player in altering the fate of glutamine is the oncogene K-Ras, which alters the normal modus 
operandi of both glucose and glutamine metabolism.  KRAS mutations led to an increase in glucose 
uptake, but the excess glucose was not used for the TCA cycle.  Rather, glutamine was used to provide 
carbons for the TCA cycle, amino acid synthesis, and nucleotide production via aspartate, rendering 
glutamine just as (if not more) important as glucose in KRAS mutant cells (Gaglio, Metallo et al. 2011).  
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This might explain why depriving colorectal carcinoma cells of glucose increased selection for clones 
with mutant KRAS (or BRAF), since they can utilize glutamine for the majority of both energetics and 
macromolecular synthesis.  These clones also had increased expression of GLUT1 for more efficient 
glucose uptake, thus giving cells the power vested by K-Ras to employ both glucose and glutamine for 
cell growth (Yun, Rago et al. 2009). 
 
Cells with oncogenic Myc are also acutely sensitive to glutamine.  In fact, Myc elicits glutamine 
dependency; apoptosis was triggered in cells with activated Myc upon glutamine deprivation.  
Replenishing TCA cycle intermediates rescued cell death, indicating that glutamine flux is largely 
required for the TCA cycle, perhaps due to the demand for reducing equivalents (Yuneva, Zamboni et al. 
2007). 
 
In a remarkable twist, it has been shown that Myc actually diverts glucose toward lactate production in 
order to render cells more dependent on glutamine for TCA cycle intermediates and phospholipid 
synthesis (Wise, DeBerardinis et al. 2008).  This is facilitated by increased production of LDH-A in Myc 
transformed cells, which converts pyruvate to lactate and thereby increases lactate production from 
glucose (LDH-B catalyzes the reverse reaction) (Shim, Dolde et al. 1997).  Furthermore, enhanced Myc 
expression leads to an increase in the levels of glutamine importers ASCT2 and SN2, thus directly 
affecting glutamine uptake (Wise, DeBerardinis et al. 2008).  Intriguingly, LDH-A function is necessary for 
c-Myc to cause anchorage-independent growth in soft agar, indicating that the metabolic 
reprogramming to glutamine dependence is requisite for c-Myc to be tumorigenic (Shim, Dolde et al. 
1997).  The upregulatation of LDH-A renders c-Myc transformed cells sensitive to glucose as well: 
blocking glycolysis led to apoptosis, and ectopic expression of LDH-A in non-transformed cells induced 
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apoptosis when these cells were deprived of glucose, indicating that LDH-A expression is at least in part 
responsible for glucose dependence (Shim, Chun et al. 1998).  It is curious that the ability of Myc to 
divert metabolic pathways towards increased glutamine usage for heightened tumorigenicity also 
(perhaps inadvertently) creates a point of vulnerability in another pathway as well.  These results 
provide evidence that metabolic reprogramming is at the crux of cancer development.  
 
As oncogenes can regulate glutamine metabolism, so too can glutamine affect oncogenes.  The uptake 
of glutamine is a rate limiting step for mTOR activation, a protein that triggers cellular growth as 
mentioned above.  Glutamine is taken up by cells, but then is quickly effluxed in exchange for essential 
amino acids which activate mTOR.  The simultaneous efflux of glutamine and influx of amino acids is 
regulated by the transporter SLC7A5/SLC3A2, the inhibition of which led to growth arrest (Nicklin, 
Bergman et al. 2009). 
 
A fascinating paper by Newsholme et al asserts that the influx of glucose or glutamine in tumor cells 
often exceeds the rate that either metabolite can be oxidized or used for precursors, and that the high 
rate of uptake serves an additional purpose: the capability to fine-tune regulation.  High flux upstream 
means that the source of a nutrient is not a limiting factor, and that a cell can control how to direct the 
flux downstream with different oncogenic changes.  For example, a cell can increase macromolecule 
synthesis without increasing or decreasing energy production, since the node for regulation is 





Mitochondrial metabolism in cancer 
Mutations in mitochondrial components can also lead to metabolic reprogramming that is advantageous 
for a tumor (Zanssen and Schon 2005).  Using 13C glucose labeling, Mullen et al showed that in 
osteosarcoma cells with complex III mutations, glucose did not contribute any carbons to making citrate.  
This is unusual, since citrate is the first TCA cycle intermediate directly derived from acetyl-CoA, 
downstream of glycolysis.  Additionally, citrate had 5 of its carbons derived from glutamine, while 
normal progression of glutamine supplementing TCA cycle intermediates would contribute 4 carbons to 
citrate.  This suggested that citrate was being synthesized directly from glutamine-derived 
alphaketoglutarate into isocitrate, rather than going around the full TCA cycle.  The authors discovered 
that isocitrate dehydrogenase 1 and 2 (IDH1 and 2) were working in a reverse direction, converting 
alphaketoglutarate to isocitrate and then generating citrate.  The reverse TCA cycle continued with 
oxaloacetate succeeding citrate, followed by malate, fumarate, and succinate.  (Succinate, actually, was 
formed in both forward and reverse directions of the TCA cycle.)  This reversal caused citrate to produce 
acetyl-CoA in another reverse reaction, which was then used as a precursor for fatty acid synthesis. The 
phenomenon was named reductive carboxylation, and was also observed in a renal tumor line. In 
addition to its anabolic function, is possible that reductive carboxylation is used to rescue the 
NAD+/NADH ratio that is disturbed by mitochondrial mutation (Mullen, Wheaton et al. 2012). 
 
Mitochondrial abnormalities can also lead to a vicious cycle of tumorigenicity.  Hypoxia and glucose 
deprivation, which can occur in the poorly vascularized tumor core, leads to the generation of reactive 
oxygen species (ROS) in mitochondria.  These stabilize HIF-1 alpha, which in the short term leads to cell 
cycle arrest.  However, prolonged hypoxia can stabilize HIF-2 alpha which activates c-MYC transcription.  
Extended hypoxia also causes DNA damage and potentially more pro-tumorigenic mutations.  
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Conversely, stimulating ROS production excessively will overwhelm the cell and cause cell death.  While 
non-cancer cells have a lower threshold for ROS toxicity, a sufficiently high amount of ROS will 
ultimately kill tumor cells as well (Ralph, Rodríguez-Enríquez et al. 2010).  We will discuss the root of 
ROS further in chapter 2.  
 
Cancer cells may depend on mitochondrial DNA as well, since cells without mtDNA proliferated more 
slowly.  An intriguing study found that mtDNA-deficient tumor cells actually facilitated horizontal 
transfer of mitochondrial DNA from host cells to tumor cells.  The restoration of mtDNA reinstated 
respiratory function and tumorigenicity (Tan, Baty et al. 2015). 
 
 
Cause and effect 
Altered metabolism isn’t necessarily only a byproduct of oncogenic change, but a cause in and of itself.  
It was found that 80% of high-grade gliomas have a specific IDH1 mutation: R132H.  This mutation 
causes loss of function for the dephosphorylation of isocitrate, but also gains the unique capability to 
reduce alphaketoglutarate using NADPH.   This results in the production of the metabolite 2-
hydroxyglutarate (2HG) (Dang, White et al. 2009).  A similar mutation in IDH2 also produces 2HG, which 
has been labeled an “oncometabolite” due to its ability to cause promoter hypermethylation and inhibit 
TET2 and DNA demethylation. 2HG also has been shown to impair myeloid differentiation and thereby 




Independently of the generation of oncometabolites, mutations in metabolic genes can have direct 
effects on cancer.  Fumarate hydratase (FH) is a tumor suppressor, and loss of FH alleles have been 
found in renal cancer (Tomlinson 2002).  Mutations in succinate dehydrogenase (SDH) have also been 
linked to hereditary paraganglioma (Baysal, Ferrell et al. 2000). 
 
The dialogue of cause and effect is an important one – while it was previously thought that metabolic 
alterations were secondary to oncogenic signaling, it may well be the opposite.  Rationally, even if a cell 
has proliferation-driving oncogenic changes, unless the cell can produce enough macromolecules to 
sustain growth proliferation can’t occur and the oncogenic changes are moot.  Altered metabolism can 
therefore be considered crucial for tumorigenesis and tumor maintenance.  Metabolic pathways are not 




Metabolism affects cancer not only at a cellular level but on the organismal scale.  For example, data 
show that consumption of animal fat increases colorectal cancer risk, while dietary fiber reduces it.  
Colorectal cancer is particularly susceptible to changes in the diet, likely due to the sensitivity of gut 
microbiota.  In fact, switching from a high fiber/low fat and sugar diet to a diet rich in animal fat and 
processed sugar changes the composition of the microbiome within a day.  This is due in part to the 
ability of digested molecules to alter the inflammatory environment of the gut.  For example, some 
plants when digested produce butyrate which is an HDAC inhibitor and is anti-carcinogenic. On the other 
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hand, hydrogen sulfide is a byproduct from the digestion of some animal fats and can have a pro-
inflammatory effect (Bultman 2016). 
 
Non-gastrointestinal cancers are also susceptible to dietary modulation.  Obesity is associated with an 
increased risk of gall bladder, ovarian, pancreatic, kidney, liver, and endometrial cancers.  Each 
additional BMI point also directly correlates with metastasis in breast cancer.  However, the implications 
of obesity rather than body weight itself might be the actual contributors to tumor development (Klil-
Drori, Azoulay et al. 2016).  For example, obesity and diabetes can lead to insulin resistance.  
Hyperinsulinemia is associated with breast cancer risk, and it has been shown that insulin resistance 
leads to cancer (Goodwin, Pritchard et al. 2008).  In addition, insulin receptor levels have been observed 
to be 6 times higher in breast cancer cells compared to normal breast tissue (Papa, Pezzino et al. 1990).  
Metformin reduces the amount of insulin in blood and increases insulin sensitivity and uptake by tissues.  
It is used to treat diabetes, and appears to have anti-cancer properties as well; administration of 
metformin improved insulin resistance in breast cancer patients, even those without diabetes (Goodwin, 
Pritchard et al. 2008).   
 
PTEN pathway and metabolism 
Our discussion of insulin is the perfect transition into describing the known interactions between the 
PTEN pathway and metabolic pathways.  Insulin binds the insulin receptor on cells, which 
phosphorylates insulin receptor substrate 1 (IRS-1) which binds PI3K (Lee and Pilch 1994).  Increased 
circulating insulin therefore promotes PI3K signaling; it is possible that the relationship between insulin 
and breast cancer coalesces at PI3K.  Interestingly, Pten heterozygous mice exhibited enhanced insulin 
sensitivity and glucose uptake in skeletal muscle, suggesting that Pten negatively regulates insulin-
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stimulated glucose uptake.  In fact, following a glucose challenge, blood glucose levels returned to 
normal twice as quickly in Pten+/- mice compared to WT (Wong, Kim et al. 2007).  Patients with Cowden 
syndrome (germline PTEN mutation) also exhibited increased insulin sensitivity and higher body weight 
(Pal, Barber et al. 2012).  Insulin receptor substrate 2 (Irs2) deficiency caused insulin resistance and β–
cell failure; heterozygous deletion of Pten in Irs2-/- mice restored insulin sensitivity and glucose 
tolerance, and improved β–cell function (Kushner, Simpson et al. 2005).  As one may expect from the 
above data, mice with increased Pten expression have been shown to have lower body weight and fat, 
and their cells exhibited less glucose uptake (Garcia-Cao, Song et al. 2012, Ortega-Molina, Efeyan et al. 
2012).  Deletion of the Pten inhibitor Prex2 in MEFs reduced glucose uptake, and it was found that 
insulin-resistant patients exhibited decreased PREX2 and increased PTEN activity in adipose tissue 
(Hodakoski, Hopkins et al. 2014).   
 
Insulin also stimulates fatty acid synthase (FAS).  Inhibitors of PI3K prevented activation of the FAS 
promoter, while transfecting AKT into cells stimulated FAS independently of insulin.  This indicated that 
FAS activation is mediated by insulin through PI3K and AKT (Sul, Latasa et al. 2000).  As a complementary 
finding, PTEN null cells overexpress FAS, and reintroduction of PTEN in LNCAP cells reversed the FAS 
increase.  FAS is found to be elevated in cancer (Van de Sande, De Schrijver et al. 2002). 
 
We have already described the importance of fatty acid synthesis in tumor progression.  The PI3K 
pathway also contributes to lipid metabolism through an alternate mechanism.  Constitutively active 
AKT increases GLUT4 translocation to the membrane and increases expression of GLUT1, both of which 
bring glucose into the cell.  This has been shown to lead to constitutive lipogenesis (Kohn, Summers et 
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al. 1996).  AKT also phosphorylates and activates ATP citrate lyase (ACL) on S454, such that it can 
convert cytosolic citrate to acetyl-CoA as a precursor for lipids (Berwick, Hers et al. 2002). 
 
Studies in prostate cancer cells have also shown that loss of PTEN leads to an increase in the uptake of 
LDL (low-density lipoprotein), which is hydrolyzed to free fatty acids and free cholesterol that is then 
esterified.  This process was found to be dependent on PI3K and AKT.   The authors showed that 
blocking cholesterol esterification reduced prostate tumor growth in vitro and in vivo.  Moreover, the 
cholesterol found in lipid droplets in prostate cancer was not synthesized de novo but was in fact 
derived from the uptake of exogenous lipids.  These data argue for the use of cholesterol-reducing drugs 
for cancer, and there is evidence that statins have had an effect on decreasing the risk of prostate 
cancer (Yue, Li et al. 2014). 
 
Bringing our metabolic conversation full-circle, it has been shown that AKT stimulates aerobic glycolysis.  
While not all tumors were detected by FDG-PET, AKT-induced cells were visible on the scans, indicating 
their higher glucose uptake.  These cells also increased glycolysis: NADH levels were elevated in spite of 
the presence of an electron transport chain inhibitor, ascertaining that the NADH was glycolysis-derived 
and not from mitochondria.  Lactate production was increased while oxygen consumption was not, 
indicating that oxidative phosphorylation was not going up.  A PI3K inhibitor prevented glucose uptake 
and lactate production, and glucose depletion led to apoptosis.  AKT-induced cells therefore appear to 
be dependent on high levels of glucose (Elstrom, Bauer et al. 2004).  PI3K also appears to upregulate 
glycolysis in an AKT-independent manner.  Fructose-bisphosphate aldolase catalyzes the splitting of 
fructose 1,6-bisphosphate into dihydroxyacetone phosphate (DHAP) and glyceraldehyde 3-phosphate 
(G3P).  Aldolase can be inhibited by its binding to actin; Rac-mediated actin remodeling, stimulated by 
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PI3K, releases aldolase from actin and allows its function in glycolysis (Hu, Juvekar et al. 2016).  Super-
PTEN mice with elevated Pten expression displayed increased energy expenditure and mitochondrial 
respiration accompanied by a reduction in lactate and the glycolysis regulator PFKFB3 (6-phosphofructo-
2-kinase/ fructose-2,6-biphosphatase isoform 3), suggestive of an anti-Warburg phenotype (Garcia-Cao, 
Song et al. 2012).  Glucose-derived lipids were also decreased in Super-PTEN cells, indicative of reduced 
anabolism.  Interestingly, these mice also had lower levels of glutaminase and concomitant diminished 
glutamine uptake, possibly regulated by APC/C-Cdh1 (anaphase-promoting complex/cyclosome-Cdh1)-
mediated ubiquitination (Garcia-Cao, Song et al. 2012).  Further evidence suggests that PTEN positively 
regulates energy expenditure by increasing the activity of brown adipose tissue (BAT), which uncouples 
the electron transport chain and ATP production.  PI3K inhibition also stimulated BAT and uncoupling 
protein 1, although in their model BAT had increased glucose uptake in the presence of increased Pten 
(Ortega-Molina, Efeyan et al. 2012). 
 
Overall, the current body of literature illustrates that metabolic changes induced by oncogenic drivers of 
cancer are important contributors to tumor growth and are therefore attractive targets for cancer 
treatment.  PTEN has a multifaceted function in the cell, including a role in metabolism.  However, we 
do not as of yet have the complete picture of the part it plays in metabolic regulation.  This thesis 
focuses on the metabolic consequences of PTEN inactivation, the therapeutic vulnerability thus exposed, 




CHAPTER 1 FIGURE LEGENDS AND FIGURES 
 
Figure 1.1.  Schematic of PTEN pathway.  A diagram of components of the PTEN/PI3K pathway, 
including PI3K and AKT activation and downstream effectors (Samuels and Ericson 2006).  While new 
research has shown that the pathway has additional complexity, this schematic provides a framework 
for our understanding.  Key:  GFs = growth factors; RTKs = receptor tyrosine kinases; IRS2 = insulin 
receptor substrate 2; PIK3CA = catalytic p110α subunit of PI3K; PIP2 = phosphatidylinositol (4,5) bi-
phosphate; PIP3 = phosphatidylinositol (3,4,5) tri-phosphate; PTEN = Phosphatase and Tensin homolog 
deleted from chromosome ten; PDK-1 = phosphoinositide-dependent kinase 1; PHLPP = PH domain and 
Leucine rich repeat Protein Phosphatases; FKHR = FOXO1; FKHRL1 = FOXO3; AFX = IKK = IκB kinase; NF-
κB = nuclear factor kappa-light-chain-enhancer of activated B cells; Tuberin = Tuberous Sclerosis 
Complex 2; GSK3β = Glycogen Synthase Kinase 3 Beta; Rheb = Ras homolog enriched in brain; mTOR = 
mammalian target of rapamycin; eIF4G = Eukaryotic translation initiation factor 4 G; p70 S6K = 
Ribosomal protein S6 kinase beta-1; 4E-BP1 = 4E-binding protein 1. 
Figure 1.2.  Contributions of glutamine.  In this schematic, glutamine is shown to contribute to 
nucleotides and TCA cycle anaplerosis (DeBerardinis, Lum et al. 2008).  The details of these pathways 










Chapter 2: Characterization of PTEN loss 
 
 
As described in the introductory chapter, loss of PTEN to varying degrees has been implicated in 
processes as diverse as lipid second messenger signaling, metabolism, regulation of other proteins, and, 
of course, tumorigenesis.  It is for this reason that fully understanding the implications of PTEN 
deficiency is central to our grasp of cancer itself, in a symphysis of intracellular and systemic knowledge.  
We therefore begin our study of PTEN by observing the changes in cellular function upon its deletion, 
with an emphasis on metabolic alterations. 
 
Results 
MEFs as a model system 
An important decision in any biological project is choosing an appropriate model system.  Since we 
wished to determine the effects of PTEN loss, we started the project using isogenic cell lines: pairs of cell 
lines derived from the same parental line but differing in their PTEN genotype.  In our early studies, we 
used MCF10A (untransformed human breast epithelial), HEC1A (human endometrial cancer), HCT116 
(human colorectal carcinoma), and DLD1 (human colorectal carcinoma) cells, each with PTEN+/+ and 
PTEN-/- genotypes.  To complement these human lines, we also studied isogenic pairs of dominant-
negative p53-immortalized mouse embryonic fibroblasts (p53dn MEFs), also with PTEN+/+ and PTEN-/- 
genotypes.   
 
We soon realized, however, that using these isogenic lines was not an ideal approach.  While one would 
expect the PTEN-/- lines to have similar phenotypes to each other, there were few consistencies across 
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lines, including little similarity in gene signatures among PTEN-/- lines (Fig. 2.1).  Although within each 
pair there were transcript differences between the PTEN-/- and WT settings, overall the signature 
changes did not highly correlate across cell lines.  It appeared that PTEN loss in each isogenic line altered 
the gene signatures in dissimilar ways rather than eliciting a consistent transcriptional response.  While 
it is possible that more pairs of immortalized MEFs would yield higher power and statistical significance, 
our results indicated that a better model system may be warranted. 
 
Additionally, we applied the eigenvector-based Principal Components Analysis (PCA) to four pairs of 
p53dn MEFs.  An eigenvector of matrix T is a vector that does not change direction when linearly 
transformed by T, although it may change in terms of scale.  PCA calculates the covariance of each gene 
across samples, and calculates the eigenvectors of the resulting matrix.  A best-fit ellipsoid (3-
dimensional ellipse) is then fit to the vectors, with each vector corresponding to an axis of the ellipsoid.  
When normalized, the longest vector is the primary axis, second longest is the secondary axis, and so on.  
The clustering of the samples based on the primary axis reveals the main distinguisher of the samples.  
Using PCA, we found that rather than the PTEN-/- cells clustering together, each line only clustered with 
its isogenic partner (Fig. 2.2A).  This may be in part because some of the PTEN+/+ lines began to lose 
PTEN expression (Fig. 2.2B).   
 
The above results suggested to us the following:  first, the isogenic cell lines we used have been cultured 
and passaged for so long that p53dn MEFs which originally started out genetically similar have likely 
diverged over time, accumulating changes in gene expression that distinguish each pair from the others 
(including deregulation of PTEN itself).  Second, it is possible that the human cell lines have amassed so 
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many genetic mutations (which can interact differently with the loss of PTEN) that the single PTEN 
genetic change didn’t make enough of a consistent difference in this setting.   
 
What we needed was a cleaner system, in which PTEN loss was the only genetic change such that we 
can say with certainty the effects of PTEN per se.  We therefore decided to use primary mouse 
embryonic fibroblasts (MEFs), non-immortalized and passaged fewer than 8 times to ensure viability.  
The MEFs were generated from mice which had LoxP sites (short sequences derived from a 
bacteriophage) surrounding exon 5 of Pten (Li, Robinson et al. 2002)(Fig. 2.3A).  After extracting 
embryos from pregnant mice, we isolated fibroblasts and grew them as adherent cells.  Infection with an 
adenovirus containing the Cre Recombinase enzyme recombined the LoxP sites, thereby deleting the 
Pten exon and preventing Pten expression (Fig. 2.3A-B).  An adenovirus not containing Cre was used as a 
control.  (To generate the p53dn MEFs used above, pairs of these otherwise genetically identical MEFs 
were immortalized with dnp53.) 
 
PCA on 4 pairs of wild-type (WT) and Pten knockout (KO) MEFs revealed the KO cells clustering together 
and the WT cells clustering together, showing that Pten status is the principal defining factor in these 
MEFs (Fig. 2.3C).  It is important to note that while the overall WT cluster and KO cluster are fairly close 
together, each pair (MEF 1, 2, etc.) has considerable separation between the WT and KO, indicating that 
Pten is the primary difference between the cells.  We therefore use primary MEFs in this thesis to 
establish the effects of Pten loss, and use other cell lines (both human and mouse) to determine 




Growth and Proliferation 
Since PTEN is a bona fide tumor suppressor and negatively regulates the PI3K/AKT pathway described 
above, we reasonably hypothesized that loss of PTEN would increase the rate of cellular growth.  To 
ascertain the role of PTEN in growth, we plated an equal number of WT and KO primary MEFs and 
measured the increase in cellular confluence over time using phase-confluence images.  Pten-/- MEFs1 
consistently grew faster over time (Fig. 2.4A-B).  These results were also reproduced using a crystal 
violet assay (Fig. 2.4C).   
 
By infecting MEFs containing no LoxP sites with Cre adenovirus, we confirmed that the Cre virus alone 
was not affecting growth (Fig. 2.4D).  We further observed that Pten-/- MEFs grew faster than those 
which were not infected at all, confirming that the virus is not toxic and the effect on growth is veritable 
and biologically meaningful (Fig. 2.4E).   
 
Associated with the increased growth rate of Pten-/- MEFs were a greater number of replication forks per 
cell, as measured by EdU.  EdU (5-ethynyl-2’-deoxyuridine) is an analog of thymidine and is incorporated 
into DNA during DNA synthesis.  A click chemistry reaction allowed us to attach a fluorescent dye to EdU 
in order to detect its levels. We visualized EdU foci using confocal microscopy, and quantified the 
number of foci per cell (Fig. 2.5A-B).  Since this method quantifies a limited number of cells, we also 
performed flow cytometry on 5000 cells per sample; the shift to the right in EdU intensity in Pten-/- 
compared to WT cells indicates more replication per cell in the Pten-/- population (Fig. 2.5C).   
 
                                                          




The faster growth of Pten-/- cells opened a two-pronged question: are Pten-/- cells growing more because 
they are dying less than WT cells, or because they are truly proliferating faster?  To address this, we 
measured cell death using Annexin V and 7-Aminoactinomycin D (7-AAD).  In healthy cells, 
phosphatidylserine is restricted to the inner leaflet of the plasma membrane by flippase; however, in 
early-stage apoptosis scramblase translocates some phosphatidylserine to the outer leaflet where it can 
be recognized and bound by the protein Annexin V.  Late-stage apoptosis is associated with loss of 
membrane integrity.  While the fluorescent chemical 7-AAD is not cell permeable, it can easily enter 
cells during late-stage apoptosis and bind to DNA.  Using these indicators in combination shows the 
population of cells which are alive (no staining for either marker), in early-stage (Annexin V-positive 
only) or late-stage apoptosis (Annexin V and 7-AAD positive), or dead via necrosis or an alternate death 
mechanism (7-AAD positive only).  As a positive control we used the RNA polymerase blocker 
actinomycin D to induce cell death.  By using these markers and detecting fluorescent readings by flow 
cytometry, we did not observe a difference in the percentage of live cells between Pten-/- and WT 
populations (Fig. 2.6A). 
 
To address proliferation, we performed a cell cycle assay using bromodeoxyuridine (BrdU) and 
propidium iodide (PI).  BrdU, like EdU, is a synthetic nucleoside analog of thymidine.  The BrdU we 
employed was conjugated to Anti-BrdU Alexa Fluor® 488 which emits green when excited by a blue 
laser.  Propidium iodide intercalates DNA and fluoresces yellow/orange when bound to nucleotides.  
Using these two in combination, we can determine the population of cells in G1 (low PI and low BrdU 
signal), S-phase (intermediate PI and high BrdU) and G2 (high PI and low BrdU) stages of the cell cycle.  
We found an increased proportion of cells within S-phase in Pten-/- cells, suggesting that they may be 
synthesizing more DNA in order to proliferate at a higher rate (Fig 2.10B).  While a greater percentage of 
cells in S-phase can in principle also indicate S-phase arrest, in this case the S-phase data coupled with 
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the greater number of replication forks and increased rate of growth indicate that the Pten-/- cells are in 
fact progressing through the cell cycle and proliferating faster than their WT counterparts.  At any given 
time, the Pten-/- population has a greater proportion of cells in S-phase and increased replication forks 
per cell in order to achieve faster proliferation. 
 
We also decided to investigate senescence in our MEFs using β-galactosidase (β-gal), a standard assay 
for senescence.  β–gal is an enzyme that cleaves galactosides, and is expressed in senescent fibroblasts 
(Dimri 1995).  By first staining cells with X-gal, a galactose that is blue upon cleavage, we could quantify 
the percentage of blue/senescent cells in the Pten-/- and WT populations.  We did not, however, observe 
a significant difference in cellular senescence between Pten-/- and WT MEFs (Fig. 2.7).   
 
Growth and metabolism are inexorably linked.  In order to sustain a higher growth rate, it stands to 
reason that PTEN mutant cells have adjusted their metabolism to produce more of the cellular entities 
required for growth.  In the next sections we identify metabolic changes induced upon Pten loss.  
 
Mitochondrial Activity 
It would be remiss to have a discussion on metabolism without investigating the mitochondrion, the 
home of the Citric Acid Cycle, electron transport chain, and multiple redox reactions.   
 
Oxygen is the final electron acceptor in the electron transport chain, and different rates of respiration 
could be indicative of changes in mitochondrial function. Additionally, a decrease in pH outside of the 
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cell can be indicative of metabolic changes just upstream of the mitochondria, due to the conversion of 
pyruvate to lactic acid which releases free protons and causes extracellular acidification.  This can occur 
either due to the inability of pyruvate to be properly processed in the mitochondria, or to aerobic 
glycolysis leading to a buildup of glycolytic intermediates (including pyruvate). 
 
To assess these mitochondrial functions, we used an instrument called the Seahorse, which is capable of 
detecting the partial pressure of dissolved oxygen and the concentration of free protons.  To achieve 
this, we plated cells in wells with a small surface area such that when the Seahorse probe was lowered 
into the well only 7μL of media remained between the cells and sensor, creating a small controlled 
volume for detection.  There are two fluorophores at the bottom of the sensor, one detecting H+ ions 
and the other quenched by O2.  Multiple measurements were taken over time, and the resulting slope 
corresponds to the rate of consumption or secretion of O2 and protons, respectively.   
 
To narrow down which part of mitochondrial function may be altered, we used inhibitors of various 
electron transport chain complexes.  Oligomycin inhibits ATP synthase, creating a backup of the electron 
transport chain and resulting in less oxygen consumption by the cell but increased extracellular 
acidification, as pyruvate is converted to lactate when not used in the mitochondrion.  FCCP (Carbonyl 
cyanide-4-(trifluoromethoxyphenylhydrazone) disrupts the proton gradient by allowing H+ ions to pass 
through the inner mitochondrial membrane.  This increases oxygen consumption, as the cells ramp up 
churning of the electron transport chain in a futile effort to generate ATP.  Extracellular acidification can 
be reduced in this case, since pyruvate is demanded by mitochondria, but if the demand for glucose is 
increased the rate of acidification may rise.  Finally, rotenone inhibits the transfer of electrons from 
complex I, blocking the electron transport chain and shutting down oxygen consumption.  By 
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sequentially adding these poisons, we can determine the differences in ATP production, maximum 
respiratory capacity, and non-mitochondrial respiration (remaining O2 consumption even after inhibition 
of electron transport chain O2 consumption).   
 
We tested primary MEFs as well as isogenic cell lines with the Seahorse.  Primary WT and Pten-/- MEFs 
did not show a significant difference in mitochondrial function, and there was no consistent trend 
among the other cell lines (Fig. 2.8-2.10).  Although one of the immortalized MEF pairs displayed a 
difference in uncoupled oxygen consumption rate, this did not repeat in other immortalized MEFs and 
therefore may not be due to PTEN per se. 
 
Hand in hand with the above mitochondrial readouts is the level of reactive oxygen species (ROS), a 
byproduct of mitochondrial respiration.  As mentioned above, oxygen is the final electron acceptor in 
the electron transport chain.  In fact, electrons are frequently “donated” to oxygen in biological systems 
because it has a greater standard reduction potential — propensity to be reduced — than other 
common cellular atoms such as nitrogen, sulfur, carbon, and hydrogen (listed in decreasing order of 
potential).  Hydrogen is often the source of electrons, as H2 can split as two electrons and two H+ ions.  
Complete reduction of molecular oxygen, O2, results in H2O.  Partial reduction of oxygen, however, 
confers a reactive state to the molecule, earning it the name reactive oxygen species.  The table below 






O2 +e-   O2.- Superoxide 
O2.- + e-    O22- +2H+    H2O2 Hydrogen peroxide 
H2O2 +e-    .OH + OH- Hydroxyl radical and hydroxide ion 
 
The most common way for ROS to be generated is in the mitochondrion itself: electrons that leak out 
between ubiquinone and complex III rather than getting passed along properly can prematurely be 
transferred to O2, resulting in superoxide.  It is important to note that a low level of ROS thus generated 
as a byproduct of respiration is normal, and about 2% of cellular oxygen is processed in this manner 
(Ames, Shigenaga et al. 1993).  Superoxide can then be further reduced spontaneously or by superoxide 
dismutase or peroxisomal oxidases to form hydrogen peroxide and ultimately hydroxyl radicals.  The 
latter is the most reactive form of ROS, and can damage lipids, proteins, and DNA, potentially leading to 
mutations (Novo and Parola 2008). 
 
Fortunately, the cell has several built-in safeguards against excess ROS.  Peroxisomes can be a defense 
against ROS as well a generator of them; the peroxisomal enzyme catalase eliminates H2O2 by 
converting it into water and molecular oxygen.  Glutathione can similarly break down H2O2, and 
antioxidant compounds such as Vitamin E block the progression of radical chains, thereby preventing 
free radicals from damaging other molecules.  The equilibrium between ROS and antioxidant 
mechanisms keep normal cells at a healthy level of oxidation. However, perturbation to any of these 
pathways can upset the redox balance and lead to levels of ROS which are higher than can be quenched 




The relationship between ROS and cancer is a complicated one.  While hypoxic conditions and 
heightened metabolism often increases ROS in tumors, cancer cells have also been able to adapt to 
oxidative stress and can upregulate antioxidant enzymes, protecting the cancer from cytotoxic effects of 
excessive ROS buildup.  It is therefore difficult to predict how a particular cancer cell will react to ROS 
inducing or extinguishing agents.  PTEN’s association with ROS is unclear as well; it has been shown both 
that loss of PTEN increases ROS due to AKT activation (Dolado and Nebreda 2008, Nogueira, Park et al. 
2008), and that PTEN loss can prevent increases in ROS (Zhu, Hoell et al. 2007).  This suggests that the 
role of PTEN in ROS production and elimination may be cancer- or tissue-specific and dependent on 
other signaling pathways with which the PTEN pathway interacts.  
 
We decided to investigate ROS in our cells as well, using two different methods of measurement.  2,7-
Dichlorodihydrofluorescein diacetate (DCF-DA) fluoresces green upon oxidation through interaction with 
ROS, and measures overall cellular ROS including what has diffused out of the mitochondria.  MitoSOXTM 
Red, on the other hand, measures superoxide specifically as it is not efficiently oxidized by other forms 
of ROS.   
 
Previous data from our lab found a lower level of total ROS in some PTEN mutant lines compared to 
their isogenic pair, but the trend did not hold true for all lines.  Here, we found that primary WT and 
Pten-/- MEFs displayed no consistent difference in mitochondrial or total ROS, suggesting that Pten loss 
alone does not significantly affect ROS (Fig. 2.11A-B).  There was also no difference in the protein level 




From these data as well as those from the Seahorse, we cannot conclude that there are significant 
mitochondrial alterations in the transport chain attributable to loss of Pten, although it is possible that 
there are other changes we did not measure.  Additionally, the different patterns in mitochondrial 
metabolism in isogenic cancer lines (i.e. ROS and Seahorse data) furthered our confidence in using 





Metabolomics and nutrient deprivation 
To understand the intracellular metabolic changes induced by Pten loss, we used an unbiased approach 
and performed steady-state metabolomic profiling of 292 aqueous metabolites by mass spectrometry.  
A program called IMPaLA (Integrated Molecular Pathway Level Analysis) sorted the metabolites into 
pathways, and revealed that seven of the ten most upregulated pathways in Pten-/- MEFs involved 
nucleotide synthesis and DNA metabolism, including a higher concentration of pyrimidine 2-
deoxyribonucleotides in Pten-/- MEFs (Fig. 2.12).  Since glutamine contributes both nitrogen and carbon 
to making pyrimidines, we hypothesized that glutamine flux into pyrimidine synthesis was elevated in 
Pten-/- cells.  To test this, we performed targeted metabolic flux analysis using heavy isotope labeling.  In 
our environment, carbon exists predominately as 12C, and nitrogen as 14N.  However, there are stable 
(non-radioactive) isotopes of these elements, 13C and 15N, each of which has an extra neutron in the 
atom’s nucleus.  We obtained glutamine which had either all carbons or the amide nitrogen (which gets 
directly incorporated into pyrimidines) exchanged for their heavy isotope versions, and replaced 
glutamine in media with either 13C glutamine or 15N glutamine.  We incubated the cells for one hour in 
the labeled media prior to collecting metabolites, allowing us to monitor the flux of glutamine.  Mass 
spectrometry showed increased synthesis of dihydroorotate, orotate, and other components of the de 
novo pyrimidine synthesis pathway in Pten-/- MEFs relative to WT (Fig. 2.13, 2.14A).  In addition, the 
pyrimidine metabolism gene set was upregulated in mRNA from Pten-/- MEFs (Fig. 2.14B).   
 
It has previously been shown by Brendan Manning’s group that active S6 kinase due to mTORC1 
activation phosphorylates and activates CAD, a de novo pyrimidine synthesis enzyme.  This led to an 
increase in pathway intermediates that could be blocked by inhibition of mTORC1 (Ben-Sahra, Howell et 
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al. 2013).  Consistent with this prior report, we found CAD phosphorylation to be increased in Pten-/- 
cells, likely contributing to the push of glutamine flux into the pyrimidine synthesis pathway (Fig. 2.14C).  
 
Moreover, we found that the growth advantage of Pten-/- MEFs was dependent on glutamine: depletion 
of glutamine collapsed the growth difference between Pten-/- and WT MEFs, as did the addition of the 
glutaminase inhibitor CB-839 which blocks the conversion from glutamine to glutamate (Fig 2.15A-B).  
The requirement of glutamine for the growth advantage conferred by Pten loss therefore connects to 
the patterns of glutamine flux in Pten-/- MEFs.  Nucleotide synthesis is a prerequisite for cellular growth, 
and Pten-/- MEFs appear to channel glutamine for this purpose.   
 
Pten-/- MEFs had somewhat elevated steady-state glucose metabolism and glycolytic flux relative to WT 
MEFs, consistent with previous literature (Fig. 2.12A and 2.15C).  Unlike many types of cancer cells 
which are highly sensitive to glucose deprivation due to the Warburg effect described above, depletion 
of glucose from the medium of MEFs did not rescue the differences in cell growth, suggesting that 
glutamine was more critical for the growth advantage of Pten-/- cells (Fig 2.15D).  We must note, 
however, that there was still a trace amount of glucose present in the media’s serum.   
 
Discussion 
In this chapter, we made the following overarching observations: 1) MEFs are a good model system for 
studying cellular changes caused by PTEN loss; 2) there are no notable differences in mitochondrial 
respiration or ROS production between WT and Pten-/- cells; 3) Pten loss increases the proliferation rate 
and the number of replication forks per cell; 4) this is supported by an increase in glutamine flux into the 
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de novo pyrimidine synthesis pathway; 5) Pten-/- cells are dependent on glutamine for their growth 
differential.  Through these results, we have performed a general characterization of the consequences 
of Pten loss in terms of metabolic capacity and nutrient dependence.   
 
Our result of a faster proliferative rate upon Pten loss is consistent with its general mechanism of tumor 
suppression as well as current literature about the pro-growth downstream effectors of the PI3K 
pathway (outlined in the introductory chapter).  However, there is a small body of research that 
suggests that loss of Pten prompts cellular senescence instead.   
 
Chen et al claim that while heterozygous loss of Pten in MEFs increases growth rate, complete loss 
decreases growth rate and induces senescence that can be rescued by additional loss of p53 (Chen, 
Trotman et al. 2005).  However, this paper used a different negative control than our group did: while 
we infected matched paired Ptenfl/fl MEFs with either Cre-containing virus or empty virus (separately 
controlling for effects of Cre itself), Chen et al used WT MEFs infected with Cre as a control.  It is possible 
that the different embryos respond differently to the Cre virus due to differences in the mice 
themselves, not necessarily the genetic status of Pten, thus producing the different result.  A 
subsequent paper by the same group did compare Ptenfl/fl MEFs with Cre or Gfp infection and still found 
poorer growth in Cre-infected cells (Alimonti, Nardella et al.).  It would be valuable to see the effects of 
their viruses on WT MEFs (like our controls in Fig. 2.4) to ensure accuracy of the results.  Interestingly, 
they see increased senescence of Pten-deficient cells in the absence of DNA damage; our results as well 
as previous reports demonstrate an endogenous level of DNA damage in Pten-/- cells as described in 
chapter 4, and this could affect the senescence phenotype.  It is also possible that subtle variations in 
mouse background can confound results.  Additionally, Pten loss may induce a senescent sub-population 
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of cells that is overshadowed by the increased growth rate of the population as a whole.  Authors of 
these papers do, however, acknowledge that complete loss of PTEN is commonly found in aggressive 
cancers (Trotman, Niki et al. 2003).   
 
It is notable in our data that pyrimidine synthesis was upregulated more than other facets of glutamine 
metabolism such as the TCA cycle.  This supports the principles justified by current literature that 
different oncogenic changes affect specific nutrient addictions for particular metabolic pathways, rather 
than indiscriminate nutrient uptake and processing.  Newsholme’s theory (discussed in the introductory 
chapter) also comes into play here (Newsholme, Crabtree et al. 1985): it is possible that all of glutamine 
metabolism is somewhat upregulated, but the change in pyrimidine flux is detectable as being magnified 
because it is under regulation by PTEN.   
 
We also note that UMP is not significantly altered in PTEN-deficient cells, although the trend is towards 
upregulation.  We think there are two possibilities as to why the UMP upregulation was not found to be 
significant.  First, UMP and pseudouridine have been shown to be difficult to differentiate from each 
other using mass spectrometry.  Pseudouridine was not measured in our panel, but it’s possible that 
some of the signal from UMP was conflated with pseudouridine.  Second, in addition to UDP, UMP is 
also directly converted to uridine which was not measured in our panel.  Some of the orotate to UMP to 
UDP pathway may be sidetracked to uridine directly from UMP, thus seemingly “skipping” a step 
(Charette and Gray 2000, Quinn, Basanta-Sanchez et al. 2013).  However, since the other measured 
metabolites in the pathway were consistently upregulated in 13C, 15N, and unlabeled metabolic extracts, 
and given the previous literature on the subject, we are confident that the pathway is in fact 




As mentioned in the introductory chapter, Myc also induces glutamine dependency, albeit for TCA cycle 
intermediates and phospholipid precursors over nucleotides (Wise, DeBerardinis et al. 2008).  While the 
paper showed that PI3K or AKT inhibition did not alter reliance on glutamine in a Myc-amplified glioma 
line, this is not necessarily inconsistent with our data.  First, unless PTEN is lost and the PI3K pathway is 
actually upregulated, blocking the pathway may be moot.  Second, Myc induction of glutamine 
dependency is likely independent of the PTEN/PI3K pathway and can therefore continue to increase 
glutamine uptake regardless of PI3K or AKT activity.  In fact, independent modes of glutamine 
upregulation could help explain the different downstream pathways of glutamine that are augmented in 
Pten-deficient versus Myc-amplified cells.   
 
Our data are also reminiscent of transformed HeLa cells, which use glutamine preferentially even in the 
presence of adequate glucose.  It is not so strange, then for Pten-/- cells to be less sensitive to glucose 
deprivation, as there is precedent for it (Reitzer, Wice et al. 1979). 
 
Our findings in this chapter are illuminating in several ways.  First, it is common in our field for 
mechanistic studies to be performed on cancer cell lines, isogenic or otherwise.  While this has the 
benefit of being a human system, we provide evidence that cell lines can confound the true nature of a 
genetic change and may be better suited for follow-up studies to show broad applicability rather than 
for initial observations in some cases.  Second, we identify a greater number of replication forks per cell 
in Pten-/- cells.  Confocal microscopy data allowed us to visualize the increased number of foci in the 
nucleus, and flow cytometry quantified the EdU signal in thousands of cells, a number that would be 
prohibitive in microscopy experiments alone.  These data also support our finding of increased 
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proliferation in Pten-/- MEFs.  Third, we have connected nutrient deprivation experiments with 
metabolomics and targeted flux mass spectrometry for a more complete picture of metabolic changes.   
 





CHAPTER 2 FIGURE LEGENDS AND FIGURES 
 
Figure 2.1.  Genetic profiling of isogenic cell lines.  RNA was collected from PTEN-/- and WT isogenic cell 
lines and microarray analysis was performed.  Data were uploaded to and analyzed by the Broad 
Institute’s Morpheus software.  Expression levels are shown; rows correspond to different genes.   
Figure 2.2.  PCA analysis and Pten expression of immortalized MEFs.  (A) PCA analysis of 3 pairs of 
isogenic immortalized MEFs.  (B) Immunoblot of Pten protein expression of the same 3 pairs of isogenic 
immortalized MEFs with loading control.   
Figure 2.3.  PCA analysis of primary MEFs. (A) Diagram of mouse model with LoxP sites.  (B) Diagram of 
how isogenic MEF pairs were produced from flox/flox mice.  Ad-Cre = adenovirus containing Cre 
recombinase; Ad-null = empty adenovirus used as a control.  (C) PCA analysis of 4 pairs of WT and Pten-/- 
primary MEFs.   
Figure 2.4.  Cellular growth rate is affected upon loss of Pten.  (A) Ptenfl/fl MEFs infected with an empty 
adenovirus (WT) or one containing Cre recombinase (KO) were plated in equal numbers in 96 well 
plates, and growth was measured over time using phase-contrast images from an Incucyte Zoom (two-
way ANOVA, *p<.0001, n=3).  (B) Immunoblot of Pten protein of Ptenfl/fl MEFs derived from two 
independent embryos, infected with an empty adenovirus or one containing Cre recombinase, 2 
passages after infection.  (C) Pten WT and KO primary MEFs were plated in equal numbers in 48 well 
plates, and growth was measured over time using crystal violet staining (two-way ANOVA, *p<.05, n=3). 
(D) WT MEFs (with no LoxP sites) were infected with an empty adenovirus or one containing Cre 
recombinase to determine whether Cre alone affects growth (two-way ANOVA, p>.05, non-significant, 
n=3).  (E) Pten fl/fl MEFs were infected with an empty virus (Ad-null) or one containing Cre Recombinase 
or GFP.  Uninfected MEFs are also shown as a control.  Cells were plated in equal numbers in 96 well 
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plates and growth was measured over time using crystal violet staining (two-way ANOVA, *p<.0001, 
n=3).  
Figure 2.5.  Pten loss increases replication forks.  (A) MEFs were pulsed with EdU for 45min, and labeled 
with an EdU-binding fluorescent tag following fixation.  Representative confocal microscopy images are 
shown.  (B) Quantification of images represented in Fig.1A (Student’s t-test, *p<.05, n=6).  (C) MEFs 
were pulsed with EdU for 45min, and labeled with an EdU-binding fluorescent tag following fixation.  
Flow cytometry determined the mean fluorescence intensity (MFI) of EdU signal among cells positively 
stained, indicating the amount of EdU incorporation in replicating cells (Student’s t-test, *p<.01, n=3). 
Figure 2.6.  Apoptosis and the cell cycle.  (A) Cells were collected and labeled with annexin V and 7AAD, 
and flow cytometry was used to determine the percentage of positively or negatively stained cells in the 
population.  Left: representative population distribution of a sample; right: quantification of replicates 
(Student’s t-test, p>.05, n=3). (B) MEFs were pulsed with BrdU for 18h, fixed, and labeled with an anti-
BrdU antibody and propidium iodide. Flow cytometry was used to determine the cells in each 
population corresponding to G1, S, and G2 phases of the cell cycle.  Top: representative population 
distribution of a sample; bottom: quantification of replicates (Student’s t-test, *p<.001, n=3). 
Figure 2.7.  Senescence assay in primary MEFs.  Primary MEFs were stained with β-gal and DAPI, and 
the percent of senescent cells was quantified by counting positive cells and normalizing to total cell 
count (Student’s t-test, p>.05, n=3). 
Figure 2.8.  Seahorse analysis of primary MEFs.  (A) Oxygen consumption rate (OCR) and (B) 
extracellular acidification rate (ECAR) of WT and Pten-/- primary MEFs.  Oligomycin, FCCP, and rotenone 
were added at points A, B, and C, respectively.   
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Figure 2.9.  Seahorse analysis of immortalized MEFs.  (A) Oxygen consumption rate (OCR) and (B) 
extracellular acidification rate (ECAR) of 2 pairs of isogenic immortalized MEFs.  Oligomycin, FCCP, and 
rotenone were added at points A, B, and C, respectively.   
Figure 2.10.  Seahorse analysis of isogenic human cancer cell lines.  (A) Oxygen consumption rate (OCR) 
and (B) extracellular acidification rate (ECAR) of isogenic human cancer cell lines.  Oligomycin, FCCP, and 
rotenone were added at points A, B, and C, respectively.   
Figure 2.11.  Reactive oxygen species.  (A) Intracellular ROS on two pairs of primary MEFs was measured 
by DCFDA.  Flow cytometry determined the mean fluorescence intensity (MFI) of DCFDA signal 
(Student’s t-test, p>.05, n=3).  (B) Mitochondrial ROS on two pairs of primary MEFs was measured by 
MitoSox.  Flow cytometry determined the mean fluorescence intensity (MFI) of MitoSox signal 
(Student’s t-test, p>.05, non-significant, n=3).  (C) Immunoblot of mitochondrial protein TOM20 in 
primary MEFs.   
Figure 2.12.  Global metabolic profiling.  (A) Over 200 soluble metabolites were measured by LC-MS/MS 
from unlabeled MEFs. Data were analyzed with the Integrated Molecular Pathway Analysis program 
(IMPaLA) and the top 5 hits for pathways upregulated in Pten-/- MEFs are shown in green, all related to 
pyrimidine metabolism. As a comparison, 5 other pathways upregulated in Pten-/- MEFs are shown: 
purine metabolism, the TCA cycle, and glucose metabolism are farther down the list.  (B) Relative 
metabolite concentrations of DNA nucleotide precursors (dGMP was unable to be measured so dGTP 
was used) show a significant increase in pyrimidine but not purine precursors (Student’s t-test, *p<.05, 
n=3).  (C) The relative levels of each metabolite listed in the “pyrimidine metabolism” and “nucleotide 
metabolism” pathways from (A) are shown (Student’s t-test, *p<.05, n=3). 
Figure 2.13.  De novo pyrimidine synthesis.  (A) Schematic of the de novo pyrimidine synthesis pathway.  
(B) MEFs were incubated with 13C glutamine or 15N glutamine for 1 hour and metabolites were measured 
by LC-MS/MS .  Relative metabolite levels of glutamine-labeled de novo pyrimidine synthesis 
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intermediates are shown (Student’s t-test, *p<.05, n=3). Data were also analyzed with IMPaLA: 13C 
glutamine-derived pyrimidine metabolism enrichment in PTEN-/- MEFs q-value = 3.92x10-09. 
Figure 2.14.  Pyrimidine enrichment in Pten-/- MEFs.  (A) Metabolites from Fig. 2.13B mapped out onto 
the de novo pyrimidine synthesis pathway.  Graphs on the left side of the figure correspond to 15N 
labeled glutamine, and on the right side to 13C labeled glutamine. Some metabolites are missing either a 
13C or 15N graph because not every metabolite was able to be measured in both panels (Student’s t-test, 
*p<.05, n=3).  (B) Gene set enrichment analysis of the pyrimidine synthesis gene set on microarray data 
from 4 pairs of primary MEFs (FDR q-value <.05).  (C) Immunoblot of pCAD S1859 and total CAD in MEFs.  
Figure 2.15.  Nutrient dependency induced by Pten loss.  (A) Pten WT and KO MEFs were plated in 
media containing full glutamine (6mM) or no glutamine, and growth was measured over time using 
phase-contrast images from an Incucyte Zoom (one-way ANOVA, *p<.0001, n=3).  (B) MEFs were treated 
with 12.5nM CB-839 or DMSO, and growth was measured over time using phase-contrast images from 
an Incucyte Zoom (one-way ANOVA, *p<.0001, n=3).  (C)  MEFs were incubated with 13C glucose and 
metabolites were measured by LC-MS/MS .  Relative metabolite levels of glucose-labeled glycolysis 
intermediates are shown (Student’s t-test, *p<.05, n=3).  (D) MEFs were grown in the presence of full 




































Chapter 3: Exploiting the metabolic vulnerability of PTEN mutant cells 
 
In the previous chapter we observed an increase in DNA synthesis and number of replication forks in 
Pten-/- cells.  We further identified the dependence of Pten-/- cells on glutamine, and believe that 
glutamine flux is upregulated in part to support the demands of increased replication via de novo 
pyrimidine synthesis.  It will therefore be illuminating to delve into the de novo pyrimidine synthesis 
pathway; in this chapter we explore an enzyme in the pathway, dihydroorotate dehydrogenase 
(DHODH), and the vulnerability of PTEN mutant tumors to DHODH inhibition.  
 
Introduction 
A brief summary of nucleotide synthesis 
Since we found an association between Pten loss and nucleotide metabolism, it will be helpful to 
understand more about the pathways involved.  Nucleotides can be made via de novo synthesis or 
through what is termed the salvage pathway.  De novo synthesis of purines involves production from 
glutamine, glycine, aspartate, and tetrahydrofolate derivatives, and pyrimidines from glutamine, 
bicarbonate, and aspartate (Cory and Cory 2006).  (More details about one-carbon metabolism for 
purine synthesis were outlined in the introductory chapter.)  Aspartate in turn can be made from 
oxaloacetate, which is derived from either glutamine or glucose in the TCA cycle; glucose contributes 
carbon while glutamate (from glutamine) contributes nitrogen and carbon.  Salvage production of 
nucleotides, on the other hand, occurs from the recycling of downstream nucleotide intermediates from 




De novo pyrimidine synthesis 
Since we found that Pten-/- cells appear to be dependent on glutamine and channel its flux into the 
manufacture of pyrimidines, we focus here on the de novo pyrimidine synthesis pathway in mammals.  
The first step of this pathway is the combination of glutamine with bicarbonate to create carbamoyl 
phosphate; through this, the amide nitrogen of glutamine is incorporated (Cory and Cory 2006).  
Carbamoyl phosphate is then fused to aspartate, creating carbamoyl aspartate, which is then converted 
to dihydroorotate.  The above reactions are catalyzed by a tri-functional protein with activity as 
carbamoylphosphate synthetase (CPS II), aspartate transcarbamoylase, and dihydroorotase, all encoded 
by the gene CAD (Coleman, Suttle et al. 1977).  The fourth step in the de novo pyrimidine synthesis 
pathway is the conversion of dihydroorotate to orotate, catalyzed by dihydroorotate dehydrogenase 
(DHODH) (Stamato and Patterson 1979).  Orotate is converted to OMP then UMP by uridine 
monophosphate synthetase (UMPS), followed by UDP by uridine monophosphate kinase (UMPK), and 
finally to dUMP (Fig. 2.13A)   
 
DHODH 
DHODH is of particular interest because there are several inhibitors to this enzyme in existence that are 
in use clinically.  Here, we first present some information about its biology.  DHODH contains a flavin 
mononucleotide (FMN), which is an oxidizing agent that is part of several enzymes involved in redox 
reactions.  By reducing FMN to FMNH2, dihydroorotate is simultaneously oxidized to orotate.  FMNH2 is 
then restored to its original oxidized state through the reduction of coenzyme Q/ubiquinone, which also 
binds DHODH.  Class 2 DHODH (present in humans) is a mitochondrial enzyme, residing in the inner 
mitochondrial membrane.  Due to its binary function, DHODH can affect both pyrimidine synthesis and 




DHODH may also have a function in transcriptional elongation.  In melanoma cell lines, DHODH 
inhibition resulted in a decrease in elongation but not of initiation, as determined by Pol II occupancy 
(White, Cech et al. 2011).  There has been considerable interest in DHODH for some time, and various 
inhibitors to the enzyme have been developed. 
 
Leflunomide was discovered to be a DHODH inhibitor in 1995, and 14C labeling experiments confirmed 
leflunomide’s target a few years later (Greene, Watanabe et al. 1995, Rückemann, Fairbanks et al. 
1998).  Even before its mechanism was known, leflunomide (HWA 486) was recognized for its ability to 
reduce inflammation and prevent the advancement of rheumatoid arthritis (RA) (Bartlett and 
Schleyerbach 1985), a disease characterized by inflammation and degradation of synovial connective 
tissue in joints (Breedveld and Dayer 2000).  More specifically, leflunomide was shown to inhibit B-cell 
and T-cell proliferation (ANITA, Finnegan et al. 1993, Siemasko, Chong et al. 1996).  Its 
immunomodulatory effects were connected to its DHODH inhibitory mechanism; T-cells treated with 
leflunomide accumulated dihydroorotate, and uridine rescued proliferation (Cherwinski, Cohn et al. 
1995).  Leflunomide was eventually produced under the trade name Arava as a rheumatoid arthritis 
medication for human use.   
 
As a drug, leflunomide has several interesting properties.  It is tightly bound to the protein albumin in 
serum, and has a half-life of about two weeks in the body (quite long for a drug) (Breedveld and Dayer 
2000).  Because of this, to achieve steady-state levels in humans a loading dose of 100mg/kg for 3 days 
is first typically required, followed by a daily dose of 20-40mg/kg to maintain steady levels.  Toxicity in 
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patients treated with leflunomide is relatively low – diarrhea and vomiting occurred upon the first few 
days of treatment, but the symptoms desisted after some time (Breedveld and Dayer 2000). 
 
Leflunomide is actually a pro-drug, and its active metabolite which physically binds DHODH is called 
teriflunomide, or A771726.  Leflunomide can be processed in either the GI tract or in plasma, and is 
converted to teriflunomide by nonenzymatic opening of its ring structure (Breedveld and Dayer 2000, 
Rozman 2002).  Normal rheumatoid arthritis dosing achieved a steady-state plasma level of 200-250μM 
teriflunomide when leflunomide was administered orally (Mone and Byrd 2004).  Teriflunomide is sold 
under the name Aubagio for use in multiple sclerosis (MS).  
 
Leflunomide and A771726 are the only clinically available DHODH inhibitors, but there are other 
commercially available inhibitors for use in the laboratory.  Brequinar is one such example.  While the 
exact mechanism of DHODH inhibition is not completely known, there is evidence that A771726 and 
brequinar are both uncompetitive for the dihydroorotate binding site, while brequinar is competitive 
and A771726 is noncompetitive for the ubiquinone binding site (McLean, Neidhardt et al. 2001).  It is 
possible that the different mode of action on DHODH of the various inhibitors influences their precise 
effects on DHODH modulation.  Brequinar caused several side effects in patients, including severe 
lymphopenia, myelosuppression, and nausea, and the clinical trial was withdrawn (Peters, 
Schwartsmann et al. 1990, Rückemann, Fairbanks et al. 1998).  Since DHODH is an important target for 
RA, MS, and perhaps malaria, additional inhibitors to the enzyme are being designed (Munier-Lehmann, 




In the following section, we examine the effects of DHODH inhibition in the setting of PTEN deficiency. 
 
Results 
In vitro sensitivity 
Given the upregulation of the de novo pyrimidine synthesis pathway in Pten-/- cells, we hypothesized 
that this could also be an Achilles’ heel — and that PTEN mutant cells would be sensitive to inhibition of 
this pathway.  Since DHODH has preexisting inhibitors (described above) readily available, we proceeded 
to test them in vitro. 
 
Pten-/- MEFs were about 3-fold more sensitive to leflunomide than WT MEFs were, suggesting that 
orotate contributes to the growth effects we observe (Fig. 3.1A).  In fact, increasing doses of leflunomide 
not only collapsed the growth difference between WT and null MEFs, but allowed the WT cells to 
overtake Pten-/- cells (Fig. 3.1B-C).  Pten-/- MEFs were also more sensitive to A771726, the active 
metabolite of leflunomide, as well as brequinar, indicating that the observed effects were likely through 
DHODH (Fig. 3.1A).  To determine whether PTEN genotype is predictive of susceptibility to DHODH 
inhibition in cancer cells, we tested human breast, glioblastoma, and prostate cell lines with DHODH 
inhibitors.  Consistently, the GI50 of the PTEN mutant lines was lower than that of WT (Fig. 3.2A-B).  
Mouse breast cancer line MCCL-357 (Myc, Pten-/-) was more sensitive than mouse breast cancer line 
MCCL-278 (Myc, Pik3ca H1047R) was, and mouse prostate cancer line CaP8 (Pten-/-) was more sensitive 
than mouse prostate cancer line Myc-CaP (Myc) was (Fig. 3.2C-E) (Jiao, Wang et al. 2007, Stratikopoulos, 
Dendy et al. 2015).  Moreover, Pten-/- MEFs, PTEN mutant human breast cancer cell lines, and Pten-/- 
mouse breast cancer cell lines displayed an increased accumulation of dead cells over time upon 
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treatment with leflunomide (Fig. 3.3).  While we can’t say with certainty that this sensitivity in PTEN 
mutant cells is universal, the many cell systems we do see this in is predictive of a strong correlation.  
 
Data from 2-dimensional culture is very informative, but doesn’t always accurately reflect how a drug 
would work on a 3-D tumor.  To this end, we seeded HCC1419, MDA-MB 468, and ZR57-1 cells in 
conditions that induce growth as mammospheres in culture.  Rather than adhering to the dish as a 
monolayer, the cells were packed into dense spherical clusters.  We disrupted the formed tumor 
spheres into single cell suspensions and re-seeded them for secondary tumor sphere assessment.  
Formation of spheres is considered a marker of the ability to regenerate tumors, and hence 
tumorigenicity (Freedman and Shin , Shaw, Harrison et al. 2012).  The suspended cells were treated with 
various concentrations of leflunomide, and the number of formed spheres was counted in each 
condition.  We found that formation of tumor spheres was inhibited at lower concentrations of 
leflunomide in PTEN-deficient samples compared to WT; however, this experiment was only done once 
and added data would be required to draw a definitive conclusion (Fig. 3.4).  We therefore address 
tumor spheres further in the following section with an additional model. 
 
To independently test if DHODH inhibition is detrimental to PTEN deficient cells, we performed a rescue 
experiment with orotate, the metabolite directly downstream of DHODH, as well as with uridine, a 
metabolite further downstream. Increasing concentrations of orotate or uridine rescued growth 
inhibition by leflunomide, verifying that DHODH was the target of the small molecule inhibitors (Fig. 
3.5). In addition, siRNA against DHODH preferentially killed PTEN mutant cells, corroborating the target 




Addition of a reducing agent, n-acetylcysteine, did not rescue growth inhibition, verifying that the 
dihydroorotate-orotate conversion by DHODH is more important for growth in this system than its 
function in reducing ubiquinone (Fig. 3.6C).  Leflunomide also did not differentially affect mitochondrial 
ROS (Fig. 3.6D).  Recall that in figure 2.8 we stressed cells with various fast-acting mitochondrial poisons 
and showed there was no difference in respiratory function between PTEN-/- and WT cells.  One of the 
poisons used was rotenone, which inhibits the transfer of electrons from Complex 1 to ubiquinone, the 
carrier that is reduced in part by DHODH.  Rotenone acts rapidly, and served as a proxy for leflunomide 
in this part of the electron transport chain.  We therefore deem the blockade of de novo pyrimidine 
synthesis to be the primary cause of sensitivity in PTEN mutant cells. 
 
It is also important to note that a faster growth rate is not the cause of — or a requirement for — 
sensitivity to DHODH inhibitors.  While we believe that cells with PTEN loss use glutamine flux to sustain 
faster proliferation, we posit that other cancer mutations which affect the growth rate of a cell (and may 
overshadow PTEN’s contribution) may not contribute to leflunomide sensitivity.  Myc, Pik3ca H1047R 
cells grow at approximately the same rate as Myc, Pten-/- cells even though it is only the Pten-/- cells that 
are sensitive to leflunomide, and the resistant Myc-CaP cells grow somewhat faster than the sensitive 
CaP8 cells (Fig. 3.7A-B).  Sensitivity to leflunomide was also not associated with the proliferation rates of 
human breast cancer cell lines (Fig. 3.7C).  It therefore appears that PTEN status is a predictor of 
susceptibility while proliferation rate is not.  This is noteworthy because association with growth rates 
would indicate that DHODH inhibitors are acting like a chemotherapeutic agent, while our data suggest 




There was no endogenous difference in DHODH protein level between Pten-/- and WT MEFs, indicating 
that the source of pyrimidine flux is not from upregulation of DHODH and instead may well be via CAD 
phosphorylation as described above (Fig. 3.8A).  It was previously shown that that re-expression of PTEN 
in the PTEN-null U87 cell line lowered the level of carbamoyl aspartate, indicating that PTEN may 
regulate CAD-mediated upregulation of de novo pyrimidine synthesis (Ben-Sahra, Howell et al. 2013).  
Phosphorylated CAD levels were increased in Pten-/- MEFs with or without the presence of leflunomide, 
as well as in Pten-/- mouse breast lines (Fig. 2.14C and Fig. 3.8B-C).  Additionally, we found that A771726 
did not affect PI3K signaling, signifying that the effects we saw were through DHODH and not inhibition 
of PI3K (Fig. 3.8D).   
 
While brequinar was effective in PTEN deficient MEFs and mouse breast cancer cell lines, there was not 
a significantly different sensitivity in human breast cancer cell lines (Fig. 3.1A, 3.9).  Since brequinar did 
not work well in our human cell systems, we chose to use leflunomide and A771726 for further studies. 
 
Interestingly, human breast cancer cell lines with a PIK3CA mutation did not exhibit a significant 
sensitivity to leflunomide, although their collective GI50 trended lower than that of WT PIK3CA/WT 
PTEN (Fig. 3.10A).  And, as described above, mouse cancer cell line MCCL-357 (Myc, Pten-/-) was more 
sensitive than MCCL-278 (Myc, Pik3ca H1047R) in terms of both growth inhibition and cell death (Fig. 
3.2D-E, 3.3B).  While PTEN and PI3K are in the same pathway, loss of PTEN and activation of PIK3CA are 
not equivalent.  This may be in part because, consistent with previous reports, we found that Pten 
homozygous deletion induced greater AKT phosphorylation than Pik3ca missense mutation did (Stemke-
Hale, Gonzalez-Angulo et al. 2008). This was particularly prominent in the nuclear fractions, where AKT 
may phosphorylate nuclear substrates (Fig. 3.10B-D).  Heightened active AKT leads to greater mTORC1 
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activation and consequently more phosphorylated CAD, likely contributing to the de novo pyrimidine 
synthesis dependency we describe.  The difference in active AKT between Pik3ca mutant and Pten-/- cells 
will also be important in cell death mechanisms described in chapter 4.  
 
We also wanted to ascertain whether any nucleotide inhibitor would be effective against PTEN mutant 
cells.  5-flurouracil inhibits thymidylate synthase upon conversion to fluorodeoxyuridine 
monophosphate, and is a nucleotide analog that is toxic to RNA when misincorporated in place of 
uridine (Yoshida, Hoshi et al. 1980).  Mercaptopurine inhibits phosphoribosyl pyrophosphate 
amidotransferase in de novo purine synthesis as well as the IMP to AMP conversion in the purine salvage 
pathway (Salser, Hutchison et al. 1960, Tay, Lilley et al. 1969).  However, treatment with either of these 
drugs did not show a differential sensitivity, demonstrating that Pten-/- MEFs are selectively vulnerable 
to inhibition of de novo pyrimidine synthesis in particular (Fig. 3.11A-B). 
 
Myc activation is also known to cause glutamine addiction. CaP8 (Pten-/-) cells were nearly as sensitive to 
glutamine deprivation as Myc-CaP (Myc) cells were, substantiating that a notable level of glutamine 
dependency is also elicited by PTEN loss (Fig. 3.11C). Since Myc-CaP cells were resistant to leflunomide, 
it seems it is not the entry alone of glutamine but its flux into pyrimidines that is important (Fig. 3.2C). 
While Myc is known to largely direct glutamine to the TCA cycle and phospholipid synthesis, our data 
show that PTEN loss in MEFs causes glutamine to cascade through the de novo pyrimidine synthesis 




These data gave us confidence that PTEN mutant cells are indeed more vulnerable than PTEN WT cells 
to DHODH inhibition.  To further the preclinical data, we tested additional models as described in the 
next section. 
Table 3.1.  Breast cancer cell lines used in this chapter: 
Cell line Genotype 
MDAMB 231 PTEN and PIK3CA WT 
HCC 1187 PTEN and PIK3CA WT 
HCC 1806 PTEN and PIK3CA WT 
HCC 1419 PTEN and PIK3CA WT 
SKBR3 PTEN and PIK3CA WT 
HCC 1937 PTEN mut 
ZR75-1 PTEN mut 
SUM 149 PTEN mut 
BT549 PTEN mut 
MDAMB 468 PTEN mut 
T47D PIK3CA mut 
HCC 1954 PIK3CA mut 
SUM 159 PIK3CA mut 
 
In vivo models and patient samples 
We next wanted to determine how clinically relevant leflunomide may be as a targeted cancer therapy.  
We focus here on two sets of models: breast cancer and glioblastoma. 
 
We proceeded to test in vivo mouse models of triple negative breast cancer, a subset with particularly 
high PTEN mutation rates.  We first tested SUM149, a human cancer cell line with PTEN deficiency that 
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was found to be sensitive to leflunomide in vitro.  Cells were xenografted into mice, and once tumors 
were established the mice were treated orally as is done clinically.  Due to the long half-life of 
leflunomide, we did not treat every day in order to prevent accumulation of the drug in the system 
beyond our intended dose.  By measuring tumor volume using calipers, we found that treatment of mice 
carrying SUM149 tumors with 100mg/kg leflunomide significantly slowed down tumor growth (Fig. 
3.12A). 
 
To confirm this result, we tested an additional triple negative breast cancer model.  Like SUM149, MDA-
MB 468 cells have PTEN deficiency and were also highly sensitive to DHODH inhibition in vitro.  We also 
expressed luciferase in these cells prior to injection into mice, allowing us to visualize tumor size by 
luminescence.  (This was accomplished using the IVIS® Spectrum In Vivo Imaging System.)  Similar to the 
model above, we treated mice orally with 100mg/kg leflunomide for four consecutive days per week.  In 
the MDA-MB 468 model, tumor size was diminished upon leflunomide treatment, and in some cases the 
tumor disappeared altogether (Fig. 3.12B).   
 
It is possible for a cancer therapy to be efficacious on small tumors, but fail to reduce or even stabilize 
large tumors.  Since vascularization of a tumor increases drug delivery, poorly perfused large tumors will 
not properly access the given drug (Allen 2004).  To test the efficacy of leflunomide in this setting, we 
allowed untreated MDA-MB 468 xenografts to grow for seven weeks until the size of the tumor was 
about 10 times larger than the starting size in figure 3.12B.  We then treated daily with 100mg/kg 
leflunmomide; remarkably, even these large tumors (4x107 photons) regressed after only 1 week of 
treatment (Fig. 3.12C).  We were also able to stabilize a large SUM149 tumor with leflunomide (Fig. 




Furthermore, we obtained patient-derived xenograft (PDX) mice, in which tumor samples from a breast 
cancer patient with known PTEN deficiency were implanted.  PDXs hold an advantage over established 
cell line xenografts: while cell lines also originated from human tumors, PDXs have been obtained more 
recently and have not been passaged over many years, and therefore are less likely to have evolved 
away from the original genetics of the patient’s tumor.  We treated a cohort of mice bearing a PTEN 
mutant PDX for four consecutive days each week, and found a significant but modest slowing of tumor 
growth compared to the control group (Fig. 3.13A).  When we checked lysates made from tumor 
sections, however, we detected a considerable amount of PTEN – it is unclear whether this is coming 
from the stroma and not the actual tumor cells, or if there is truly PTEN expression in the tumor itself, 
explaining the modest effect we see with leflunomide (Fig. 3.13B). 
 
To confirm that the Pten-specificity of leflunomide sensitivity we observed in vitro is upheld in vivo, we 
xenografted MCCL-357 and MCCL-278 cells into mice and measured the tumors’ response.  Treatment of 
the mice with leflunomide resulted in a 4-fold greater response in MCCL-357 xenografts than in MCCL-
278 xenografts (Fig. 3.13C). 
 
Based on the above in vivo experiments, we concluded that leflunomide could indeed have efficacy for 
patients with PTEN mutant breast cancers.  We next proceeded to test models of glioblastoma. 
 
From Dr. Raymund Yong, a neurosurgeon at Mt Sinai hospital, we obtained four patient glioblastoma 
samples which we were able to grow as 3-dimensional tumor spheres in culture.  This model gave us the 
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advantage of testing leflunomide’s efficacy in penetrating a 3-D tumor, more closely resembling a real-
life scenario than 2-D adherent cells would.  And, like PDXs, these samples held the advantage of being 
recent acquisitions from patients and therefore likely to maintain the original tumor genetics.  Two of 
our samples expressed PTEN and two did not (Fig. 3.14A).  We first disrupted the tumor spheres into 
single cell suspensions; as described above, formation of spheres is considered a marker of 
tumorigenicity (Grimshaw, Cooper et al. 2008, Shaw, Harrison et al. 2012).  The suspended cells were 
treated with various concentrations of leflunomide, and the number of formed tumor spheres was 
counted in each condition.  We found that formation of tumor spheres was inhibited at lower 
concentrations of leflunomide in PTEN-deficient samples compared to WT; in fact, one of the PTEN-
expressing tumors was not inhibited by leflunomide even at the highest concentration used, while both 
of the PTEN-deficient tumors were inhibited at the lowest drug concentration used (Fig. 3.14B).  We 
concluded that leflunomide can penetrate tightly-packed 3-D clusters of human cells and can inhibit at 
least some PTEN-deficient patient-derived glioblastomas.  
 
Combination therapy 
A common problem with cancer therapy is the eventual development of resistance.  Combining multiple 
therapies may be a way to overcome acquired resistance or enhance the tumor-reducing ability of 
leflunomide in the first place in sensitive cells.  We therefore performed numerous combination therapy 
experiments. 
 
We first tried a few rational approaches: combining leflunomide with other drugs in the same pathway.  
The first was actually a double-hit on DHODH, with brequinar.  Adding brequinar to MEFs reduced the 
GI50 of leflunomide for both WT and Pten-/- cells, but thereby removed the differential sensitivity 
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between the two (Fig. 3.15A).  Adding brequinar on top of leflunomide to PTEN mutant human breast 
cancer cell lines did not have an effect (Fig. 3.15B).   
 
We next tried various steps of the PI3K pathway.  A PI3K inhibitor also reduced the GI50 of leflunomide 
for both WT and Pten-/- MEFs but eliminated the differential sensitivity between the two (Fig. 3.15C).  
Additionally, the PI3K-leflunomide combination seemed to work better in PTEN WT human breast 
cancer cell lines compared to PTEN mutant lines (Fig. 3.15D).   
 
Rad001 is a rapamycin analog, acting on mTORC1.  It has previously been shown that cells with Pten loss 
are more sensitive to rapamycin than WT cells, and our data were consistent with this finding (Neshat, 
Mellinghoff et al. 2001, Podsypanina, Lee et al. 2001).  However, rad001 did not synergize with 
leflunomide in Pten-/- cells: in both MEFs and mouse breast cancer cells, addition of the GI25 of 
leflunomide did not decrease the GI50 of rad001.  The GI25 of rad001 also did not decrease the GI50 of 
leflunomide in MEFs, and in mouse breast lines the addition of the GI25 of rad001 eliminated the 
leflunomide GI50 difference between MCCL-357 and MCCL-278 cells (Fig. 3.16).   
 
Since leflunomide is a pyrimidine synthesis inhibitor, we questioned whether other nucleotide 
disruptors could crash the system, leading to enhanced cell death.  Adding leflunomide to a 5FU titration 
lowered the GI50 of 5FU in MCCL-278 cells only, and yielded no difference in sensitivity between the 
genotypes. At a GI25 dose, 5FU lowered the GI50 of leflunomide in MCCL-278 but not MCCL-357 cells, 




Methotrexate inhibits dihydrofolate reductase (DHFR) in the folate cycle for one-carbon metabolism 
involved in primarily purine synthesis.  There was no difference in methotrexate GI50 at baseline 
between Pten-/- and WT cells, and addition of leflunomide lowered the GI50 to an approximately equal 
degree in both.  The GI25 of methotrexate lowered the leflunomide GI50 to a greater degree in MCCL-
278 compared to MCCL-357 cells, losing the difference in sensitivity between the two genotypes (Fig. 
3.17C-D). 
 
Our data show that our rational combinations thus far did not synergize.  We therefore also tried 
combining leflunomide with various chemotherapies that are used as standard of care for cancer 
treatment. 
 
Pten-/- and WT cells were neither differentially sensitive to carboplatin at baseline nor with the addition 
of leflunomide, although leflunomide lowered the carboplatin GI50 for both genotypes.  The GI25 of 
carboplatin lowered the leflunomide GI50 to a greater degree in MCCL-278 compared to MCCL-357 cells, 
losing the difference in leflunomide sensitivity between the two (Fig. 3.18A-B). 
 
Pten-/- and WT cells were also not differentially sensitive to doxorubicin at baseline.  Interestingly, the 
combination with leflunomide enhanced WT sensitivity to doxorubicin, although there was still no 
significant difference between genotypes in the combination. Doxorubicin also decreased the GI50 of 
leflunomide for Pten WT cells, and there was no difference between the genotypes with the 




Lastly, we tried a combination therapy experiment with paclitaxel.  Addition of the GI25 of paclitaxel did 
not affect the GI50 of leflunomide in the dose response experiment.  However, despite no baseline 
difference in paclitaxel sensitivity, addition of leflunomide created a profound GI50 difference between 
Pten-/- and WT cells (Fig. 3.19A-B).  This interesting in vitro result prompted an in vivo experiment: 
 
We treated MDA-MB 468 xenografts with vehicle or 100mg/kg leflunomide.  After 4 weeks, half of the 
vehicle-treated and half of the leflunomide-treated cohorts were then treated with 20mg/kg paclitaxel, 
creating 4 arms of the experiment: vehicle, leflunomide alone, paclitaxel alone, and combination 
treatment.  However, there were no significant differences between leflunomide alone, paclitaxel alone, 
or combination-treated mice in terms of tumor size (Fig. 3.19C).  It appears that leflunomide and 
paclitaxel are fairly equivalent for tumor reduction, and combining the two at these doses was not 
efficacious.   
 
While our attempts at an effective combination therapy have so far been unsuccessful, these data do 
not close the door on finding a good combination option in the future.  
 
Discussion 
We find the results of this chapter to be quite exciting.  Our evidence that DHODH inhibition is effective 
against PTEN mutant cancers could have terrific impact in the clinic; in fact, we are currently working to 
initiate a clinical trial in patients with TNBC.  Further experiments will show the validity of the model in 
other tumor types, and if successful could launch clinical trials in glioblastoma and prostate cancer 
patients.  For example, we found in vitro that the PTEN mutant human glioblastoma cell line DBTRG was 
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sensitive to leflunomide.  We therefore plan to use this line for a xenograft experiment in collaboration 
with Drs. Hadjipanayis and Boras at Mt. Sinai, as a model for invasive brain tumors.   
 
Our results are also satisfying at a conceptual level.  Through DHODH inhibition we prove that de novo 
pyrimidine synthesis is in fact as important for PTEN deficient cells as we conjectured from our results in 
chapter 2.  These data also provide proof of principle that studying metabolic consequences of 
oncogene or tumor suppressor alterations and interfering with the deregulated pathways could be 
effective treatments.  We also show the specificity of de novo pyrimidine synthesis inhibition over other 
nucleotide inhibition in Pten-/- cells, demonstrating that metabolic data can be predictive of drug 
response.   
 
An interesting paper by Hail et al found cytostatic effects of A771726 in prostate cancer cells in the short 
term, and some cytotoxicity with prolonged treatment.  Notably, the DU-145 cell line they used is PTEN 
heterozygous.  The partial loss of PTEN function could explain the inhibitory effects of A771726, but 
could also explain why toxicity was only seen at high doses since PTEN was not fully inactivated.  Excess 
uridine did not rescue the effects of A771726 in the cells, and the authors claim that in some cases the 
salvage pathway for pyrimidines is not sufficient to compensate for blocking de novo synthesis.  It would 
be informative to see whether orotate would rescue the inhibition, then, since the de novo pathway 
could resume just after the inhibited enzyme.  Interestingly, they observed that short-term exposure to 
A771726 decreased ROS production, and only a very high dose for extended time caused mitochondrial 
dysfunction in their study (Hail, Chen et al. 2010).  This could explain why we do not observe 




There is some controversy about whether leflunomide/A771726 has effects other than on DHODH.  
Some literature suggests it can inhibit tyrosine kinases in T- and B-cells, in particular p56, Jak1, and Jak3, 
or indirectly AKT (Breedveld and Dayer 2000, Sawamukai, Saito et al. 2007).  Conversely, other studies 
claim it can activate tyrosine kinases such as ERK and AKT, and thereby protect cells from apoptosis and 
DNA fragmentation (Leger, Liagre et al. 2006).  Our ability to rescue leflunomide-induced growth defects 
with orotate and uridine gives us confidence that DHODH is the target of the effects we see.  
Furthermore, siRNA to DHODH recapitulated cell death in PTEN mutant cells, and we did not see 
differences in phospho-AKT upon teriflunomide treatment of MEFs.  We therefore believe that at least 
in our system, leflunomide is acting primarily on DHODH and not tyrosine kinases to exact its effects on 
PTEN mutant cells.  
 
It is also important to note discrepancies between enzymatic IC50s and intracellular GI50s.  Since 
leflunomide binds tightly to serum proteins, the amount of leflunomide added to cells in culture may 
exceed the level getting into the cells, which further exceeds that which actually interacts with and 
inhibits DHODH.  The concentration required to achieve growth inhibition of 50% is therefore likely 
greater than the enzymatic IC50, and relatively high concentrations are required for inhibitory effects as 
demonstrated by us and previous studies; these concentrations are also normally maintained in RA 
patients (Hail, Chen et al. 2010, White, Cech et al. 2011).  Our experiments with glioblastoma tumor 
spheres were performed in serum-free media, but are not directly comparable to adherent cell 
experiments since the amount of leflunomide required to penetrate 3-dimensional spheres could be 
greater.  It would be illuminating to try adherent cell leflunomide experiments in a serum gradient, 




In the current literature, there is some evidence of DHODH inhibition being effective against cancer 
cells.  A771726 was cytostatic in a human T-lymphoblastoma cell line, which could be rescued by uridine 
(Greene, Watanabe et al. 1995).  Brequinar was also shown to be efficacious in acute myeloid leukemia 
(AML) models by triggering myeloid differentiation (Sykes, Kfoury et al.), perhaps unsurprisingly due to 
the known ability of leflunomide to affect B-cell and T-cell proliferation.  Treatment of BRAFV600E mutant 
melanomas with a DHODH inhibitor in combination with a BRAFV600E inhibitor slowed down tumor 
growth in vitro and in vivo (White, Cech et al. 2011).  To our knowledge, our data are the first to claim 
that leflunomide could be used as a single agent therapy for patients with PTEN mutant cancers.  
However, even good targeted therapies incur a problem: that of tumor resistance, in which alterations 
in additional pathways are selected for in order to bypass the block of a targeted therapy.  Combination 
therapies may avert or delay resistance, and in the final chapter of this thesis we discuss in more detail 




CHAPTER 3 FIGURE LEGENDS AND FIGURES  
 
Figure 3.1.  Pten-/- MEFs are sensitive to DHODH inhibitors. (A) Pten WT and KO cells were treated with 
dose titrations of leflunomide, A771726, or brequinar to determine GI50s (Student’s t-test, p*<.05, n=3).  
(B) MEFs were treated with 25µM leflunomide or DMSO, and growth was measured over time using 
phase-contrast images from an Incucyte Zoom.  (C) MEFs were treated with 100µM leflunomide and 
growth was measured over time using phase-contrast images from an Incucyte Zoom (one-way ANOVA, 
*p<.001, n=3).   
Figure 3.2.  PTEN mutant cancer cells are sensitive to DHODH inhibitors.  (A) Cells were treated with 
dose titrations of leflunomide to determine GI50s (Student’s t-test, p*<.05, n=3). (B-E) Cells were 
treated with dose titrations of DHODH inhibitors as indicated to determine GI50s (Student’s t-test, *p-
values as reported on the figures, n=3). 
Figure 3.3.  DHODH inhibitors kill PTEN mutant cells.  (A-B) Cells were treated with 100µM leflunomide 
and DRAQ7.  Live cell imaging of phase confluence and red fluorescence over time was used to 
determine accumulation of cell death (two-way ANOVA, *p<.01).  (C) Cells were treated with 100µM 
leflunomide and DRAQ7.  Live cell imaging of phase confluence and red fluorescence over time was used 
to determine accumulation of cell death (two-way ANOVA between PTEN WT and mut, *p<.0001). 
Figure 3.4.  Human breast cancer cell line tumor spheres.  PTEN WT and mutant breast cancer cell lines 
were grown as tumor spheres in untreated media, DMSO, or 50, 100, or 200μM leflunomide.  After 5 
days, the number of tumor spheres in each condition was counted.  
Figure 3.5.  Rescue of growth inhibition.  (A) Cells were treated with 50µM leflunomide in combination 
with 0 or 640µM orotate. Confluence of cells after 5 days of treatment was measured (Student’s t-test, 
*p<.05, n=3).  (B) Cells were treated with 100µM leflunomide in combination with 0 or 3.125mM 
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uridine. Confluence of cells after 5 days of treatment was measured (Student’s t-test, *p<.05, n=3).  (C) 
Cells were treated with 50µM leflunomide in combination with 0, 31.25, 62.5 or 125µM orotate. 
Confluence of cells after 5 days was measured (Student’s t-test, *p<.05, n=3).  (D) Cells were treated 
with 25µM leflunomide in combination with 0, 312.5, or 625µM orotate. Confluence of cells after 5 days 
was measured (Student’s t-test, *p<.05, n=3). Note that here as well as in A-C a large amount of DMSO 
was used in each condition to match the amount of orotate needed, narrowing the growth differential 
we normally observe between leflunomide treated and untreated cells in the PTEN mutant setting.  (E) 
Cells were treated with 100µM leflunomide in combination with 0, 3.125, or 6.25mM uridine. 
Confluence of cells after 5 days was measured (Student’s t-test, *p<.05, n=3).  (F) Cells were treated 
with 100µM leflunomide in combination with 0, 3.125, or 6.25mM uridine. Confluence of cells after 5 
days of treatment was measured (Student’s t-test, *p<.05, n=3). (G) Cells were treated with 25µM 
leflunomide in combination with 0, 6.25, or 12.5mM uridine. Confluence of cells after 5 days was 
measured (Student’s t-test, *p<.05, n=3). 
Figure 3.6.  The role of DHODH.  (A) Cells were transfected with siRNA against DHODH or control 
(scrambled) siRNA; cell viability was measured using Annexin V and 7AAD via flow cytometry and the 
percentage of live cells in each condition was normalized to control.  0.5µg/mL actinomycin D was a 
positive control for cell death (Student’s t-test, *p<.05, n=3).  (B) Immunoblot of DHODH after 
knockdown with one of 2 DHODH siRNAs or with control siRNA.  (C) Cells were treated with 50µM 
leflunomide in combination with DMSO or 10mM n-acetylcysteine. Confluence of cells after 5 days of 
treatment was measured.  (D) Cells were incubated with 100µM leflunomide or DMSO and stained with 
MitoSox Red.  Flow cytometry was used to determine the mean fluorescence intensity (MFI), indicating 
the relative level of mitochondrial superoxide (Student’s t-test, p>.05, n=3). 
Figure 3.7.  Growth rate does not predict sensitivity to DHODH inhibition.  (A) MCCL-278 and MCCL-
357 growth rates, measured over time using phase-contrast images from an Incucyte Zoom.  (B) Myc-
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CaP and CaP8 growth rates, measured over time using phase-contrast images from an Incucyte Zoom.  
(C) Human breast cancer cell line growth rates, measured over time using phase-contrast images from 
an Incucyte Zoom. 
Figure 3.8.  The source of pyrimidine flux.  (A) Immunoblot of DHODH in MEFs.  (B) Immunoblot of 
pCAD before and after treatment with 100µM leflunomide in MEFs. (C) Immunoblot of pCAD S1859 in 
mouse breast cancer cell lines. (D) Immunoblot of pAKT T308 before and after treatment with 50µM 
A771726.   
Figure 3.9.  Sensitivity to brequinar.  (A) MEFs were incubated with 12.5µM brequinar or DMSO and 
growth was measured over time using phase-contrast images from an Incucyte Zoom.  (B) Cells were 
treated with dose titrations of brequinar to determine the GI50s (Student’s t-test, *p<.05, n=3).  (C) Cells 
were treated with dose titrations of brequinar to determine the GI50s (Student’s t-test, p>.05, n=3).  5 
WT, 5 PTEN mutant and 3 PIK3CA mutant cell lines were used, listed in table 3.1. 
Figure 3.10.  Differential AKT signaling.  (A) Cells were treated with dose titrations of leflunomide to 
determine the GI50s (Student’s t-test, *p<.05, n=3).  5 WT, 5 PTEN mutant and 3 PIK3CA mutant cell 
lines were used, listed in table 3.1.  (B) Immunoblots of pAKT and total AKT in nuclear fractions of Pten-/- 
and Pik3ca mutant MEFs.  (C) Immunoblot of pAKT and total AKT in whole cell lysate of Pten-/- and 
Pik3ca mouse cancer cell lines.  (D) Immunoblot of pAKT and total AKT in nuclear fractions of Pten-/- and 
Pik3ca mutant mouse cancer cell lines. 
Figure 3.11.  Specificity of nucleotide inhibition sensitivity.  (A-B) Cells were treated with dose titrations 
of 5-fluorouracil or mercaptopurine, respectively, to determine GI50s (Student’s t-test, p>.05, n=3).  (C) 
Cells were grown in media containing full glutamine (4mM) or no glutamine.  
Figure 3.12.  In vivo treatment with leflunomide of triple negative breast cancer models.  (A) SUM149 
xenografts.  Mice were treated with 100mg/kg leflunomide or vehicle on days indicated with arrows and 
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tumor size was measured by calipers (two-way ANOVA with multiple t-tests, corrected for multiple 
comparisons, *p<.01 for ANOVA and t-tests, n=6).  (B) MDA-MB 468 xenografts expressing luciferase.  
Treatment was started on day 7, with 100mg/kg leflunomide or vehicle for four consecutive days each 
week.  Tumor size was measured by assessing luminescence, quantified by 
photons/second/cm2/steradian and normalized to control (one-way ANOVA with multiple t-tests, 
corrected for multiple comparisons, *p<.05 for ANOVA and t-tests, n=5).  Right panel: luminescence of 
treated and control mice after 2 weeks of treatment.  (C) MDA-MB 468 xenografts which were never 
treated and allowed to grow for seven weeks were then treated with 100mg/kg leflunomide for 7 days. 
Tumor size was measured by assessing luminescence, quantified by photons/second/cm2/steradian 
(multiple t-tests, corrected for multiple comparisons, *p<.05, n=2).  (D) SUM149 xenografts which were 
never treated and allowed to grow for four weeks were then treated with 100mg/kg leflunomide on 
days indicated by arrows. Tumor size was measured by calipers (n=4).   
Figure 3.13.  In vivo treatments with leflunomide of additional models.  (A) PDX xenografts.  Mice were 
treated with 100mg/kg leflunomide or vehicle 4 consecutive days per week on days indicated with 
arrows and tumor size was measured by calipers (two-way ANOVA with multiple t-tests, corrected for 
multiple comparisons, *p<.01 for ANOVA and t-tests, n=6).  (B) Immunoblots of PTEN protein in PDX 
samples and MCCL-278 as a positive control for Pten expression.  (C) Xenografts of MCCL-278 (Myc, 
Pik3ca HR) and MCCL-357 (Myc, Pten-/-) cell lines.  Mice were treated with 100mg/kg leflunomide or 
vehicle for four consecutive days each week on days indicated by arrows and tumor volume was 
measured by calipers. Growth rate of the tumors was determined by calculating the slope of the tumor 
growth.  (Student’s t-test, *p<.01, n=8).  
Figure 3.14.  Leflunomide treatment of patient-derived glioblastomas.  (A) Immunoblot of PTEN of four 
patient-derived glioblastomas.  (B) Dispersed (single cell suspension) glioblastomas were treated with 
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DMSO or 50, 100, or 200µM leflunomide for 5 days.  At the endpoint, the number of 3-dimensional 
tumor spheres was quantified and normalized to untreated samples. (Student’s t-test, *p<.05, n=3).   
Figure 3.15.  Combination of leflunomide with brequinar or GDC0941.  (A-B) Cells were treated with 
dose titrations of leflunomide in the presence or absence of brequinar to determine GI50s (Student’s t-
test, *p-values on figures, ns not significant, n=3).  (C) Cells were treated with dose titrations of 
leflunomide in the presence or absence of 20 or 100nM GDC0941 to determine GI50s (Student’s t-test, 
*p-values on figure, n=3).  (D) Cells were treated with dose titrations of leflunomide in the presence or 
absence of GDC0941 to determine GI50s (Student’s t-test, *p-values on figure, n=3). 
Figure 3.16.  Combination of leflunomide with rad001.  (A) Cells were treated with dose titrations of 
rad001 in the presence or absence of leflunomide to determine GI50s (Student’s t-test, p>.05, n=3).  (B) 
Cells were treated with dose titrations of leflunomide in the presence or absence of rad001 to 
determine GI50s (Student’s t-test, *p-values on figures, n=3).  (C) Cells were treated with dose titrations 
of rad001 in the presence or absence of leflunomide to determine GI50s (Student’s t-test, p>.05, n=3).  
(D) Cells were treated with dose titrations of leflunomide in the presence or absence of rad001 to 
determine GI50s (Student’s t-test, *p-values on figures, n=3).  (D) Immunoblot of pS6 to ensure potency 
of rad001; less signal in the treated samples indicated that rad001 was effective.  
Figure 3.17.  Nucleotide inhibitor combinations.  (A) Cells were treated with dose titrations of 5FU in 
the presence or absence of leflunomide to determine GI50s (Student’s t-test, p>.05, n=3).  (B) Cells were 
treated with dose titrations of leflunomide in the presence or absence of 5FU to determine GI50s 
(Student’s t-test, *p-values on figures, n=3).  (C) Cells were treated with dose titrations of methotrexate 
in the presence or absence of leflunomide to determine GI50s (Student’s t-test, p>.05, n=3).  (D) Cells 
were treated with dose titrations of leflunomide in the presence or absence of methotrexate to 
determine GI50s (Student’s t-test, *p-values on figures, n=3).   
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Figure 3.18.  Chemotherapy combinations.  (A) Cells were treated with dose titrations of carboplatin in 
the presence or absence of leflunomide to determine GI50s (Student’s t-test, *p-values on figures, n=3).  
(B) Cells were treated with dose titrations of leflunomide in the presence or absence of carboplatin to 
determine GI50s (Student’s t-test, *p-values on figures, n=3).   (C) Cells were treated with dose titrations 
of doxorubicin in the presence or absence of leflunomide to determine GI50s (Student’s t-test, *p-values 
on figures, n=3).  (D) Cells were treated with dose titrations of leflunomide in the presence or absence of 
doxorubicin to determine GI50s (Student’s t-test, *p-values on figures, n=3).   
Figure 3.19.  Combination treatment of leflunomide and paclitaxel.  (A) Cells were treated with dose 
titrations of leflunomide in the presence or absence of paclitaxel to determine GI50s (Student’s t-test, 
*p-values on figures, n=3).  (B) Cells were treated with dose titrations of paclitaxel in the presence or 
absence of leflunomide to determine GI50s (Student’s t-test, *p-values on figures, n=3).  (C)  Mice 
xenografted with MDA-MB 468 cells were treated with 100mg/kg leflunomide or vehicle for 4 weeks, 4 
times per week.  About half of the vehicle treated mice were then treated with 20mg/kg paclitaxel 
alone, and half of the leflunomide treated mice were treated with paclitaxel + leflunomide.  Arrows 
correspond to paclitaxel treatments which were given once a week while leflunomide was still 
administered 4 times per week.  Tumor size was measured by assessing luminescence, quantified by 












































Chapter 4: Mechanism of Death 
 
In the previous chapter we discovered the vulnerability of PTEN-deficient cells to DHODH inhibition due 
to dependence on the de novo pyrimidine synthesis pathway.  These data raised the following question: 
upon DHODH inhibition, what is occurring downstream to drive cell death?  As mentioned in the 
introductory chapter, the PTEN pathway can affect cell cycle regulation and DNA damage.  The majority 
of this chapter will expand upon these concepts, and will pertain to how DNA damage and a deficient 
checkpoint response induces synthetic lethality upon DHODH inhibition. 
 
Introduction 
Cell cycle checkpoints 
It is important for a cell to ensure that DNA integrity is intact prior to cell division, including checking for 
errors in replication and chromosome segregation.  Cell cycle checkpoint pathways assess the level of 
DNA damage, and regulate cell cycle progression (Elledge 1996).  The G0 phase consists of non-
replicating cells; interphase consists of the G1, S, and G2 phases and is followed by mitosis and 
cytokinesis.   
 
Injury to a cell’s DNA through ionizing radiation, DNA-intercalating agents, or induction of stalled 
replication such as by ultraviolet light normally instigates checkpoints.  Checkpoint activation can be 
through the kinases ATM (ataxia telangiectasia mutated) or ATR (ataxia telangiectasia and Rad3-related 
protein).  It is generally considered that ATM is activated by double strand breaks (such as those caused 
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by ionizing radiation) and ATR by stalled replication or chemotherapeutics, but there can be overlap in 
the signaling pathways between the two (Bartek and Lukas 2003). 
 
Since nucleotide inhibition can cause stalled replication, we focus here primarily on ATR, the activation 
of which is dependent on two signals.  The first signal is replication protein A (RPA), which coats single 
stranded DNA and recruits ATRIP (ATR interacting protein).  ATR-ATRIP binding allows ATR to associate 
with DNA (Zou and Elledge 2003).  The second signal is via TOPBP1 (DNA Topoisomerase II-Binding 
Protein 1), which is involved in normal DNA replication and binds to DNA gaps and breaks.  TOPBP1 also 
induces the kinase activity of ATR, and is required for the ability of ATR to phosphorylate its downstream 
effectors (Kumagai, Lee et al. 2006).  Thus, the integration of RPA and TOPBP1 signals yields recruitment 
and activation of ATR. 
 
Downstream of operational ATR is the activation of the checkpoint protein CHK1; phosphorylation on 
S317 by ATM and S345 by ATR activates the protein to carry out its function in halting cell cycle 
progression (Liu, Guntuku et al. 2000, Zhao and Piwnica-Worms 2001, Gatei, Sloper et al. 2003), allowing 
proper DNA repair (which itself is mediated by numerous proteins).  Cells without CHK1 have been 
shown to have defects in the S and G2 checkpoints after insult with ionizing radiation (Zhao, Watkins et 
al. 2002). 
 
Hydroxyurea is an inhibitor of ribonucleotide reductase, an enzyme that converts ribonucleotides to 
deoxyribonucleotides for synthesis of DNA; this drug can therefore cause stalled replication (Yarbro 
1992).  Depletion of nucleotide pools by hydroxyurea activates the ATR checkpoint at replication forks in 
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S-phase cells, and treatment with hydroxyurea in cells with CHK1 knockdown increased DNA damage 
and cell death (Tibbetts, Cortez et al. 2000, Cho, Toouli et al. 2005).  Toledo et al showed that ATR 
normally restrains origin firing to preserve adequate amounts of RPA, and that cells treated with 
hydroxyurea and an ATR inhibitor had an excess of single-stranded DNA due to unrestrained origin firing 
and stalled forks.  This exhausted the RPA pool, leading to a conversion of stalled forks to double strand 
breaks and triggering replication catastrophe (Toledo, Altmeyer et al. 2013). 
 
The PTEN pathway and checkpoint regulation 
While there is considerable literature about the role of PTEN in DNA damage and checkpoint signaling, 
some of it is conflicted.  Shen et al proposed that Pten is localized at centromeres in order to contribute 
to DNA stability.  The authors showed that mutants of the C-terminal of Pten caused loss of robustness 
of centromeres in MEFs, and that Pten-/- MEFs had more DNA breaks and less RAD51, an important 
protein in double strand break repair (Shen, Balajee et al. 2007).  However, a contradictory paper by 
Gupta et al did not find any compelling DNA-Pten interaction in WT MEFs or difference in ATM 
activation, RAD51 expression, or homologous repair, even when the cells were treated with ionizing 
radiation.  The authors of this paper claim that the increase in DNA damage in Pten deficient cells is not 
due to defects in repair but rather due to aberrant cell cycle checkpoints.  They found that a CHK1 
inhibitor only affected WT cells in terms of chromosomal abnormalities, suggesting that Pten-/- cells 
were already deficient in functional CHK1.  To further support their hypothesis, the authors found that 
Pten-/- cells bypassed taxol-induced mitotic arrest, indicating that the real crisis may be that these cells 
do not have enough time for proper repair before cell division (Gupta, Yang et al. 2009).  Additional 
evidence showed a lack of differential RAD51 expression or homologous recombination between PTEN 




A paper by Bassi et al may help resolve the conflict.  The authors found that RAD51 is still expressed in in 
PTEN mutant cells, but is not recruited to sites of damage as well as in PTEN WT cells.  The authors also 
demonstrate that SUMO-PTEN (localized to the nucleus) is needed for homologous recombination repair 
of double stranded breaks.  Furthermore, it was shown that PTEN is phosphorylated by ATM and that 
mutation of this phosphorylation site prevented nuclear exclusion of SUMO-PTEN.  There was both less 
nuclear PTEN in cells exposed to genotoxic stress due to ATM activation, and cells were more sensitive 
to this stress when PTEN was consequently absent from the nucleus (Bassi, Ho et al. 2013). 
 
PTEN has also been shown to interact with RPA in isogenic HCT116 cell lines.  PTEN may stabilize RPA by 
binding both RPA and a deubiquitinase to prevent proteasomal degradation of RPA; stabilization of RPA 
would then protect DNA.  RPA and PTEN are often co-lost in colorectal carcinoma, and tumors were 
more poorly differentiated in in RPA heterozygous mice compared to WT in a colon cancer mouse model 
(Wang, Li et al. 2015). 
 
Interestingly, AKT has been shown to phosphorylate TOPBP1 on its S1159 site, allowing TOPBP1 to 
oligomerize and suppress E2F1 (E2F Transcription Factor 1)-mediated apoptosis (Liu, Paik et al. 2006).  
This process simultaneously inhibits the ability of TOPBP1 to activate ATR in the checkpoint response, by 
preventing its recruitment to chromatin in favor of its other function.  The phosphorylation and ensuing 
oligomerization state of TOPBP1 is therefore a regulatory switch for its roles in transcriptional regulation 




PTEN and the PI3K pathway have also been directly linked to CHK1.  Literature shows that Pten-/- cells 
have a partially defective checkpoint upon exposure to ionizing radiation, and that AKT phosphorylates 
CHK1 on its S280 site causing it to be ubiquitinated and localized to the cytoplasm (King, Skeen et al. 
2004, Puc, Keniry et al. 2005).  This led to increased aneuploidy in PTEN mutant primary breast 
carcinomas (Puc, Keniry et al. 2005).  A subsequent paper by Puc et al found that K274 is the 
ubiquitination site on CHK1 that follows S280 phosphorylation, and mutation to K274R eliminated 
ubiquitination of CHK1 and increased its nuclear localization.  The authors further concluded that 
inhibition of CHK1 function due to PTEN loss causes double stranded breaks (Puc and Parsons 2005). 
 
Results 
Using the above information as a framework for our studies, we can further our understanding of the 
cell death mechanisms in play in PTEN mutant cells upon inhibition of DHODH.   
 
DNA damage 
It is logical that a blockade of pyrimidine synthesis would stop cells from dividing, as the cells would no 
longer have the requisite nucleotides for DNA replication.  As discussed in chapter 3, leflunomide has in 
fact been previously established as a cytostatic drug (Greene, Watanabe et al. 1995, Rückemann, 
Fairbanks et al. 1998).  What is more enigmatic, however, is why DHODH inhibition would cause PTEN-/- 
cells to die.  What is inducing cytotoxicity, and why is this specific to PTEN-deficient cells? 
 
Based on the literature discussed above, we hypothesized that the answer may lie within checkpoint 
pathway defects.  To solve this mystery, we had a couple of clues.  First, we observed that Pten-/- MEFs 
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had a higher level of the DNA-damage indicator gamma-H2AX, consistent with prior reports (Fig. 4.1A).  
(DNA damage is followed by phosphorylation of the histone H2AX, which in its phosphorylated form is 
called gamma-H2AX.)  We hypothesized that the dearth of pyrimidine deoxynucleotides caused by 
DHODH inhibition would exacerbate this defect, and indeed discovered that leflunomide (or A771726) 
augmented DNA damage to a significantly greater degree in PTEN-deficient cells compared to PTEN WT 
(Fig. 4.1B-F).  Furthermore, gamma-H2AX co-localized with replication forks labeled with EdU, indicating 
that the source of damage was originating at (or very close to) sites of DNA replication (Fig. 4.2A).  
Leflunomide-induced DNA damage was rescued by uridine, demonstrating that damage is likely 
instigated by pyrimidine depletion (Fig. 4.2B).   
 
Our second clue concerned the number of replication forks per cell.  Recall from chapter 2 that Pten-/- 
MEFs had a greater number of replication forks per cell compared to WT MEFs as measured by EdU (Fig. 
2.5).  We also see a greater EdU signal in MCCL-357 (Myc, Pten-/-) than in MCCL-278 (Myc, Pik3ca 
H1047R) cells (Fig. 4.3A).  Interestingly, the greater number of replication forks in Pten-/- cells remained 
intact after 24h of treatment with leflunomide, showing that the cells continue to replicate despite the 
presence of DNA damage (Fig. 4.3B-D).  We initially expected the number of replication forks to 
decrease upon leflunomide treatment, since we are blocking nucleotide synthesis.  However, while 
initially counterintuitive, these data demonstrate that Pten-/- cells are not properly sensing the blockade 
of pyrimidines, and attempting to continue growth as usual; it reasonably follows that this will lead to 





ATR pathway defects 
Since depletion of nucleotide pools normally activates the ATR checkpoint, we next examined whether 
there could be defects in ATR signaling leading to inappropriate growth signals.   
 
As discussed above, ATR checkpoint activation at stalled forks requires both RPA interaction with single-
strand DNA to recruit the ATRIP-ATR complex, and TOPBP1 interaction with the ATR activation domain 
so that ATR is functional and can activate CHK1.  We investigated each part of this pathway. 
 
First, we inspected the interaction of RPA and gamma-H2AX by flow cytometry.  This dual-staining 
created a quadrant of possible outcomes:  cells with low RPA and low gamma-H2AX, low RPA and high 
gamma-H2AX, high RPA and low gamma-h2AX, or high RPA and high gamma-H2AX.  We found that at 
early time points an increase in RPA signal was achieved in the presence of A771726 treatment 
regardless of PTEN genotype.  In this setting, the population of cells shifted from low RPA and low 
gamma-H2AX in the untreated condition to high RPA and low gamma-H2AX in the short-term treated 
condition.  At later time points, this was followed by a shift toward both high RPA and high gamma-
H2AX-positive cells in Pten-/- MCCL-357 but not in Pten WT MCCL-278 cells.  The RPA signal in Pten WT 
cells declined after sustained treatment, while Pten-/- cells maintained the RPA signal and gained the 
high gamma-H2AX signal (Fig. 4.4A). Moreover, gamma-H2AX appeared almost exclusively in RPA-
positive MCCL-357 cells treated with A771726; there were negligible cells in the low RPA high gamma-




From these data, we learned that 1) DHODH inhibition initially triggers RPA loading regardless of Pten 
status, 2) Pten WT cells lose RPA signal despite sustained treatment while 3) Pten-/- cells continue loading 
RPA and start presenting gamma-H2AX, and 4) gamma-H2AX only occurs after RPA loading in this 
setting.  We surmise that nucleotide depletion triggers RPA in any cell, but only Pten-/- cells compared to 
PTEN WT cells exhibit significant damage.  It is likely that a defect in ATR signaling is downstream of RPA. 
 
We next investigated the second signal required to activate ATR: TOPBP1.  As mentioned above, AKT 
phosphorylation of TOPBP1 on serine 1159 inhibits its ATR-activating function by preventing its 
recruitment to DNA.  We indeed found greater TOPBP1 S1159 phosphorylation and concomitantly less 
TOPBP1 localization to replication forks in Pten-/- cells compared to Pten WT cells (Fig. 4.5A-C).  
Interestingly, TOPBP1 localization in WT cells increased initially upon leflunomide treatment but then 
declined, similar to its RPA pattern.  Diminished AKT activity through PI3K inhibition reduced both 
phospho-TOPBP1 levels and leflunomide-induced DNA damage (Fig. 4.5D-E).  It is likely that Pten-/- cells 
cannot properly activate ATR due to a lack of TOPBP1 signal.  Therefore, when faced with DHODH 
inhibition, the ATR pathway activated in Pten WT cells is abruptly halted in Pten-/- cells.   
 
If phosphorylated TOPBP1 leads to deficient ATR activation in PTEN mutant cells, CHK1 would not be 
properly activated due to insufficient functional ATR.  Additionally, as mentioned above, AKT 
phosphorylation of CHK1 on serine 280 is inhibitory, and prior work from our lab showed increased 
CHK1 serine 280 phosphorylation and consequent reduced CHK1 activity in PTEN-/- cells compared to WT 
cells.  We measured the active CHK1 signal in our cells and found that A771726 triggered ATR 
phosphorylation of CHK1 at serine 345 at early time points in Pten WT cells, and this activation of CHK1 
declined as RPA declined suggesting that Pten WT cells eventually recovered from DHODH inhibition.  
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(The recruitment and then decline of TOPBP1 localization to replication forks also suggests recovery in 
WT cells.)  Conversely, Pten-/- cells activated CHK1 to a much lesser extent upon A771726 treatment (Fig. 
4.6A-B).  Thus, Pten-/- cells appear to be incapable of generating an appropriate activation of the ATR-
CHK1 checkpoint at replication forks, and instead accumulated damage at 18h. 
 
By 48h this genomic stress manifested in a greater number of chromosome gaps, breaks, and multiradial 
formations in MCCL-357 cells treated with A771726 compared to MCCL-278 cells (Fig. 4.6C-F).  These 
findings are reminiscent of the sensitivity to hydroxyurea that occurs in the setting of an ATR inhibitor 
(Toledo, Altmeyer et al. 2013). 
 
To test that our proposed mechanism is indeed the method by which cell death is induced, we 
transfected PTEN mutant cells with TOPBP1 and CHK1 mutants incapable of being phosphorylated by 
AKT (S1159A and S280A, respectively).  These mutants rescued DNA damage and cell death in 
leflunomide-treated PTEN mutant cells, demonstrating that the synthetic lethality between pyrimidine 
depletion and mutation of PTEN is due to the AKT-mediated defects in the ATR pathway (Fig. 4.7A-B).  
The AKT-dependence of this mechanism of toxicity explains why Pten-/- cells were more sensitive to 
DHODH inhibition than Pik3ca mutant cells — as shown in chapter 3, phosphorylated AKT is higher in 
Pten-/- cells compared to Pik3ca mutant cells, especially in the nucleus.   
 
The actual induction of death could be mediated by multiple known cell death mechanisms downstream 
of DNA damage, such as mitotic catastrophe or apoptosis.  Mitotic catastrophe is defined by a cell’s 
premature entry into mitosis without proper DNA repair, consistent with our hypothesis.  It is also 
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characterized by abnormal nuclei, polyploidy, and mitotic abnormalities, all of which were observed in 
Pten-/- cells (but not Pten WT cells) upon A771726 treatment.  Mitotic catastrophe can be followed by 
apoptosis or can be an independent cell death mechanism.  We did observe apoptosis in Pten-/- MEFs 
upon treatment with leflunomide, as detected by cleaved caspase 3 (Fig. 4.7C).  Interestingly, DNA 
damage triggered by the same event can elicit completely different modes of death in different cells, 
and it is not clear why one method will be used over another in a given cell (Surova and Zhivotovsky 
2013).  We suspect that more than one operation of death occurs in our model.  
 
Based on our data, we propose that inhibition of DHODH in PTEN deficient cells first causes stalled forks 
due to inadequate nucleotide pools required to support increased replication, and that sustained 
treatment leads to insufficient ATR activation due to AKT phosphorylation of TOPBP1 and CHK1, leading 
to a buildup of DNA damage and cell death. PTEN WT cells do not exhibit this dependency on pyrimidine 
synthesis and have fewer replication forks per cell.  In PTEN WT cells, treatment initially increased the 
RPA signal and triggered transient phosphorylation of CHK1, while longer treatment led to abated RPA 
with little concurrent increase in gamma-H2AX, explaining the largely unaffected WT population upon 
DHODH inhibition.  While Pik3ca mutant cells also exhibit AKT signaling, their relative resistance to 
DHODH inhibitors suggests that a PI3K signaling dosage-effect due to their lower level of AKT activation 
as compared to PTEN mutant cells may be important (Fig. 4.8). 
 
Alternate hypotheses  
In an effort to be thorough, we also investigated potential alternate explanations beyond the hypothesis 
described above for the specific toxicity to DHODH inhibition in PTEN deficient cells.  The first possibility 




The unfolded protein response (Chang, Kamata et al.) is a built-in stress response in cells.  Stress to the 
endoplasmic reticulum (ER) in the form of accumulated misfolded proteins initiates the UPR, including 
activation of signaling protein IRE1 (inositol-requiring enzyme 1).  IRE1 splices an intron from XBP-1, 
generating active XBP-1 which transcribes genes involved in the transport and degradation of misfolded 
proteins (Xu 2005).  However, prolonged ER stress leads to apoptosis by several proposed mechanisms 
(Sano and Reed 2013).  There is evidence that the PTEN pathway affects the UPR: cells with active AKT 
have increased levels of ENTPD5 (Ectonucleoside Triphosphate Diphosphohydrolase 5), an endoplasmic 
reticulum protein.  ENTPD5 hydrolyzes UMP to UDP, causing increased N-glycosylation and proper 
protein folding in the ER.  Knockdown of ENTPD5 in PTEN-deficient cells has been shown to cause ER 
stress, triggering the UPR and apoptosis (Shen, Huang et al. 2011).  We hypothesized that if DHODH 
inhibition depletes the pool of UDP, it could have the same effect as an ENTPD5 knockdown.   
 
We therefore measured levels of CHOP10 (GADD153) and ATF4 (CREB2), proteins that are upregulated 
upon ER stress and are involved in its apoptotic response (Xu, Bailly-Maitre et al. 2005).  There was no 
difference between Pten-/- or WT cells in the levels of either of these proteins at baseline nor upon 
treatment with leflunomide.  However, treatment with Brefeldin A, a known inducer of ER stress that 
was used as a positive control (Oslowski and Urano 2011) increased ER stress to a greater degree in 
Pten-/- cells (Fig. 4.9A).   
 
The second possibility we explored is PARP-mediated cell death.  Poly ADP-ribosylation (PARylation) of 
proteins by poly(ADP-ribose) polymerases (PARPs) can occur after DNA damage.  PARP can bind to both 
single and double stranded DNA breaks, and may help recruit DNA repair proteins.  Somewhat 
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paradoxically, while low levels of DNA damage causes PARP to initiate repair, high levels of DNA damage 
can cause PARP to promote cell death (Kim, Zhang et al. 2005).  We hypothesized that high levels of DNA 
damage caused by leflunomide could lead to PARP-mediated cell death.  The PARP inhibitor AZD2218 
did partially rescue leflunomide-induced cell death in MCC-357 cells, but did not in another Pten-/- cell 
line (Fig. 4.9B-C).  Therefore, our data do not support PARP-mediated cell death as a key mechanism of 
death in the setting of DHODH inhibition in PTEN deficient cells.  
 
Discussion 
In this section, we discovered that DHODH inhibition kills PTEN-deficient cells in a synthetically lethal 
manner.  First, DHODH inhibition obstructs a pathway that PTEN mutant cells are dependent on for 
growth and sufficient support of DNA replication.  Second, the inherent ATR and CHK1 defects in PTEN-
deficient cells are exploited, crashing the system and causing cell death.  To our knowledge, this is the 
first time specific nutrient dependency induced by PTEN loss has been mechanistically linked to DNA 
damage and checkpoint defects, intersecting at the inhibition of a metabolic pathway.   
 
There are a few points in regards to our data that should be noted.   
 
The rescue of DNA damage by TOPBP1 and CHK1 mutants in leflunomide-treated PTEN mutant cells was 
not 100%, and this is likely because the WT TOPBP1 and CHK1 proteins were still present in the cells.  It 
is also of course possible that the checkpoint defect mechanism is the primary but not only source of 




While our data seem largely consistent with prior knowledge in the field, there are a few points of 
contention.  There is evidence in the literature that PTEN mutant cells have less RAD51 expression and 
recruitment, leading to a deficiency in homologous recombination repair and a resulting sensitivity to 
PARP inhibitors (Mendes-Pereira, Martin et al. 2009).  Our results do not reflect this sensitivity; we see 
either no effect or a protective effect of PARP inhibition in leflunomide-treated PTEN mutant cells 
(although we have not tried PARP inhibition alone).  Since there was variability in response among our 
cell lines, perhaps the effects of PARP on PTEN mutant cells is context- and cell line-dependent.  
Additionally, the sensitivity to PARP inhibition was observed in isogenic HCT116 and HEC1A lines, which 
— as we described in chapter 2 — may not always be reliable for mechanistic studies. 
 
There are also a couple of papers that may not be fully consistent with our findings.  One paper reports 
that loss of PTEN leads to an inability to continue the cell cycle after replication stress (Martin and Ouchi 
2008).  Contrary to other reports, the authors show that loss of CHK1 prevents cell cycle progression, 
while other literature shows that loss of CHK1 leads to progression through S/G2 (Zhao, Watkins et al. 
2002).  Martin et al further state that activation of CHK1 on S317 after stalled replication induces 
phosphorylation of PTEN on T383 to promote cellular reentry into G2/M, and that WT PTEN but not a 
T383A mutation leads to cell cycle recovery (Martin and Ouchi 2008).  It is unclear whether this could be 
consistent with our data: S317 is the ATM activation site, which we did not explore, and replication 
stress in the paper was induced by hydroxyurea which we also did not use.  However, we show that loss 
of PTEN without replication stress increases proliferation, and that adding DHODH inhibitors does not 
affect the number of replication forks.  This paper could possibly be reconciled with our results if the 
effects of different replication stressors causes PTEN to switch functions between promotion and 




An additional report found that PTEN deletion led to impairment of both replication fork progression 
and recovery from stalled forks.  However, the authors also report that PTEN loss causes a premature 
exit from S phase and increased anaphase bridges and endogenous replication stress.  The authors claim 
that PTEN is needed to restart replication after a stalled fork (He, Kang et al. 2015).  We see a higher 
number of replication forks in PTEN deficient cells; while it is possible that progression at these forks is 
impaired, this is not likely due to the faster growth rate of Pten-/- cells.  Our data is consistent, however, 
with their findings of premature S-phase exit which may contribute to cellular death after DHODH 
inhibition. 
 
Consistent with our findings are reports that show high AKT activity in G2/M, which can be caused by 
PTEN loss, and accumulation of mutations instead of apoptosis in mutagen-exposed cells with activated 
AKT (Kandel, Skeen et al. 2002, Shtivelman, Sussman et al. 2002).  The studies further show that 
inhibition of PI3K induced apoptosis at this cell cycle transition and activated CHK1 (Shtivelman, 
Sussman et al. 2002).  An additional report discussed in the introductory chapter also showed that WT 
PTEN induces G1 arrest (Weng, Brown et al. 2001).  It is clear that the role of PTEN in replication and the 
cell cycle is not completely agreed upon, and we hope that our findings shed some light on PTEN’s effect 
on growth at baseline and on checkpoint activation under stress from DHODH inhibition.  
  
We did not uncover any effects on UPR with DHODH inhibition.  However, our data with Brefeldin A 
suggest that PTEN may be protective against ER stress, and there could therefore be a non-DHODH 
mediated mechanism of inducing UPR-mediated death in PTEN mutant cells.  Understanding the effects 
of ER stress inducers on cancer cell lines with PTEN mutations would reveal whether there could be 
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another potential cancer therapy option in this regard.  There is, however, the danger of increasing ER 
stress in normal cells and having a detrimental effect in patients. 
 
It would be interesting to see the effects of DHODH inhibition on cells with BRCA1 mutations, which are 
commonly found in breast cancer.  BRCA1 is also downstream of ATR and is recruited as a DNA repair 
protein (Tibbetts, Cortez et al. 2000).  It is possible that cells with both PTEN and BRCA1 mutations 
would be more sensitive to DHODH inhibition, since the ATR pathway would be even more disrupted.  
On the other hand, it is possible that there will be no effect if there is redundancy in the defect.   
 
Even without DNA damage, ATM and ATR control origin firing.  Shechter et al found that inhibition of 
ATM and ATR with caffeine or antibodies led to a rapid increase in the number of origins, perhaps due to 
the regulation of S-phase-promoting kinase (SPK) (Shechter, Costanzo et al. 2004).  The inherent ATR 
defects in PTEN mutant cells due to AKT-mediated phosphorylation of TOPBP1 could therefore explain 
why we see a naturally higher number of replication forks in PTEN deficient cells.  Bringing our data full 
circle, our exploration of the events leading to cell death following DHODH inhibition in PTEN mutant 
cells may have uncovered the fundamental cause of increased replication in these cells.  We explore this 






CHAPTER 4 FIGURE LEGENDS AND FIGURES 
Figure 4.1.  DNA damage is exacerbated by DHODH inhibition.  (A) Cells were labeled with a gamma-
H2AX antibody.  Flow cytometry determined the mean fluorescence intensity (MFI) of gamma-H2AX 
signal, indicating the level of gamma-H2AX in the cells (Student’s t-test, *p<.05, n=3).  (B-F) Cells treated 
with 100µM leflunomide or A771726 overnight were labeled with a gamma-H2AX antibody.  Flow 
cytometry determined the mean fluorescence intensity (MFI) of gamma-H2AX signal in each condition 
(Student’s t-test, *p-values on figures, n=3). 
Figure 4.2.  The source of DNA damage.  (A) MEFs were treated with 150µM A771726 for 24h, and 
labeled with an EdU-binding fluorescent tag and gamma-H2AX antibody following a 45min EdU pulse.  
Left: representative confocal microscopy images. Right: quantified EdU and gamma-H2AX colocalized 
foci per cell (Student’s t-test, *p<.05, n=3).  (B) Cells were treated with 100µM leflunomide with or 
without uridine and labeled with a gamma-H2AX antibody. Flow cytometry determined the mean 
fluorescence intensity (MFI) of gamma-H2AX signal in each condition (Student’s t-test, *p-values on 
figures, n=3). 
Figure 4.3.  The status of replication forks upon DHODH inhibition.  (A) Cells were pulsed with EdU for 
45min, and labeled with an EdU-binding fluorescent tag following fixation.  Flow cytometry determined 
the mean fluorescence intensity (MFI) of EdU signal, indicating the amount of EdU incorporation in cells 
(Student’s t-test, *p<.05, n=3).  (B) MEFs were treated with 100µM leflunomide or control for 48h, 
pulsed with EdU for 45min prior to fixation, and were labeled with an EdU-binding fluorescent tag.  Left: 
representative confocal microscopy images.  Right: quantification of the number of EdU foci per cell 
(Student’s t-test, p>.05, n=6).  (C) Images in Fig. 4F were used to quantify the percent of cell area 
covered by EdU staining, a metric used to normalize foci to cell size to ensure that cell size is not a 
confounding factor (Student’s t-test, p>.05, ns not significant, n=6). (D) MEFs were treated with 100µM 
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leflunomide or control for 48 hours, pulsed with EdU for 45min prior to fixation, and were labeled with 
an EdU-binding fluorescent tag.  Flow cytometry determined the MFI of EdU signal among cells 
positively stained for EdU, to measure the difference in EdU incorporation in replicating cells in each 
condition (Student’s t-test, p>.05, n=3).   
Figure 4.4.  RPA and DNA damage.  Cells were treated with 150µM A771726 for times indicated and 
labeled with antibodies to RPA and gamma-H2AX.  Flow cytometry determined the percentage of the 
cell population positively-stained for (A) RPA alone (“high RPA”) or both RPA and gamma-H2AX (“high 
RPA + high gamma-H2AX”), or (B) the percentage of cells positively-stained for gamma-H2AX and 
negatively-stained for RPA (“low RPA + high gamma-H2AX”).  (Student’s t-test, *p-values on figures, 
n=4). 
Figure 4.5.  Localization and phosphorylation of TOPBP1.  (A) Cells were labeled with a pTOPBP1 S1159 
antibody. Flow cytometry determined the mean fluorescence intensity (MFI) of pTOPBP1 signal 
(Student’s t-test, *p<.01, n=3).  (B) MEFs were treated with 100µM leflunomide for times indicated, 
pulsed with EdU for 45min, and labeled with an EdU-binding fluorescent tag and TOPBP1 antibody 
following fixation.  Representative confocal microscopy images are shown.  (C) Quantified EdU and 
TOPBP1 colocalized foci per cell (Student’s t-test, *p<.05, n=3).  (D) Cells were treated with 100nM PI3K 
inhibitor GDC0941 or control and labeled with a pTOPBP1 antibody.  Flow cytometry determined the 
mean fluorescence intensity (MFI) of pTOPBP1 signal in each condition (Student’s t-test, *p<.05, n=3).  
(E) Cells were treated with 100µM leflunomide with or without the presence of 100nM GDC0941 
overnight and labeled with a gamma-H2AX antibody. Flow cytometry determined the mean 
fluorescence intensity (MFI) of gamma-H2AX signal in each condition (Student’s t-test, *p<.05, n=3). 
Figure 4.6.  Deterioration of the checkpoint response.  (A) pCHK1 S345 immunoblot after cells were 
treated with 150µM A771726 for times indicated.  (B) pCHK1 S345 immunoblot after cells were treated 
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with 200µM leflunomide for 24 hours.  (C) MCCL-357 cells were treated with 50µM A771726 for 48 
hours.  Representative images of types of DNA damage accrued.  (D-F) Cells were treated with 50 or 
100µM A771726 for 48 hours.  Quantified chromosomal breaks and multiradial formations per haploid 
genome (Student’s t-test, *p-values on figure, cells scored/replicate>100).  Pulverized chromosomes 
could not be quantified due to the very high number of fragments. 
Figure 4.7.  Rescue of DNA damage and cell death.  (A) PTEN mutant cells were transfected with either 
WT TOPBP1 and CHK1, or mutants incapable of being phosphorylated by AKT, and labeled with a 
gamma-H2AX antibody following 100µM leflunomide treatment overnight. Flow cytometry determined 
the mean fluorescence intensity (MFI) of gamma-H2AX signal (Student’s t-test, *p<.05, n=3). (B) PTEN 
mutant cells were transfected with either WT TOPBP1 and CHK1, or mutants incapable of being 
phosphorylated by AKT.  Live imaging of phase confluence and DRAQ7 staining (red fluorescence) over 
time was used to determine accumulation of cell death (two-way ANOVA, *p<.05, n=3).  (C) Cleaved 
caspase 3 immunoblot after MEFs were treated with 200µM leflunomide for 24 hours. 
Figure 4.8.  Model.  Model of WT (left) and Pten-/- cells (right) before and after DHODH inhibition.  After 
glutamine enters Pten-/- cells, it is largely channeled into pyrimidine synthesis to help sustain the greater 
number of replication forks relative to WT cells.  DHODH inhibition blocks pyrimidine synthesis leading 
to stalled forks and RPA loading.  In the setting of PTEN deficiency, AKT phosphorylates CHK1 and 
TOPBP1, releasing TOPBP1 from chromatin and preventing checkpoint activation in a dual manner.  Cells 
continue to attempt division while DNA damage accumulates, leading to cell death. WT cells do not have 
the same dependency on glutamine flux into pyrimidine synthesis, high number of replication forks, nor 
inherent checkpoint pathway defects, and therefore do not exhibit the same downstream consequences 
of DHODH inhibition. 
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Figure 4.9.  Assessment of UPR and PARP inhibition.  (A) Immunoblot of UPR pathway proteins after 
cells were treated for 18h with 100µM leflunomide, 18µM brefeldin A, or DMSO.  (B-C) Cells were 
treated with 100µM leflunomide with or without the presence of 5µM AZD2281.  Live imaging of phase 
























Chapter 5: Summary and Perspectives  
 
The findings of this thesis have unveiled metabolic consequences of PTEN loss and the role they play in 
proliferation.  This created a double-edged sword for tumor cells, exposing a therapeutic vulnerability 
we were able to exploit by inhibiting the de novo pyrimidine synthesis enzyme DHODH.  Furthermore, 
we identified DNA damage and checkpoint defects induced by PTEN deficiency as the basis of synthetic 
lethality upon DHODH inhibition.  In this final chapter, we present a summary of our work and offer 
perspectives for future advancements in the field.  
 
Summary 
In the introductory chapter of this thesis we ventured into the world of cancer metabolism, describing 
old and new findings in the field.  We also focused on the tumor suppressor PTEN and its pathway, a hub 
of scientific inquiry for our understanding of cell biology as well as for development of cancer 
therapeutics.  Linking these ideas, we presented the current literature investigating how various 
components of the pathway affect metabolism, and summarize the questions that have yet to be 
answered.  The remainder of the thesis endeavored to answer some of these questions. 
 
In chapter 2, we found that loss of Pten causes an increase in the rate of growth, associated with an 
increased number of replication forks per cell.  The enhanced proliferation did not appear to be 
associated with changes in mitochondrial respiration, but rather with the induction of glutamine 
dependency.  Historically, an increased uptake and addiction to glucose has been defined as a 
characteristic of tumor cells, but the relative importance of glutamine for tumors is coming to light 




We also realized that the use of isogenic lines can be misleading.  This is an interesting finding, because 
the cell lines in question are often used in our field, and the inconsistencies we have uncovered may 
help explain some of the lack of reproducibility of results across the world.  We decided that the use of 
primary cells for mechanistic studies and cancer cell lines for applicability and follow-up studies was a 
good strategy for achieving accurate results.   
 
In primary Pten-/- MEFs, we further found that glutamine was being directed to de novo synthesis of 
pyrimidines.  In chapter 3, we discovered that this created a point of vulnerability for PTEN-deficient 
cells.  Inhibition of DHODH, a key enzyme in the de novo pyrimidine synthesis pathway, preferentially 
killed cells with PTEN loss.  Remarkably, we were also able to diminish tumor growth in vivo with the 
DHODH inhibitor leflunomide, giving us hope that this will be useful for cancer patients with PTEN 
mutations.   
 
Although several attempts at identifying a valuable combination therapy with leflunomide were 
unsuccessful (including with chemotherapeutic agents, PI3K pathway inhibitors, and other metabolic 
disruptors), leflunomide was an effective single-agent therapy.  We do plan to continue the search for a 
viable combination strategy as well.   
 
Chapter 4 uncovered a mode of synthetic lethality.  Inherent defects in the checkpoint signaling pathway 
are exacerbated by the upstream block of de novo pyrimidine synthesis, thus exemplifying a duality of 
sensitivity to DHODH inhibitors.  This illustrates a fascinating circular concept: PTEN loss drives ATR 
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signaling defects and subsequent replication fork increases, which encourages glutamine dependency 
and pyrimidine flux to sustain growth while simultaneously being the cause of cell death upon inhibition 
of the metabolic pathway. 
 
Perspectives 
In the introductory chapter we discussed the role of altered metabolism in cancer development in a 
broad sense: are deregulated metabolic pathways a byproduct of oncogenic signaling changes, or is 
altered metabolism actually the ultimate goal in order to produce sufficient cellular components for 
growth, with oncogenic changes simply the means to an end?  A survey of the literature indicates a 
combination of the two, with neither stark viewpoint completely encompassing the true nature of the 
interaction between oncogenic signaling, metabolism, and tumor development. 
 
In PTEN mutant cells, for example, glutamine flux into de novo pyrimidine synthesis helps support 
increased replication, but other downstream signaling effects in the cell cycle, etc. also contribute to 
proliferation and may even be the cause of increased replication forks in the first place.  The integration 
of enhanced metabolism with signaling alterations not only encourages tumorigenicity, but in this case 
also exposed a therapeutic vulnerability.  We present a model of specific nutrient dependency 
mechanistically linked to DNA damage and checkpoint defects, converging at a tumor suppressor-driven 
metabolic pathway and its inhibition.   
 
This brings to light an important question:  within this system, what is the cause of glutamine flux and 
what is the effect?  Is the push of glutamine into the de novo pyrimidine synthesis pathway by CAD 
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responsible for creating the flux, or are increased replication forks downstream pulling glutamine into 
the pathway to sustain themselves and merely using CAD phosphorylation to facilitate this?  It is 
probable that both are true – that it is a supply as well as a demand, a push as well as a pull – coalescing 
on the de novo pyrimidine synthesis pathway.  This is particularly likely because evidence suggests that 
enzyme alterations alone could be buffered, so to speak, leading to homeostasis of metabolites rather 
than chronic increases in a pathway.  An outlet for the pathway, on the other hand, could maintain the 
upregulation (Fendt, Buescher et al. 2010).  This dual-dependence may also be why the synthetic 
lethality is so effective.    
 
Pathway specificity 
We can wonder, then, whether DHODH inhibition per se is required to take advantage of this sensitivity 
in PTEN mutant cells, or whether other inhibitors in the same pathway will achieve the same goal.  Our 
experiments with DHODH inhibitors began because of the availability of FDA-approved drugs against this 
enzyme, but it’s possible that targeting other components of the de novo pyrimidine pathway will have 
the same effect.  
 
This has launched a series of experiments we are currently conducting in the lab to tackle the question 
of specificity.  To address this, we will determine the effects of PALA, an inhibitor of CAD, and move 
upstream to mTORC1 inhibition and then glutaminase inhibition.  If our hypothesized mechanism is 
correct, it is likely that PALA will phenocopy leflunomide or A771726, although we do not yet know if 
PALA has off-target effects and is not as “clean” of a drug, confounding results.  A CRISPR mutant of CAD 
that cannot be phosphorylated could also help determine the necessity of pCAD in our mechanism.  





We do have some preliminary data to assist us: we found, consistent with prior reports, that PTEN 
mutant cells are more sensitive to the rapamycin analog rad001.  What we don’t know is whether this is 
in actuality due to its effects on CAD.  Inhibiting mTORC1 will indeed effect CAD (Ben-Sahra, Howell et al. 
2013), but will also affect the myriad other downstream effectors we discussed in the introductory 
chapter.  Since these components of the pathway are also more upregulated in PTEN deficient cells it is 
tenable that only PTEN deficient cells will be targeted, as we and others have seen.  The ability of 
orotate or uridine to rescue rad001 inhibition will answer this question — if the rescue is successful, CAD 
is likely responsible for rad001 sensitivity; if not, other components of the mTORC1 signaling pathway 
are likely mediating the sensitivity.  Interestingly, additional literature suggests that mTORC1 increases 
expression of glutamate dehydrogenase, which is downstream of the glutaminase activity but could 
affect the TCA cycle pathway for pyrimidines from glutamine (Csibi, Fendt et al. 2013).  Blocking this 
could have an effect on the amount of aspartate available for pyrimidine synthesis, unless glucose is 
able to compensate for the deficiency.  However, inhibitors of mTORC1 have had limited efficacy in the 
clinic, and leflunomide or A771726 may be better in that regard (Statz, Patterson et al. 2016).   
 
We also know that the glutaminase inhibitor CB-839 collapsed the growth difference between WT and 
Pten-/- MEFs, but as of yet do not know whether the effects were primarily through growth arrest or cell 
death, or of its applicability to PTEN human cancer cell lines.  CB-839 has been shown to have efficacy in 
triple negative breast xenografts (Gross, Demo et al. 2014), and given the frequency of PTEN mutations 
in this disease it is possible that glutaminase inhibition will be efficacious.  However, DHODH inhibition 
has the advantage of affecting a specific pathway of glutamine flux downstream of glutaminase, thus 
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preserving glutamine’s other important functions in the cell such as the TCA cycle.  This increases the 
specificity of DHODH inhibitors to those cells which are dependent on glutamine’s role in pyrimidine 
synthesis per se, and is perhaps why their toxicity is low enough to be taken as a daily medication by 
rheumatoid arthritis and multiple sclerosis patients (Munier-Lehmann, Vidalain et al. 2013).  
Furthermore, the escalated effect of shutting down other glutamate-derived substrates could have the 
counterproductive outcome of narrowing the differential sensitivity between the two genotypes, since 
other components of glutamine metabolism were less upregulated than de novo pyrimidine synthesis in 
Pten-/- cells. 
 
As described above, our current plans include determining whether inhibition of proteins upstream of 
DHODH phenocopy our results with leflunomide/A771726.  This will not only give us insight into the 
mechanistic underpinnings of the synthetic lethality in PTEN deficient cells, but could open possibilities 
for combination therapies.   
 
Further affirmation of the hypothesis 
While we are quite confident in the results of this thesis, there are additional experiments which could 
further solidify our hypothesis.  
 
Genes are highly interconnected in complex networks.  It is possible, therefore, that loss of PTEN could 
lead to transcriptional changes in other genes or epigenetic changes in the genome.  Reintroduction of 
PTEN into PTEN-deficient cell lines and subsequent rescue of leflunomide sensitivity and DNA damage 
would confirm that it is the loss of PTEN in particular that is causing our observed phenotypes, rather 
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than a downstream rewiring that may not be reversed by the addition of PTEN.  Specific reintroduction 
of a lipid phosphatase-dead mutant PTEN which cannot dephosphorylate PIP3 would also be 
illuminating; theoretically, it should not rescue PTEN null cells while a protein phosphatase-dead PTEN 
mutant would.   
 
This idea of phenotype reversal brings up another interesting speculation: if AKT is responsible for the 
phosphorylation of TOPBP1, could PTEN be a phosphatase for TOPBP1?  A phosphatase assay in the 
presence of PTEN protein would be revealing, and if found to be a phosphatase for TOPBP1 would add a 
function to the role of PTEN in the nucleus.   
 
ρ0 cells are cells in which the mitochondria have no mitochondrial DNA.  These can be generated by 
treatment with ethidium bromide or ditercalinium (Segal-Bendirdjian, Coulaud et al. 1988).  With 
oxidative phosphorylation thus disrupted, electron transfer in the respiratory chain is also disrupted, 
affecting the ability of DHODH to utilize ubiquinone.  Theoretically, then, addition of leflunomide should 
not affect the cells, since DHODH is already disrupted.  This would complement our rescue data to 
further prove that the effects we see are due to targeting of DHODH; if cells are further affected by 
leflunomide, it’s possible that off target effects are in play. 
 
Relatedly, it would be interesting to determine the levels of pCAD in the human cancer cell lines we 
used.  Because PIK3CA mutant breast cancer cell lines had an intermediate level of leflunomide 
sensitivity, it is possible that they also exhibit intermediate flux into the pyrimidine pathway.  A 
moderate level of pCAD would be consistent with this, since PIK3CA mutations elicit mTORC1 activation 
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via AKT but to a lesser extent than PTEN mutation does.  In fact, it would be interesting if our cell lines 
exhibited a gradient of pCAD (as well as pTOPBP1) protein levels, correlated to leflunomide sensitivity.  If 
so, it would add further credence that the influx of glutamine into pyrimidine synthesis mediated by 
pCAD and the inability of TOPBP1 to localize to forks directly lead to sensitivity to DHODH inhibition.  
However, it is also possible that cancer cell lines enhance flux of pyrimidine synthesis by additional or 
alternate mechanisms, such that a neat correlation is not found.  While it is known that AKT2 is primarily 
responsible for modulation of glycolysis, it is not clear which isoform is involved in phosphorylation of 
TOPBP1.  It would be interesting if different isoforms of AKT are involved in affecting different aspects of 
metabolism.   
 
Resistance 
Even if leflunomide proves to be the best drug for treating PTEN mutant tumors in terms of greatest 
efficacy and least toxicity, it is likely that the cancer will eventually evolve resistance.  The strategy that 
has been proposed in the field to combat resistance is the use of combinatorial therapies, to block 
multiple pathways and shut down the tumor before it is able to select for resistant clones.  It is 
therefore important to discuss the combination therapies we have tried thus far. 
 
First, brequinar and leflunomide did not have a synergistic or even additive effect in human PTEN 
mutant breast cancer cell lines.  Perhaps we needed to use a higher dose of brequinar to see an effect, 
or perhaps double-targeting DHODH is fruitless.  Second, it is interesting that the addition of a PI3K 
inhibitor to leflunomide not only did not enhance PTEN mutant sensitivity but seemed to work better in 
WT human breast cancer cells.  This may be because PI3K is upstream of mTORC1 — if CAD isn’t being 
phosphorylated due to the upstream block and glutamine is hence not being directed to pyrimidine 
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synthesis, it is possible that the sensitivity to leflunomide is no longer created in PTEN mutant cells.  
Additionally, AKT-mediated phosphorylation of TOPBP1 and CHK1 is central to the synthetic lethality 
observed in PTEN-deficient cells, and diminishing AKT signaling may prevent leflunomide-induced cell 
death.  mTORC1 inhibition also did not enhance the effects of leflunomide, or vice versa.  As with the 
PI3K inhibitor, this may be due to the obstruction of CAD phosphorylation and pyrimidine flux.  This can 
also indicate redundancy in the pathway; if PTEN is regulating pyrimidine synthesis through mTORC1 
downstream, blocking mTORC1 may not have an effect if a DHODH inhibitor is already applied.  
 
Many of the results from this thesis will be published in Cancer Discovery.  We co-submitted our paper 
with one from Dr. Alex Toker’s group from Harvard, who found that breast cancer cells that were 
treated with the chemotherapeutic agent doxorubicin then become sensitive to leflunomide/A771726.  
In light of their results, it is interesting that doxorubicin enhanced PTEN WT but not mutant cell 
sensitivity to leflunomide.  The metabolic signature genetically produced by PTEN loss, in particular 
pyrimidine influx, may be paralleled chemically by doxorubicin.  If true, it would explain why doxorubicin 
had no added effect on PTEN mutant cells, since they are already dependent on pyrimidine synthesis.  
On the other hand, doxorubicin treatment of PTEN WT cells could stimulate pyrimidine flux to the 
approximate level of PTEN mutant cells, creating sensitivity to leflunomide.   
 
In vitro, the chemotherapeutic agent paclitaxel did not affect the sensitivity to leflunomide, but 
leflunomide augmented the effect of paclitaxel in Pten-/- cells.  Our subsequent in vivo experiment 
treated mice with paclitaxel after they were exposed to leflunomide, with no effect in part because 
leflunomide acted so well as a single agent.  Additionally, perhaps we ought to have reversed the 
experiment: since the in vitro data showed leflunomide enhancing the effects of paclitaxel, it may be 
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worthwhile to pretreat tumors with paclitaxel and then add leflunomide to try to induce synergy in PTEN 
mutant cells.  If the combination is ultimately only slightly beneficial, it may be worthwhile to forego 
paclitaxel in favor of increasing the dose of leflunomide instead; prior clinical evidence demonstrates the 
relatively fewer toxic side effects of leflunomide at normal doses, and at escalated doses may still be 
lower than the side effects of chemotherapy.   
 
Additionally, it will be valuable to determine resistance mechanisms, either inherent or induced by 
DHODH inhibitors.  We plan to address this by screening additional PTEN mutant cell lines and 
comparing genetic differences between sensitive and resistant lines.  We also plan to treat sensitive 
lines with low doses of leflunomide for extensive periods of time in an attempt to stimulate resistance, 
and use the “before and after” to predict and eventually circumvent resistance mechanisms in vivo. 
 
Additional future directions 
From a broader perspective, we believe that additional metabolic changes induced upon PTEN loss 
present interesting lines of investigation.  Preliminary data from our lab suggest that, compared to WT 
cells, Pten-/- cells increase serine and glycine synthesis from 3-phosphoglycerate.  This could indicate the 
importance of single-carbon metabolism, perhaps in an effort to bring balance to purine and pyrimidines 
in PTEN-deficient cells.  Pyrimidine metabolism was found to be upregulated to a greater extent than 
purine synthesis, but perhaps the cells attempt to normalize the difference through glucose redirection 




The screen of soluble metabolites pointed us in the direction of pyrimidine metabolism.  We have not, 
however, explored insoluble metabolites.  It is possible that there are alterations in fatty acid anabolism 
to help support heightened proliferation or for other purposes as yet undetermined.  Heavy isotope 
labeling and extraction of insoluble metabolites will help us understand the role of lipids in PTEN mutant 
cells. 
 
Our results also expose a very basic question: independently of DHODH inhibition, how are PTEN 
deficient cells increasing their number of replication forks?  Future work into this question will include 
research into the coordination of origin firing and its determinants, including ATR as described above.  
Additionally, it will be important to know whether PTEN deficiency alters the recruitment of repair 
proteins to chromatin, both at endogenous levels and upon DHODH inhibition.  The current literature on 
this subject is conflicted, but perhaps our model of primary MEFs will help elucidate mechanistic 
changes.  ATR deficiency has been shown to impair localization of the repair protein FANCD2 to DNA, 
leading to chromosomal instability (Andreassen, D'Andrea et al. 2004).  It will be interesting to measure 
FANCD2 foci in the setting of PTEN deficiency and DHODH inhibition, to see whether the ATR signaling 
defects we observed have additional downstream consequences.  Perhaps the most interesting question 
in this realm of discussion is whether DHODH inhibition of PTEN mutant cells increases the overall 
probability of error in DNA replication.  It is possible that the inability of cells in these conditions to 
adequately sustain nucleotide levels at the higher number of forks leads to more frequent mistakes 
during replication.  Or, perhaps an imbalance of pyrimidines and purines at baseline conditions also 
increases the rate of error.  We plan to examine RNA-seq data to determine whether there is an 
increase in the random distribution of point mutations in PTEN mutant cells, either with or without 




Overall, the work presented in this thesis has launched several lines of investigation, from the 
mechanistic to the clinical. Our in vivo studies thus far have been in triple negative breast cancer 
models, and it will be important to expand this to glioblastoma, prostate, and endometrial cancers 
which also have high frequency of PTEN mutations.  Our in vitro studies on prostate and glioblastoma 
lines suggest a reasonable chance of success in these tumor types. 
 
Significance 
The findings of this thesis offer an understanding of the role of tumor suppression in metabolic signaling, 
and solidify the importance of metabolism in tumor development and therapeutic intervention.  We 
have found a prospective targeted therapy for PTEN deficient tumors, with efficacy in vitro and in vivo in 
tumors derived from different tissues.  Our results also open fascinating opportunities for further 




Materials and Methods 
 
Cell culture: MEFs and mouse breast tumor lines used the following media: DMEM (Corning mt10013cv) 
supplemented with 10% FBS (Atlanta Biologicals), 1% pen/strep (Fisher 30002ci) and 2mM L-glutamine 
(total 6mM) (Fisher MT25005CI). MDA-MB468, MDA-MB 231, Myc-CaP, and U87 used the following 
media: DMEM supplemented with 10% FBS and 1% pen/strep.  HCC1419, HCC1187, HCC 1937, HCC 
1806, BT549, ZR75-1, PC3, LNCAP, DBTRG, T-47D, HCC1954 used the following media: RPMI (Fisher 
10040cv) supplemented with 10% FBS and 1% pen/strep.  SUM149 and SUM159 used the following 
media: HAM’s F-12 with 5% FBS, 1% pen/strep, .01mg/mL insulin, 500ng/mL hydrocortisone.  CaP8 cells 
used the following media: DMEM with 10% FBS, 1% pen/strep, and 5µg/mL insulin (Sigma I9278).  
Neurospheres used the following media: stem cell media with 10ug/mL FGF (R&D Systems 233-FB-025), 
20ug/mL EGF (Peprotech AF-100-15) and heparin. All cells were cultured in a 37°C incubator with 
humidity and 5% CO2.  Cell lines were obtained from ATCC (which authenticate cell lines using several 
methods including DNA fingerprinting), with the exception of MEFs, MCCL-278, and MCCL-357 which 
were produced in our lab from mice.  Neurospheres were obtained from Dr. Raymund Yong, and 
prostate cancer organoids from Drs. Stuart Aaronson and Pamela Cheung.  Cell lines were clear of 
mycoplasma as determined by the luminescence-based Lonza kit (LT07-418) within 6 months of their 
use.  Cell lines were frozen in media containing 5-10% DMSO, in containers with isopropanol in the -80°C 
freezer prior to transfer to liquid nitrogen for long-term storage.  Cell lines were further authenticated in 
2015 by LabCorp using a short tandem repeat method.   
 
Mouse Embryonic Fibroblasts: Embryos were harvested from pregnant B6.129S4 Pten flox/flox mice 
(from Jackson Laboratory) 15 days after setting up the cross.   This timeline was used because the mice 
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typically do not actually mate until late that night; therefore, the embryos are collected effectively 14 
days after the actual mating event.  Head, limbs, liver, and other highly vascularized regions of the 
embryo were removed. The remaining trunk was minced using a scalpel in .25% trypsin, and 
resuspended in trypsin using a 5mL pipet. After 10 minutes of incubation at 37°C and 5% CO2, cells were 
further resuspended in trypsin with a 1mL pipet to generate a single-cell suspension. Cells were spun 
down and resuspended in fresh media before plating onto 10cm dishes. Cells were treated with an 
adenovirus with or without Cre recombinase (1:1000 of Vector Biolabs #1300 and #1045, respectively) 
as well as 4µg/mL polybrene in order to enhance infection efficiency.  MEFs were studied passage 2 or 
later after infection to ensure proper Pten deletion (checked by western blot) as well as recovery from 
infection, and before passage 6 after infection while the MEFs were still viable.  
 
Immunoblotting:  Samples were lysed in 2x Laemelli sample buffer with mercaptoethanol and were 
boiled before separation by SDS-PAGE on Tris-Glycine gels (Invitrogen EC60352) at 100V. Wet-transfer to 
PVDF (Fisher ipvh00010) for 1.5h at 180mA was followed by blocking for 1 hour in 10% nonfat milk 
(Fisher M-0841) in TBST. Membranes were incubated in primary antibody overnight at 4°C, and washed 
with TBST prior to addition of secondary antibody (Fisher 31432, 31460) for 1 hour at room 
temperature. Blots were developed using ECL (Fisher 34080) and autoradiography film (Denville E3018). 
Antibodies: PTEN 6H2.1 (Millipore 04-035), DHODH (Protein Tech 14877-1-AP), vinculin (Sigma V9131), 
actin (Sigma A4700), pCHK1 (Cell Signaling 2341), p-AKT (S473) (Cell Signaling 3787), CHK1 G-4 (Santa 
Cruz sc-8408), pCAD (Cell Signaling 12662), CAD (Cell Signaling 11933), cleaved caspase 3 (Cell Signaling 




Microarray:  RNA from cell lines was analyzed using the Affymetrix® GeneChips and the procedure 
dictated by The Ambion® Whole Transcript (WT) Expression Array from Applied Biosystems.  250ng RNA 
per sample was used for poly-A controls and first and second strand cDNA synthesis, followed by cRNA 
synthesis and purification.  Second cycle cDNA was synthesized and purified, and quantity was assessed 
with a nanodrop.  Samples were sent to Applied Biosystems for analysis.  Results were imported into R 
for quality control (including consistency of probe hybridization and signal intensity) and normalization 
using the affymetrix package.   
 
Cluster analysis: Microarray data from cell lines were uploaded to and analyzed by the Broad Institute’s 
Morpheus software. 
 
Principal Component Analysis:  PCA on MEFs was performed using the online program ClustVis (Metsalu 
and Vilo 2015) or on Matlab.  
 
Proliferation assay: 1500 cells per well (mouse cells) or 3000 cells per well (human cells) were plated in 
96 well plates (Corning 720089).  Growth rates were determined using the phase-confluency readings on 
an IncuCyte ZOOM (Essen Biosciences) on live cells over time. A 4x objective was used in the instrument, 
and images were either collected once every 24h using the scan-on-demand feature or once every 6h 
using the scheduled scan feature.  Unique processing definitions were created for different cell lines to 




Crystal violet assay: 3000 cells per well were plated into 48-well plates, one plate per time point.  For 
each time point, wells were aspirated and washed with PBS, after which 300µL .05% crystal violet (in 
formalin, diluted 1:10 with PBS) was added.  Cells were incubated 20-30 min at room temperature, and 
then washed 3 times with PBS.  500µL 10% acetic acid was added to each well, and put on a plate shaker 
for 20min-1hr at 400rpm until dissolved.  Absorbance was read on a plate reader at 590nm wavelength. 
 
Immunofluorescence: Cells were plated on fibronectin-coated cover slips in media.  For detecting 
replication forks: following a 45min EdU pulse, cover slip-attached cells were fixed (4% 
paraformaldehyde for 15min room temperature), permeabilized and blocked (10% goat 
serum/PBS/0.1% Triton X-100), and detected after azide conjugation to EdU.  For detecting gamma-
H2AX or TOPBP1: following the above fixation and permeabilization/blocking protocols, cells were 
incubated with primary antibody (Upstate Cell Signaling and Bethyl A300-111A-M, respectively) 
overnight at 4°C (in 10% goat serum/PBS) and with secondary antibody (in PBS) for 2 hours at room 
temperature.  Cells were washed with PBS in between each step, mounted on slides with prolong anti-
fade with DAPI, allowed to dry overnight, and sealed with clear nail polish.  Images were taken using a 
Zeiss LSM880 Airyscan confocal microscope at 63X, and foci number and colocalization was quantified 
with Image J using “colocalization” and “analyze particles” plugins. 
 
EdU detection: Instructions for the EdU cell proliferation Kit (Millipore 17-10525) were followed:  Cells 
were fixed (4% paraformaldehyde for 15min room temperature) and permeabilized (0.5% Triton X-100 
in PBS for 20 min) following a 45min EdU pulse on live cells.  The click chemistry reaction to add a 
fluorescent tag included an azide dye, catalyst, and buffer solutions, and cells were incubated for 30min.  
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Cells were washed and fluorescence was measured on a Guava® flow cytometer or by 
immunofluorescence. 
 
Cell death: Instructions for the FlowCellect™ Annexin Red Kit (Millipore FCCH100108) were followed: 
both floating and adherent cells were collected, and resuspended in buffer.  Cells were incubated in 
1:200 Annexin V for 15min in a 37°C CO2 incubator.  Following washes, cells were resuspended in buffer 
and 1:200 7AAD was added for 5 min at room temperature in the dark.  Fluorescence was measured on 
a Guava® flow cytometer.   
 
Cell cycle Analysis: Instructions for the FlowCellect™ Bivariate Cell Cycle Kit (Millipore FCCH025102) 
were followed: prior to collection, cells were incubated with 1:2000 BrdU in culture (BrdU was pulsed 
for 18hrs).  Cells were then fixed and permeabilized on ice, and DNA was denatured with DNaseI.    Cells 
were incubated with Anti-BrdU direct conjugate to Alexa Fluor 488 for one hour in the dark followed by 
propidium iodide and RNase for 30min at room temperature in the dark.  Fluorescence was measured 
on a Guava® flow cytometer.  
 
Senescence assay: Cells were washed, fixed, and stained with β-gal staining solution (Cell Signaling) 
overnight in the dark.  DAPI was added and cells were covered with 70% glycerol.  Pictures were taken 
on a microscope and quantified with ImageJ.   
 
Seahorse Analysis: A Seahorse XF (Agilent) was used to determine the oxygen consumption and 
extracellular acidification rates.  Cells were seeded at 12.5, 25, or 50K cells per well in 100µL volume in 
160 
 
the Seahorse cartridge (well size equivalent to 96 well plate well).  5 hours later, 150µL pH-adjusted (to 
7.4) DMEM XF Seahorse media was added to get a total volume of 250µL.  1mL of calibrant was added 
to an additional cartridge and warmed at 37°C in a non-CO2 incubator.  The following day, this cartridge 
was used to calibrate the machine.  Cells were washed and 550µL media was put in each well and 
incubated for 30min.  10µM oligomycin (55µL), 30µM FCCP (61µL), and 10µM rotenone (68µL) 
(Seahorse XF kit, Agilent) were injected into cartridge wells (volume reflects taking into account the 
additional volume added each time, therefore keeping concentration precise).  Controls for establishing 
baseline were used.  Plate was inserted into the machine for readings. 
 
ROS:  1mL of 2.5µM DCFDA in PBS was added to cells and incubated for 30 min at 37°C protected from 
light.  Cells were washed and collected in PBS for flow cytometry.   
 
Mitochondrial ROS: A 5mM stock of MitoSOX™ reagent was made in DMSO.  1mL of 2.5µM 
(Mukhopadhyay, Rajesh et al. 2007) reagent in HBSS buffer was added to cells and incubated for 15min 
at 37°C protected from light.  Cells were washed and collected in buffer for flow cytometry.   
 
Metabolite labeling:  For glutamine flux, media without glutamine was supplemented with 13C 
glutamine (fully labeled) or 15N glutamine (amide labeled) (Cambridge Isotope Labs).  For glucose flux, 
media without added glucose was supplemented with 13C glucose (fully labeled) (Cambridge Isotope 
Labs).  Cells were plated in 10cm dishes; WT and Pten-/- MEFs were plated at slightly different 
confluencies (1:.8) to achieve equal confluency the day of the extraction and were grown in normal 
media (control plates were counted day-of experiment to ensure equal cell numbers).  1 hour prior to 
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metabolite extraction, media was aspirated and replaced with heavy isotope-labeled media for flux 
experiments. 
 
Metabolic extraction: Metabolites were collected as previously described (Yuan, Breitkopf et al. 2012): 
Media was aspirated from plates, and 2.5mL 80% methanol (kept at -80°C) was added. Plates were 
incubated at 80°C for 20 minutes, after which cells were scraped into tubes and centrifuged to pellet 
insoluble cellular material. The soluble supernatant was saved. 2 more extractions on the insoluble 
pellet were performed with 500µL 80% methanol, and all extractions were pooled. Extractions were 
dried in a speed-vac and frozen at -80°C until analysis. All steps of the extraction were kept cold on dry 
ice.  
 
Targeted Mass Spectrometry: Mass Spec was performed by the core facility at Beth Israel Deaconess 
Medical Center.  Samples were re-suspended using 20 μL HPLC grade water for mass spectrometry. 5-7 
μL were injected and analyzed using a hybrid 5500 QTRAP triple quadrupole mass spectrometer 
(AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) via selected reaction monitoring 
(SRM) of a total of 259 endogenous water soluble metabolites for steady-state analyses of samples. 
Some metabolites were targeted in both positive and negative ion mode for a total of 294 SRM 3 
transitions using positive/negative ion polarity switching. ESI voltage was +4900V in positive ion mode 
and –4500V in negative ion mode. The dwell time was 3 ms per SRM transition and the total cycle time 
was 1.55 seconds. Approximately 10-14 data points were acquired per detected metabolite. Samples 
were delivered to the mass spectrometer via hydrophilic interaction chromatography (HILIC) using a 4.6 
mm i.d x 10 cm Amide XBridge column (Waters) at 400 μL/min. Gradients were run starting from 85% 
buffer B (HPLC grade acetonitrile) to 42% B from 0-5 minutes; 42% B to 0% B from 5-16 minutes; 0% B 
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was held from 16-24 minutes; 0% B to 85% B from 24-25 minutes; 85% B was held for 7 minutes to re-
equilibrate the column. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM ammonium 
acetate (pH=9.0) in 95:5 water:acetonitrile.  Peak areas from the total ion current for each metabolite 
SRM transition were integrated using MultiQuant v2.1 software (AB/SCIEX). ~150 SRM transitions were 
set up for 13C glutamine and 15N glutamine labeled metabolites in addition to unlabeled metabolites. 
Integrated Molecular Pathway Analysis (IMPaLA) was used to analyze metabolic pathways (Kamburov, 
Cavill et al. 2011).  For cell-labeling experiments, the concentration of isotope-labeled metabolite = 
[labeled metabolite amount]/ [total metabolite amount] for each metabolite. 
 
Gene Set Enrichment Analysis: Microarray data from Pten WT and KO MEFs (4 each) were analyzed 
using the GSEA program by the Broad Institute (Mootha, Lindgren et al. 2003, Subramanian, Tamayo et 
al. 2005). 
 
Drug response assays: Cells were plated in 96-well plates at a density of 1500 or 3000 cells per well. 
Leflunomide (Sigma PHR1378-1G), A771726 (Sigma SML0936), mercaptopurine (Sigma 852678), 
brequinar (Sigma SML0113), 5-fluorouracil (Millipore 343922), rad001 and GDC0941(Stand Up to Cancer 
PI3K Dream Team), carboplatin (Selleckchem S1215), paclitaxel (Sigma T7402), carboplatin (Sigma 
44583-1MG) and CB-839 (MedChemexpress HY-12248) were dissolved in DMSO. Sensitivity was 
determined by a dose-response titration for each cell line, with an equivalent amount of DMSO in each 
well: 300µL media with drug was added to one column of wells, and 150µL media with equivalent DMSO 
was added to remaining wells.  Serial dilutions of 150µL resulted in a gradient with half the drug 
concentration as the previous column while maintaining the same amount of DMSO.  GI50 was defined 
as the drug concentration required to achieve 50% of maximal growth in the cell line, and was calculated 
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by linear interpolation adapted from the Nature analysis of the NCI60 panel (Shoemaker 2006): the 
maximum growth confluence for a cell line prior to growth plateau was divided by 2 to obtain the 50% 
confluence value.  A linear regression curve was calculated using drug concentrations as x-values and 
confluence as y-values for points surrounding the 50% value.  Linear interpolation using the regression 
line yielded the GI50 concentration.  For cell death assays, DRAQ7TM (Cell Signaling 7406S) was added to 
the media at a 1:200 dilution and red fluorescence was measured in addition to phase in live-cell 
imaging to measure accumulation of dead cells.  For DRAQ7 readings, the number of dead cells was 
normalized to confluency and background red signal.  An IncuCyte ZOOM was used to measure 
confluency and fluorescence.   
 
Mammospheres: Cells were grown in serum-free DMEM or RPMI with B-27 supplement and rEGF.  Cells 
were plated in non-adherent plates, and pictures covering the whole well were taken 5 days after 
treatment.  Dense clusters >.05mm in diameter were counted as true tumor spheres.  Spheres were 
measured on ImageJ and quantified.  
 
Orotate Rescue: Orotate (Sigma O2750) was dissolved in DMSO.  Cells were plated at fixed 
concentration leflunomide with increasing concentrations of orotate, keeping DMSO constant in all 
wells.   
 
Uridine Rescue: Uridine (Sigma U 3750) was dissolved in media.  Cells were plated at fixed concentration 




RNA interference:  siRNA for DHODH was purchased from Qiagen.  Cells were transfected using 
lipofectamine (Invitrogen 11668-019): 250µL Optimem with 5µL siRNA at 20µM and 250µL Optimem 
with 5µL lipfectamine were incubated at room temperature for 5 minutes and then mixed and left to sit 
at room temperature for approximately 10min.  Media on cells was replaced with 500µL antibiotic-free 
media, and the Optimem solution was added drop-wise.  After 7 hours, the cells were switched to 
regular media, and knockdown was confirmed at 48 hours via western blot.  Scrambled siRNA was used 
as a control. 
 
Antioxidant rescue: N-acetyl-cysteine (Sigma A7250-10G) was dissolved in DMSO.  Cells were plated at 
fixed concentration leflunomide with increasing concentrations of N-acetyl-cysteine, keeping DMSO 
constant in all wells.   
 
Xenografts:  6-week old female nu/nu mice were engrafted orthotopically with either 5 million SUM149, 
5 million MDAMB 468-luciferase, 1 million MCCL-357, or .75million MCCL-278 cells.  Mice with PDX 
implants at passage 2-3 were obtained from Jackson Labs (model TM00090: breast metaplasmic 
carcinoma, primary malignancy, deficiency in PTEN greater than any other gene tested based on RNAseq 
and second most based on copy number analysis).  Mice were treated by oral gavage with 100mg/kg 
leflunomide or vehicle (1% carboxymethylcelluose in water).  Tumor size was measured by calipers 
(modified ellipsoid formula = ½(length*width2)) or luminescence, which was quantified as 
photons/second/cm2/steradian and normalized to baseline.  Mice were treated orally as is done 
clinically; leflunomide binds tightly to serum proteins and has a long half-life (about 2 weeks), precluding 
daily treatments for the duration of the experiment (Breedveld and Dayer 2000, Rozman 2002).  
Paclitaxel was dissolved in 160µL 1:1 ethanol to Crempohor EL and diluted in PBS; 200L per mouse was 
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injected intraperitoneal.  Vehicle-treated mice in this experiment were given both 
ethanol/Cremophor/PBS and 1% carboxymethylcellulose.   Mice were from Jackson Laboratory and were 
20-25g.  Animal experiments were approved by an Institutional Animal Care and Use Committee. 
 
Neurosphere sensitivity assay: Neurospheres were disrupted by manual pipetting until single cell 
suspension was achieved, and 10,000cells/well were plated in low-attachment 6-well plates (Fisher 
3471).  After 5 days, neurosphere formation was counted; pictures covering the whole well were taken 5 
days after treatment.  Dense clusters >.05mm in diameter were counted as true tumor spheres.  Spheres 
were measured on ImageJ and quantified.  
 
Gamma-H2AX measurement: Instructions for the FlowCellect™ Cell Cycle Checkpoint H2A.X DNA 
Damage Kit (Millipore FCCH12542) were followed:  cells were fixed and permeabilized, followed by 
staining with an anti-phospho-H2A.X antibody and propidium iodide.  For co-staining with RPA, an 
additional step was performed during which cells were incubated with an RPA antibody (Abcam 
ab79398) for 1 hour and secondary antibody for 1 hour. (Propidium iodide was not used in this setting.)  
Fluorescence was measured on a Guava® flow cytometer.   
 
pTOPBP1 measurement: Cells were fixed and permeabilized, followed by incubation with primary 
antibody (Abgent AP3774a) for 2 hours at room temperature and secondary antibody for 2 hours at 




Transfection:  Plasmids were electroporated into cells using an Amaxa Nucleofector™ 2b (Lonza) and 
Cell Line Nucleofector® Kit V (Lonza VCA-1003).  TOPBP1 WT and mutant plasmids were graciously 
supplied by Dr. Weei-Chin Lin. An mcherry plasmid was kindly given to us by Dr. Papapetrou and was co-
transfected to determine transfection efficiency and to gate transfected cells for flow cytometry 
experiments.   
 
Karyotyping:  Chromosomal analysis was done by Dr. Murty Vundavalli at Columbia University as 
follows: Mouse PTEN-/- and PTEN WT cells were sub-cultured and the drug was added at the indicated 
concentrations 24h after sub-culturing. The cells were processed for metaphases preparations by 
standard protocols after 48h and 72h of drug exposure with the addition of colcemid for the last 2hr. A 
total of 100 metaphases were analyzed from replicate experiments to identify chromatid- and 
chromosome-type aberrations such as chromatid and chromosome breaks, multi-radial chromosomes, 
extensive breakage resulting in pulverization. Chromatid and chromosome breaks were considered as a 
single break, multi-radial chromosomes were considered as 3 breaks in assessing the frequency of 
abnormal metaphases and chromosome breaks. However, extensive breakage resulting in pulverization 
in rare metaphases was not considered in calculating the frequency of breaks. Experiment was repeated 
twice. 
 
Statistical Analysis: ANOVA or student’s t-tests were used to test means between groups.  Correction 
for multiple comparisons was added where needed.  Analysis was done using GraphPad Prism 6 or 
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